Revvity (RVTY) 10-K 2 Mar 21 2020 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Jan. 03, 2021	Feb. 26, 2021	Jul. 02, 2020	Dec. 29, 2019
Entity Listings [Line Items]
Document Annual Report	true
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Public Float			$ 10,743,749,481
ICFR Auditor Attestation Flag	true
Sale of Stock, Price Per Share			$ 97.94
Common stock, par value	$ 1			$ 1
Document Type	10-K
Document Period End Date	Jan. 3, 2021
Document Transition Report	false
Entity File Number	001-5075
Entity Registrant Name	PERKINELMER, INC.
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2052042
Entity Address, Address Line One	940 Winter Street,
Entity Address, City or Town	Waltham,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	663-6900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		112,061,794
Entity Central Index Key	0000031791
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Current Fiscal Year End Date	--01-03
PKI [Member]
Entity Listings [Line Items]
Trading Symbol	PKI
Trading Symbol	PKI
PKI 21A [Member]
Entity Listings [Line Items]
Trading Symbol	PKI 21A
Trading Symbol	PKI 21A
PKI 21B [Member]
Entity Listings [Line Items]
Trading Symbol	PKI 21B
Trading Symbol	PKI 21B
Common stock, $1 par value per share [Member]
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $1 Par Value
Title of 12(b) Security	Common Stock, $1 Par Value
1.875% Notes due 2026 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2026
Title of 12(b) Security	1.875% Notes due 2026
0.60% Notes due 2021 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	0.600% Notes due 2021
Title of 12(b) Security	0.600% Notes due 2021
NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Listings [Line Items]
Security Exchange Name	NYSE
Security Exchange Name	NYSE

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jan. 03, 2021	Feb. 26, 2021	Jul. 02, 2020
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jan. 3, 2021
Document Transition Report	false
Entity File Number	001-5075
Entity Registrant Name	PERKINELMER, INC.
Entity Central Index Key	0000031791
Current Fiscal Year End Date	--01-03
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2052042
Entity Address, Address Line One	940 Winter Street,
Entity Address, City or Town	Waltham,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	663-6900
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 10,743,749,481
Entity Common Stock, Shares Outstanding		112,061,794
Documents Incorporated by Reference	Portions of PerkinElmer, Inc.’s Definitive Proxy Statement for its Annual Meeting of Shareholders to be h eld on April 27, 2021 are incorporated by reference into Part III of this Form 10-K.
Common stock, $1 par value per share [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $1 Par Value
1.875% Notes due 2026 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.875% Notes due 2026
0.60% Notes due 2021 [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.600% Notes due 2021
NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Security Exchange Name	NYSE
PKI [Member]
Entity Information [Line Items]
Trading Symbol	PKI
PKI 21A [Member]
Entity Information [Line Items]
Trading Symbol	PKI 21A
PKI 21B [Member]
Entity Information [Line Items]
Trading Symbol	PKI 21B

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended									12 Months Ended
	Jan. 03, 2021		Oct. 04, 2020	Jul. 05, 2020	Apr. 05, 2020	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Revenue
Revenue from Contract with Customer, Excluding Assessed Tax										$ 3,782,745	$ 2,883,673	$ 2,777,996
Selling, general and administrative expenses										917,894	815,318	811,913
Research and development expenses										205,389	189,336	193,998
Restructuring and other costs, net	$ (3,062)		$ 4,059	$ 1,158	$ 5,858	$ 1,560	$ 14,068	$ 6,161	$ 7,639	8,013	29,428	11,144
Operating income from continuing operations	510,254	[1]	248,006	175,639	44,682	138,248	78,660	91,735	53,330	978,581	361,973	323,884
Interest and other expense, net										72,217	124,831	66,201
Income from continuing operations before income taxes	473,091	[1]	233,757	164,827	34,689	65,296	63,254	71,827	36,765	906,364	237,142	257,683
Provision for income taxes										178,266	9,389	20,208
Income from continuing operations	380,434	[1]	176,736	137,213	33,715	64,549	58,610	69,141	35,453	728,098	227,753	237,475
(Loss) gain on disposition of discontinued operations before income taxes										(76)	0	(859)
(Benefit from) provision for income taxes on discontinued operations and dispositions										(135)	195	(1,311)
Income from discontinued operations and dispositions	(73)		(37)	(51)	(50)	(48)	(52)	(54)	(41)	(211)	(195)	452
Net income	$ 380,361	[1]	$ 176,699	$ 137,162	$ 33,665	$ 64,501	$ 58,558	$ 69,087	$ 35,412	$ 727,887	$ 227,558	$ 237,927
Basic earnings per share:
Income from continuing operations	$ 3.40	[1]	$ 1.58	$ 1.23	$ 0.30	$ 0.58	$ 0.53	$ 0.62	$ 0.32	$ 6.53	$ 2.06	$ 2.15
Income from discontinued operations and dispositions	0		0	0	0	0	0	0	0	0	0	0
Net income	3.40	[1]	1.58	1.23	0.30	0.58	0.53	0.62	0.32	6.53	2.06	2.15
Diluted earnings per share:
Income from continuing operations	3.38	[1]	1.57	1.23	0.30	0.58	0.53	0.62	0.32	6.50	2.04	2.13
Income from discontinued operations and dispositions	0		0	0	0	0	0	0	0	0	0	0
Net income	$ 3.38	[1]	$ 1.57	$ 1.23	$ 0.30	$ 0.58	$ 0.52	$ 0.62	$ 0.32	$ 6.49	$ 2.04	$ 2.13
Product [Member]
Revenue
Revenue from Contract with Customer, Excluding Assessed Tax										$ 2,778,725	$ 2,017,042	$ 1,935,493
Cost of Goods and Services Sold										1,105,614	956,398	908,228
Service [Member]
Revenue
Revenue from Contract with Customer, Excluding Assessed Tax										1,004,020	866,631	842,503
Cost of Goods and Services Sold										$ 567,254	$ 531,220	$ 528,829
[1]	The fourth quarter of fiscal year 2020 includes a pre-tax loss of $25.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustments Reclassification From AOCI to Earnings Due to ASU 2018-02	$ 0	$ 0	$ 6,489
Net income	727,887	227,558	237,927
Other comprehensive income (loss)
Foreign currency translation adjustments, net of tax	169,500	(23,978)	(123,388)
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustments Reclassification From AOCI to Earnings Due to ASU 2018-02	0	0	6,489
Unrecognized prior service (cost) credit, net of tax	(1,799)	807	(77)
Unrealized (losses) gains on securities, net of tax	(16)	6	(9)
Other comprehensive income (loss)	167,685	(23,165)	(129,963)
Comprehensive income	$ 895,572	$ 204,393	$ 107,964

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019
Current assets:
Cash and cash equivalents	$ 402,036	$ 191,877
Accounts receivable, net	1,155,109	725,184
Inventories	514,567	356,937
Other current assets	167,208	100,381
Total current assets	2,238,920	1,374,379
Property, plant and equipment, net	368,304	318,223
Operating Lease, Right-of-Use Asset	207,236	167,276
Intangible assets, net	1,365,693	1,283,286
Goodwill	3,447,114	3,111,227
Other assets, net	333,048	284,173
Total assets	7,960,315	6,538,564
Current liabilities:
Current portion of long-term debt	380,948	9,974
Accounts payable	327,325	235,855
Accrued restructuring and contract termination costs	4,716	11,559
Accrued expenses and other current liabilities	937,027	503,332
Current liabilities of discontinued operations	2,173	2,112
Total current liabilities	1,652,189	762,832
Long-term debt	1,609,701	2,064,041
Long-term liabilities	774,531	751,468
Operating Lease, Liability, Noncurrent	188,402	146,399
Total liabilities	4,224,823	3,724,740
Commitments and contingencies (see Notes 14 and 17)
Stockholders' equity:
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 112,090,000 and 111,140,000 shares at January 3, 2021 and December 29, 2019, respectively	112,090	111,140
Capital in excess of par value	148,101	90,357
Retained earnings	3,507,262	2,811,973
Accumulated other comprehensive loss	(31,961)	(199,646)
Total stockholders' equity	3,735,492	2,813,824
Total liabilities and stockholders' equity	$ 7,960,315	$ 6,538,564

Consolidated Balance Sheet Pare

Consolidated Balance Sheet Parenthetical - $ / shares	Jan. 03, 2021	Dec. 29, 2019
Balance Sheet Parenthetical [Abstract]
Preferred stock, par value	$ 1	$ 1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 1	$ 1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	112,090,000	111,140,000
Common stock, outstanding	112,090,000	111,140,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock Amount [Member]	Capital In Excess of Par Value [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Dec. 31, 2017	$ 2,503,188	$ 110,361	$ 58,828	$ 2,380,517	$ (46,518)
Net income	237,927		0	237,927
Other comprehensive income (loss)	(129,963)
Dividends	(31,013)			(31,013)	0
Exercise of employee stock options and related income tax benefits	24,833	709	24,124
Issuance of common stock for employee benefit plans	1,485	21	1,464
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	57,393	717	56,676
Issuance of common stock for long-term incentive program	15,873	223	15,650
Stock compensation	5,382	0	5,382	0	0
Ending Balance at Dec. 30, 2018	2,584,955	110,597	48,772	2,602,067	(176,481)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	(123,474)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	(123,474)				(123,474)
Net income	227,558			227,558
Other comprehensive income (loss)	(23,165)
Dividends	(30,941)			(30,941)
Exercise of employee stock options and related income tax benefits	19,732	415	19,317
Issuance of common stock for employee benefit plans	2,776	33	2,743
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	6,313	67	6,246
Issuance of common stock for long-term incentive program	19,307	162	19,145
Stock compensation	6,626	0	6,626	0	0
Ending Balance at Dec. 29, 2019	2,813,824	111,140	90,357	2,811,973	(199,646)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	(23,165)				(23,165)
Net income	727,887			727,887
Other comprehensive income (loss)	167,685
Dividends	(31,270)			(31,270)
Exercise of employee stock options and related income tax benefits	37,671	764	36,907
Issuance of common stock for employee benefit plans	4,101	39	4,062
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	6,944	72	6,872
Issuance of common stock for long-term incentive program	20,204	219	19,985
Stock compensation	3,662	0	3,662	0	0
Ending Balance at Jan. 03, 2021	3,735,492	$ 112,090	$ 148,101	$ 3,507,262	(31,961)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	$ 167,685				$ 167,685

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Restricted Cash	$ 578	$ 17	$ 3,204
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	402,614	191,894	166,315
Operating activities:
Net income	727,887	227,558	237,927
Loss (gain) from discontinued operations and dispositions, net of income taxes	211	195	(452)
Income from continuing operations	728,098	227,753	237,475
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and other costs, net	8,013	29,428	11,144
Depreciation and amortization	246,507	214,025	180,588
Stock-based compensation	29,126	31,514	28,767
Pension and other post-retirement expense	18,012	26,107	11,915
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	(8,827)	3,881	14,639
Deferred taxes	(29,121)	(61,353)	(51,103)
Deferred Income Tax Expense (Benefit), Continuing Operations, Discontinuing Operations	(29,121)	(61,353)	(51,103)
Contingencies and Non-Cash Tax Matters	4,518	(424)	(671)
Amortization of deferred debt issuance costs, interest rate hedge and accretion of discounts	3,391	3,846	3,341
Loss (gain) on disposition of businesses and assets, net	886	2,469	(12,844)
Amortization of acquired inventory revaluation	2,793	21,590	19,272
Asset Impairment Charges	7,937	0	0
Gain on Sale of Investments	0	0	(557)
Change in fair value of financial securities	(35)	(3,249)	0
Gain (Loss) on Extinguishment of Debt	0	32,541	0
Changes in assets and liabilities which (used) provided cash, excluding effects from companies purchased and divested:
Accounts receivable, net	(373,895)	(100,630)	(94,512)
Inventories, net	(122,513)	(9,607)	(30,183)
Accounts payable	62,753	7,351	8,900
Accrued expenses and other	314,534	(61,773)	(14,933)
Net cash provided by operating activities of continuing operations	892,177	363,469	311,238
Net cash used in operating activities of discontinued operations	0	0	(200)
Net cash provided by operating activities	892,177	363,469	311,038
Investing activities:
Capital expenditures	(77,506)	(76,331)	(93,253)
Payments to Acquire Investments	(20,059)	(6,387)	(7,019)
Payments to Acquire Intangible Assets	0	(5,000)	0
Proceeds from Divestiture of Businesses	4,280	550	38,027
Proceeds from surrender of life insurance policies	282	0	72
Activity related to acquisitions, net of cash, cash equivalents and restricted cash acquired	(411,495)	(400,405)	(97,686)
Net cash used in investing activities of continuing operations	(504,498)	(487,573)	(159,859)
Net cash provided by investing activities of discontinued operations	0	0	0
Net cash used in investing activities	(504,498)	(487,573)	(159,859)
Financing activities:
Payments on revolving credit facility	(897,674)	(1,692,489)	(1,264,000)
Proceeds from Long-term Lines of Credit	714,698	1,599,416	857,000
Payments of Senior Debt	0	(530,276)	0
Proceeds from sale of senior debt	0	847,195	369,340
Payments of debt financing costs	0	(9,879)	(2,634)
Proceeds from (Repayments of) Other Debt	(4,494)	(14,975)	(28,383)
Settlement of cash flow hedges	(4,554)	(1,280)	(34,132)
Payments for acquisition-related contingent consideration	(10,363)	(29,942)	(12,800)
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	37,671	19,732	24,833
Purchases of common stock	(6,944)	(6,313)	(57,445)
Dividends paid	(31,212)	(31,059)	(31,009)
Net cash provided by (used in) financing activities of continuing operations	(202,872)	150,130	(179,230)
Net cash used in financing activities of discontinued operations	0	0	0
Net cash (used in) provided by financing activities	(202,872)	150,130	(179,230)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	25,913	(447)	(8,004)
Net increase (decrease) in cash, cash equivalents and restricted cash	210,720	25,579	(36,055)
Cash and cash equivalents at beginning of year	191,877	163,111
Cash and cash equivalents at end of year	402,036	191,877	163,111
Supplemental disclosures of cash flow information
Interest Paid, Excluding Capitalized Interest, Operating Activities	42,142	82,693	56,451
Income taxes	$ 162,454	$ 77,059	$ 59,844

Interest and Other Expense (Inc

Interest and Other Expense (Income), Net	12 Months Ended
	Jan. 03, 2021
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and Other Expense, Net Interest and other expense, net, consisted of the following for the fiscal years ended: January 3, December 29, December 30, (In thousands) Interest income $ (1,010) $ (1,495) $ (1,141) Interest expense 49,712 63,627 66,976 Loss (gain) on disposition of businesses and assets, net (see Note 4) — 2,469 (12,844) Debt extinguishment costs (see Note 14) — 32,541 — Other expense, net 23,515 27,689 13,210 Total interest and other expense, net $ 72,217 $ 124,831 $ 66,201

Interest and Other Expense (I_2

Interest and Other Expense (Income), Net (Tables)	12 Months Ended
	Jan. 03, 2021
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and other expense, net, consisted of the following for the fiscal years ended: January 3, December 29, December 30, (In thousands) Interest income $ (1,010) $ (1,495) $ (1,141) Interest expense 49,712 63,627 66,976 Loss (gain) on disposition of businesses and assets, net (see Note 4) — 2,469 (12,844) Debt extinguishment costs (see Note 14) — 32,541 — Other expense, net 23,515 27,689 13,210 Total interest and other expense, net $ 72,217 $ 124,831 $ 66,201

Interest and Other Expense (I_3

Interest and Other Expense (Income), Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Foreign Currency Transaction Gain (Loss), before Tax	$ (2,700)	$ 6,500	$ (9,400)
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	7,700	(3,500)	11,700
Gain on disposition of businesses and assets, net	0	2,469	(12,844)
Defined Benefit Plan, Other Cost (Credit)	18,800	25,300	11,500
Interest income	(1,010)	(1,495)	(1,141)
Interest expense	49,712	63,627	66,976
Gain (Loss) on Extinguishment of Debt	0	32,541	0
Other expense, net	23,515	27,689	13,210
Total interest and other expense, net	$ 72,217	$ 124,831	$ 66,201

Business Combinations and Asset

Business Combinations and Asset Purchases	12 Months Ended
	Jan. 03, 2021
Business Combinations [Abstract]
Business Combinations and Asset Purchases	Business Combinations Acquisitions in fiscal year 2020 During the fiscal year 2020, the Company completed the acquisition of four businesses for aggregate consideration of $438.7 million. The acquired businesses include Horizon Discovery Group plc (“Horizon”), a company based in Cambridge, UK with approximately 400 employees, which was acquired on December 23, 2020 for a total consideration of $399.4 million (£296.0 million), and three other businesses which were acquired for a total consideration of $39.3 million. The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations for these acquisitions within the results of the Company's Diagnostics and Discovery & Analytical Solutions segments, as applicable, from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names, customer relationships and IPR&D, acquired as part of these acquisitions had a weighted average amortization period of 11.0 years. The total purchase price for the acquisitions in fiscal year 2020 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Preliminary Horizon Other (In thousands) Fair value of business combination: Cash payments $ 399,005 $ 38,243 Other liability 396 1,263 Working capital and other adjustments — (176) Less: cash acquired (25,539) (1,300) Total $ 373,862 $ 38,030 Identifiable assets acquired and liabilities assumed: Current assets $ 29,762 $ 5,770 Property, plant and equipment 17,729 2,673 Other assets 17,743 371 Identifiable intangible assets: Core technology 60,000 5,730 Trade names 4,900 680 Customer relationships 96,600 10,923 IPR&D 10,800 — Goodwill 200,745 16,224 Deferred taxes (22,480) (1,132) Deferred revenue (2,031) — Debt assumed — (29) Liabilities assumed (39,906) (3,180) Total $ 373,862 $ 38,030 Acquisitions in fiscal year 2019 During the fiscal year 2019, the Company completed the acquisition of five businesses for aggregate consideration of $433.1 million. The acquired businesses include Cisbio Bioassays SAS (“Cisbio”), a company based in Codolet, France, which was acquired for a total consideration of $219.9 million, Shandong Meizheng Bio-Tech Co., Ltd. ("Meizheng Group"), a company headquartered in Beijing, China, for a total consideration of $166.5 million, and three other businesses which were acquired for a total consideration of $46.6 million. The Company has a potential obligation to pay the former shareholders of certain of these acquired businesses additional contingent consideration of up to $31.8 million. The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations for these acquisitions within the results of the Company's Diagnostics and Discovery & Analytical Solutions segments, as applicable, from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 11.0 years. The total purchase price for the acquisitions in fiscal year 2019 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Cisbio Meizheng Group Other (In thousands) Fair value of business combination: Cash payments $ 219,795 $ 145,000 $ 45,042 Other liability — 6,446 638 Contingent consideration — 12,100 634 Working capital and other adjustments 138 2,961 302 Less: cash acquired (12,542) (2,108) (1,334) Total $ 207,391 $ 164,399 $ 45,282 Identifiable assets acquired and liabilities assumed: Current assets $ 43,554 $ 15,077 $ 4,125 Property, plant and equipment 4,835 6,278 727 Other assets 100 24 502 Identifiable intangible assets: Core technology 89,000 36,600 27,667 Trade names 5,000 4,900 1,310 Customer relationships 39,000 55,800 6,700 Goodwill 73,417 78,612 17,079 Deferred taxes (34,962) (21,548) (6,603) Debt assumed — (706) (2,698) Liabilities assumed (12,553) (10,638) (3,527) Total $ 207,391 $ 164,399 $ 45,282 Acquisitions in fiscal year 2018 During fiscal year 2018, the Company completed the acquisition of four businesses for aggregate consideration of $105.8 million. The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations for these acquisitions within the results of the Company's Diagnostics and Discovery & Analytical Solutions segments from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 11.2 years. The total purchase price for the acquisitions in fiscal year 2018 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: (In thousands) Fair value of business combination: Cash payments $ 95,950 Other liability 3,354 Contingent consideration 6,200 Working capital and other adjustments 261 Less: cash acquired (1,132) Total $ 104,633 Identifiable assets acquired and liabilities assumed: Current assets $ 4,905 Property, plant and equipment 1,166 Other assets 776 Identifiable intangible assets: Core technology 31,956 Trade names 1,070 GC Libraries 2,065 Customer relationships 10,200 Goodwill 65,886 Deferred taxes (9,049) Debt assumed (461) Liabilities assumed (3,881) Total $ 104,633 The Company does not consider the acquisitions completed during fiscal years 2020, 2019 and 2018 to be material to its consolidated results of operations; therefore, the Company is not presenting pro forma financial information of operations for these acquisitions. The aggregate revenue and the results of operations for the acquisitions completed during fiscal year 2020 for the period from their acquisition dates to January 3, 2021 were not material. The aggregate revenue and the results of operations for the acquisitions completed during fiscal year 2019 for the period from their acquisition dates to December 29, 2019 were not material. The aggregate revenue for the acquisitions completed during fiscal year 2018 for the period from their acquisition dates to December 30, 2018 were not material. The Company has also determined that the presentation of the results of operations for each of those acquisitions, from the date of acquisition, is impracticable due to the integration of the operations upon acquisition. As of January 3, 2021, the allocations of purchase prices for acquisitions completed in fiscal years 2019 and 2018 were final. The preliminary allocations of the purchase prices for acquisitions completed in fiscal year 2020 were based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. These adjustments will be made in the periods in which the amounts are determined and the cumulative effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition dates. All changes that do not qualify as adjustments made during the measurement periods are also included in current period earnings. During fiscal year 2020, the Company obtained information relevant to determining the fair values of certain tangible and intangible assets acquired, and liabilities assumed, related to recent acquisitions and adjusted its purchase price allocations. Based on this information, the Company recognized an increase in intangible assets of $1.9 million, an increase in deferred tax liabilities of $0.4 million, a decrease in goodwill of $1.8 million, and a decrease in liabilities assumed of $0.4 million. Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. As of January 3, 2021, the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $7.3 million. As of January 3, 2021, the Company has recorded contingent consideration obligations of $3.0 million, of which $2.9 million was recorded in accrued expenses and other current liabilities, and $0.1 million was recorded in long-term liabilities. As of December 29, 2019, the Company has recorded contingent consideration obligations of $35.5 million, of which $20.8 million was recorded in accrued expenses and other current liabilities, and $14.7 million was recorded in long-term liabilities. The expected maximum earnout period for acquisitions with open contingency periods does not exceed 2.9 years from January 3, 2021, and the remaining weighted average expected earnout period at January 3, 2021 was 1.9 years. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional contingent consideration which would be recognized as a component of operating expenses from continuing operations. In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of deferred revenue assumed with its acquisitions. The estimated fair value of deferred revenue is determined by the legal performance obligation at the date of acquisition, and is generally based on the nature of the activities to be performed and the related costs to be incurred after the acquisition date. The fair value of an assumed liability related to deferred revenue is estimated based on the current market cost of fulfilling the obligation, plus a normal profit margin thereon. The estimated costs to fulfill the deferred revenue are based on the historical direct costs related to providing the services. The Company does not include any costs associated with selling effort, research and development, or the related margins on these costs. In most acquisitions, profit associated with selling effort is excluded because the acquired businesses would have concluded the selling effort on the support contracts prior to the acquisition date. The estimated research and development costs are not included in the fair value determination, as these costs are not deemed to represent a legal obligation at the time of acquisition. The sum of the costs and operating income approximates, in theory, the amount that the Company would be required to pay a third-party to assume the obligation. Total acquisition and divestiture-related costs for fiscal years 2020 and 2019 were $9.3 million and $6.6 million, respectively. These amounts included $4.7 million of incentive award associated with the Company's acquisition of Meizheng Group for fiscal year 2020, and $0.5 million of compensation expense related to Tulip Diagnostics Private Limited ("Tulip") and $2.6 million of net foreign exchange loss related mainly to the Company's acquisition of Cisbio for fiscal year 2019. Acquisition-related interest expenses was $0.5 million in fiscal year 2020. These acquisition and divestiture-related costs were expensed as incurred and recorded in selling, general and administrative expenses and interest and other expense, net in the Company's consolidated statements of operations.

Nature of Operations and Accoun

Nature of Operations and Accounting Policies	12 Months Ended
	Jan. 03, 2021
Accounting Policies [Abstract]
Nature of Operations and Accounting Policies	Nature of Operations and Accounting Policies Nature of Operations: PerkinElmer, Inc. is a leading provider of products, services and solutions to the diagnostics, life sciences and applied markets. Through its advanced technologies and differentiated solutions, critical issues are addressed that help to improve lives and the world around us. The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation. The Company has two operating segments: Discovery & Analytical Solutions and Diagnostics. The Company's Discovery & Analytical Solutions segment focuses on service and innovating for customers spanning the life sciences and applied markets. The Company's Diagnostics segment is targeted towards meeting the needs of clinically-oriented customers, especially within the growing areas of reproductive health, emerging market diagnostics and applied genomics. The Company's fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ended January 3, 2021 ("fiscal year 2020") included 53 weeks. Each of the fiscal years ended December 29, 2019 ("fiscal year 2019") and December 30, 2018 ("fiscal year 2018") included 52 weeks. The fiscal year ending January 2, 2022 ("fiscal year 2021") will include 52 weeks. Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Revenue Recognition: The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. The Company recognizes revenue in an amount that reflects the consideration the Company expects to receive in exchange for the promised products or services when a performance obligation is satisfied by transferring control of those products or services to customers. See Note 2 below for additional details. Taxes that are collected by the Company from a customer and assessed by a governmental authority, that are both imposed on and concurrent with a specific revenue-producing transaction, are excluded from revenue. Warranty Costs: The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period. Shipping and Handling Costs: The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue. Inventories : Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements. Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings. When the Company determines during the period that previously undistributed earnings of certain international subsidiaries no longer meet the requirements of indefinite reinvestment, the Company recognizes the income tax expense in that period. The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 7 below for additional details. The Company uses an individual unit of account approach for releasing the income tax effects of unrealized gains and losses from accumulated other comprehensive income ("AOCI"). Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 8 years. Certain tooling costs are capitalized and amortized over a 3-year life, while repairs and maintenance costs are expensed. Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company's fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds. Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in AOCI, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net. Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. Measurement period adjustments are made in the period in which the amounts are determined and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed. Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of a trade name that is not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships and purchased technologies, which are being amortized over their estimated useful lives. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of the amortizing intangible asset . In addition, the Company evaluates the remaining useful life of its non-amortizing intangible asset at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful life of non-amortizing intangible asset is no longer indefinite, the asset will be tested for impairment. The intangible asset will then be amortized prospectively over its estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 13 below for additional details. Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 19 below. Marketable Securities and Investments: Investments in debt securities that are classified as available for sale are recorded at their fair values with unrealized gains and losses included in accumulated other comprehensive (loss) income until realized. Investments in equity securities are recorded at their fair values with unrealized holding gains and losses included in earnings. Investments in equity securities without a readily determinable fair value are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, with changes included in earnings. Upon the Company's adoption of ASU 2019-04, beginning on December 30, 2019, equity investments without readily determinable fair value are carried at cost minus impairment, if any. When an observable price change in orderly transactions for the identical or a similar investment of the same issuer has occurred, the Company elects to carry those equity investments at fair value as of the date that the observable transaction occurred. Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments. Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted. Research and Development: Research and development costs are expensed as incurred. The fair value of acquired IPR&D costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned. Restructuring and Other Costs: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with its growth strategy, the integration of its business units and its productivity initiatives. In connection with these initiatives, the Company has recorded restructuring and other charges, as more fully described in Note 5 below, which include employee severance, other exit costs as well as costs of terminating certain lease agreements or contracts and other costs associated with relocating facilities. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Prior to adoption of Accounting Standards Codification ("ASC") 842, Leases , costs related to lease terminations were recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceased use. Comprehensive Income: Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income. Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive (loss) income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements. The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of AOCI, as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. Leases: Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized based on the present value of the remaining lease payments over the lease term. When the Company's lease did not provide an implicit rate, the Company used its incremental borrowing rate in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component. Additionally, for certain equipment leases, the Company applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities. The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statement of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred. As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under ASC 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with ASC 842. Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In March 2020, the FASB issued Accounting Standards Update No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting ("ASU 2020-04"). This update provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in ASU 2020-04 provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The following optional expedients for applying the requirements of certain Topics or Industry Subtopics in the FASB's ASC are permitted for contracts that are modified because of reference rate reform and that meet certain scope guidance: (1) modifications of contracts within the scope of Topic 310, Receivables , and Topic 470, Debt , should be accounted for by prospectively adjusting the effective interest rate; and (2) modifications of contracts within the scope of Topic 840, Leases , and Topic 842, Leases , should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of lease payments. For other Topics or Industry Subtopics in the ASC, the amendments also include a general principle that permits an entity to consider contract modification due to reference rate reform to be an event that does not require contract remeasurement at the modification date or reassessment of a previous accounting determination. When elected, the optional expedients for contract modifications must be applied consistently for all eligible contracts or eligible transactions within the relevant Topic or Industry Subtopic. ASU 2020-04 is effective for any contract modifications or hedging relationships as of March 12, 2020 through December 31, 2022. In accordance with ASU 2020-04, the Company adopted the guidance as of March 12, 2020. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In March 2020, the FASB issued Accounting Standards Update No. 2020-03, Codification Improvements to Financial Instruments ("ASU 2020-03"). This guidance clarifies various ASC Topics related to financial instruments, including the following, among others: (1) Fair Value Option Disclosures: all entities are required to provide the fair value option disclosures in paragraphs 825-10-50-24 through 50-32 of the ASC; (2) Cross-Reference to Line-of-Credit or Revolving-Debt Arrangements Guidance in Subtopic 470-50, Modifications and Extinguishments : the amendments improve the understandability of the guidance; (3) Interaction of Topic 842 and Topic 326: the contractual term of a net investment in a lease determined in accordance with Topic 842, Leases should be the contractual term used to measure expected credit losses under Topic 326, Financial Instruments - Credit Losses ; and (4) Interaction of Topic 326 and Subtopic 860-20: the amendments to Subtopic 860- 20 clarify that when an entity regains control of financial assets sold, an allowance for credit losses should be recorded in accordance with Topic 326. For Fair Value Option Disclosures and Cross-Reference to Line-of-Credit or Revolving-Debt Arrangements Guidance, the provisions are effective upon issuance of this guidance. For Interaction of Topic 842 and Topic 326 and Interaction of Topic 326 and 860-20, the effective dates and transition requirements for the amendments are the same as the effective dates and transition requirements in ASU 2016-13, as described below. In accordance with ASU 2020-03, the Company adopted the guidance as of April 5, 2020. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In January 2020, the FASB issued Accounting Standards Update No. 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 ("ASU 2020-01"). This guidance addresses the accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The amendments clarify that: (a) an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method; and (b) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The provisions of this guidance are to be applied prospectively upon their effective date. ASU 2020-01 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those years. The standard was effective for the Company beginning on January 4, 2021, the first day of fiscal year 2021. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASU 2019-12 eliminates certain exceptions and adds guidance to reduce complexity in accounting for income taxes. Specifically, this guidance: (1) removes the intraperiod tax allocation exception to the incremental approach; (2) removes the ownership changes in investments exception in determining when a deferred tax liability is recognized after an investor in a foreign entity transitions to or from the equity method of accounting and applies this provision on a modified retrospective basis through a cumulative-effect adjustment to retained earnings at the beginning of the period of adoption; and (3) removes the exception to using the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. ASU 2019-12 also simplifies accounting principles by making other changes, including requiring an entity to: (1) evaluate whether a step-up in tax basis of goodwill relates to a business combination or a separate transaction; (2) make a policy election to not allocate consolidated income taxes when a member of a consolidated tax return is not subject to income tax and to apply this provision retrospectively to all periods presented; and (3) recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and apply this provision either retrospectively for all periods presented or on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The provisions of this guidance (except as specifically mentioned above) are to be applied prospectively upon their effective date. ASU 2019-12 is effective for annual reporting periods beginning after December 15, 2020, and interim p eriods within those years. The standard was effective for the Company beginning on January 4, 2021, the first day of fiscal year 2021. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In April 2019, the FASB issued Accounting Standards Update No. 2019-04, Codification Impro vem ents to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ("ASU 2019-04"). ASU 2019-04 clarifies certain aspects of previously issued accounting standards related to: (1) ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements ("ASU 2016-13"), in areas of accrued interest receivable, transfers of loans and debt securities between classifications, recoveries and prepayments, (2) ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities ("ASU 2017-12"), in areas of partial-term fair value hedges, fair value hedge basis adjustments, certain disclosures and transition requirements and (3) ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"), in areas of remeasurement of equity securities under ASC 820, Fair Value Measurement , when using the measurement alternative and remeasurement of equity securities at historical exchange rates. The amendments related to ASU 2016-13 are required to be adopted in conjunction with that accounting standards update, as further described below. Since the Company has already adopted ASU 2017-12 and ASU 2016-01, the related amendments in ASU 2019-04 are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted in any interim period. The amendments to ASU 2017-12 can either be adopted retrospectively as of the date of adoption of ASU 2017-12 or they c

Revenue from Contract with Cust

Revenue from Contract with Customer	12 Months Ended
	Jan. 03, 2021
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Revenue Nature of goods and services The following is a description of principal activities, by reportable segments, from which the Company generates its revenue. For more detailed information about the reportable segments, see Note 24. i. Discovery & Analytical Solutions The Discovery & Analytical Solutions segment of the Company principally generates revenue from sales of (a) instruments, consumables and services in the applied markets and (b) instruments, reagents, informatics, detection and imaging technologies, extended warranties, training and services in the life sciences market. Products and services may be sold separately or in bundled packages. The typical length of a contract for service is 12 to 36 months. For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis. The Company sells products and services predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including distributors. Payment terms granted to distributors are the same as those granted to end-customers and payments are not dependent upon the distributor's receipt of payment from their end-user customers. In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. The primary purpose of its invoicing terms is to provide customers with simplified and predictable ways of purchasing products and services, rather than to receive financing from the customers or to provide customers with financing. Examples include invoicing at the beginning of a subscription term with revenue recognized ratably over the contract period, and multi-year software licenses or software subscriptions that are invoiced annually with revenue recognized upfront. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical expedient and only adjusts the transaction price for the effects of the time value of money and only on contracts where the duration of financing is more than one year. Products and services Nature, timing of satisfaction of performance obligations, and significant payment terms Instruments For instruments that include installation, and if the installation meets the criteria to be considered a separate performance obligation, product revenue is generally recognized upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers, and installation revenue is recognized when the installation is complete. Certain of the Company's products require specialized installation and configuration at the customer's site. Revenue for these products is deferred until installation is complete and customer acceptance has been received. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days. Consumables and reagents The Company recognizes revenue from the sale of consumables and reagents upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 days. Software licenses and subscriptions Customers may purchase perpetual or term licenses, or subscribe to licenses, which provide customers with the same functionality and differ mainly in the duration over which the customer benefits from the software. The Company sells its software subscriptions or software licenses with maintenance services and, in some cases, with consulting services. The Company recognizes revenue for the software upfront at the point in time when the software is made available to the customer. For maintenance and consulting services, revenue is recognized ratably over the period in which the services are provided. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 60 days. Subscription contracts are typically billed annually on the anniversary date of the contract. Software subscriptions and maintenance service contracts are non-cancelable. Cloud services Cloud services, which allow customers to use hosted software over the contract period without taking possession of the software, are provided on either a subscription or consumption basis. Revenue related to cloud services provided on a subscription basis is recognized ratably over the contract period. Revenue related to cloud services provided on a consumption basis, such as the amount of storage used in a period, is recognized based on the customer utilization of such resources. Payment terms are generally net 30 days from signing of contract and contracts are non-cancelable. Extended warranty The Company recognizes revenue for extended warranties on a straight-line basis over the extended warranty period in service revenue. In the majority of countries in which the Company operates, the customary warranty period is one year and the extended warranty covers periods beyond year one. Customers typically pay for extended warranties on an annual basis over the term of the warranty. In general, customers can cancel the extended warranty at any time with 30 days notice without significant penalty. Laboratory services and training The Company's service offerings include service contracts, field service, including related time and materials, and training. The Company recognizes revenue as the services are performed. Revenue for the service contracts is recognized over the contract period or at a point in time when the service is billable based on time and materials. The Company recognizes revenue as training is provided in service revenue. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 60 days. In general, customers can cancel the service contracts at any time with 30 to 90 days notice without significant penalty. ii. Diagnostics The Diagnostics segment of the Company principally generates revenue from sales of instruments, solutions, consumables, reagents, extended warranties and services in the diagnostics market. Products and services may be sold separately or in bundled packages. For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis. The Company sells products and services predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including distributors. Payment terms granted to distributors are the same as those granted to end-customers and payments are not dependent upon the distributor's receipt of payment from their end-user customers. In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. The primary purpose of its invoicing terms is to provide customers with simplified and predictable ways of purchasing products and services, rather than to receive financing from the customers or to provide customers with financing. Examples include invoicing at the beginning of a storage period with revenue recognized ratably over the contract period. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical expedient and only adjusts the transaction price for the effects of the time value of money and only on contracts where the duration of financing is more than one year. Products and services Nature, timing of satisfaction of performance obligations, and significant payment terms Instruments For instruments that include installation, and if the installation meets the criteria to be considered a separate performance obligation, product revenue is generally recognized upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers, and installation revenue is recognized when the installation is complete. Certain of the Company's products require specialized installation and configuration at the customer's site. Revenue for these products is deferred until installation is complete and customer acceptance has been received. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days. Consumables and reagents The Company recognizes revenue from the sale of consumables and reagents upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 days. Solutions When the Company sells the instrument and reagents that work only on those instruments to a customer or distributor, the Company considers the instrument and reagents as separate performance obligations. The Company recognizes revenue when an instrument is sold to the customer upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers. Revenue from the sale of reagents is also recognized at the time of delivery or when title has transferred to the customer. Payment terms for instrument and reagent sales are usually net 30 days from invoice date. Extended warranty The Company recognizes revenue for extended warranties on a straight-line basis over the extended warranty period in service revenue. In the majority of countries in which the Company operates, the customary warranty period is one year and the extended warranty covers periods beyond year one. Customers typically pay for extended warranties on an annual basis over the term of the warranty. In general, customers can cancel the extended warranty at any time with 30 days notice without significant penalty. Services The Company's service offerings include genetic testing, COVID-19 testing, cord blood processing and storage, and training. The Company recognizes revenue for the genetic testing, cord blood processing and training as the services are performed in service revenue. Revenue for the storage contracts are recognized over the contract period. Storage is typically for a period of 1, 20, or 25 years or lifetime. Lifetime storage is recognized over a certain period that is based on the life expectancy estimate from Social Security data. For genetic testing and cord blood processing, customers pay the fee in full at the point of sale. The fee is non-refundable unless the cord blood is non-viable for storage. For storage, customers are required to pay the storage fees in full upfront. Storage fees are refundable to the customer on a pro-rated basis if the contract is canceled. In August 2020, the Company entered into a contract with the State of California to perform COVID-19 testing for a term of 14 months with automatic renewal for two successive terms of one year unless the State of California provides notice of termination within 90 days prior to expiration of the current term. The Company has determined that providing monthly testing capacity and individual tests are two separate performance obligations. The pricing in the contract is variable based on the testing capacity and the number of testing results provided in a month. The customer is entitled to a credit on previous tests such that, at the conclusion of the contract, the customer will pay, on average, the price per test result based on the highest volume. The Company allocates the contract consideration to each of these performance obligations based on estimated stand-alone selling price. As the stand-alone selling price is not directly observable, the Company estimates stand-alone selling prices based on the expected cost plus margin approach. The Company recognizes revenue for the monthly testing capacity on a per day basis once the Company has confirmed that it ha s met the requested capacity level. The Company recognizes revenue for the individual tests as the tests are performed. The amount recognized per test is based on the Company's forecast of tests to be performed per month over the contract period. The contract includes upfront prepayments based on completion of milestones that are non-refundable except due to breach of contract. These prepayments are recorded as contract liabilities and will be recognized as revenue on a per test basis. Monthly testing capacity is billed one month in advance and individual tests are billed monthly for the duration of the contract. Payment terms are net 45 days from invoice date. Disaggregation of revenue In the following tables, revenue is disaggregated by primary geographical market, end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments revenue. Reportable Segments For the fiscal year ended January 3, 2021 December 29, 2019 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 695,960 $ 750,641 $ 1,446,601 $ 717,205 $ 401,591 $ 1,118,796 Europe 490,789 864,687 1,355,476 495,768 291,610 787,378 Asia 529,054 451,614 980,668 533,188 444,311 977,499 $ 1,715,803 $ 2,066,942 $ 3,782,745 $ 1,746,161 $ 1,137,512 $ 2,883,673 Primary end-markets Diagnostics $ — $ 2,066,942 $ 2,066,942 $ — $ 1,137,512 $ 1,137,512 Life sciences 1,032,209 — 1,032,209 977,200 — 977,200 Applied markets 683,594 — 683,594 768,961 — 768,961 $ 1,715,803 $ 2,066,942 $ 3,782,745 $ 1,746,161 $ 1,137,512 $ 2,883,673 Timing of revenue recognition Products and services transferred at a point in time $ 1,195,249 $ 1,891,482 $ 3,086,731 $ 1,276,499 $ 1,053,974 $ 2,330,473 Services transferred over time 520,554 175,460 696,014 469,662 83,538 553,200 $ 1,715,803 $ 2,066,942 $ 3,782,745 $ 1,746,161 $ 1,137,512 $ 2,883,673 Contract Balances Contract assets: The unbilled receivables (contract assets) primarily relate to the Company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheets. The balances of contract assets as of January 3, 2021 and December 29, 2019 were $59.5 million and $37.0 million, respectively. The amount of unbilled receivables recognized at the beginning of fiscal year 2020 that were transferred to trade receivables during the fiscal year ended January 3, 2021 was $33.2 million. The increase in unbilled receivables during the fiscal year ended January 3, 2021 as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period, amounted to $55.7 million. The amount of unbilled receivables recognized at the beginning of fiscal year 2019 that were transferred to trade receivables during the fiscal year ended December 29, 2019 was $17.3 million. The increase in unbilled receivables during the fiscal year ended December 29, 2019 as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period, amounted to $22.4 million. Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related installation for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in "Accounts payable" or "Accrued expenses and other current liabilities" or as long-term in "Long-term liabilities" in the consolidated balance sheets based on the timing of when the Company expects to recognize revenue. The balances of contract liabilities as of January 3, 2021 and December 29, 2019 were $238.1 million and $29.9 million, respectively. The increase in contract liabilities during the fiscal year ended January 3, 2021 due to cash received, excluding amounts recognized as revenue during the period, was $235.5 million. The amount of revenue recognized during the fiscal year ended January 3, 2021 that was included in the contract liability balance at the beginning of the period was $27.3 million. The increase in contract liabilities during the fiscal year ended December 29, 2019 due to cash received, excluding amounts recognized as revenue during the period, was $20.4 million. The amount of revenue recognized during the fiscal year ended December 29, 2019 that was included in the contract liability balance at the beginning of the period was $21.2 million. Contract costs: The Company recognizes the incremental costs of obtaining a contract with a customer as an asset if it expects the benefit of those costs to be longer than one year. The Company determined that certain sales incentive programs meet the requirements to be capitalized. Total capitalized costs to obtain a contract were immaterial during the period and are included in other current and long-term assets on the consolidated balance sheet. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the Company's internal sales force compensation program, as the Company determined that annual compensation is commensurate with annual sales activities. Transaction price allocated to the remaining performance obligations The Company applies the practical expedient in ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized beyond one year in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders and noncancelable software subscriptions and cloud service contracts.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Jan. 03, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Disposition of Businesses and Assets As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. When the discontinued operations represented a strategic shift that will have a major effect on the Company's operations and financial statements, the Company has accounted for these businesses as discontinued operations and accordingly, has presented the results of operations and related cash flows as discontinued operations. Any business deemed to be a discontinued operation prior to the adoption of Accounting Standards Update 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of An Entity, continues to be reported as a discontinued operation, and the results of operations and related cash flows are presented as discontinued operations for all periods presented. Any remaining assets and liabilities of these businesses have been presented separately, and are reflected within assets and liabilities from discontinued operations in the accompanying consolidated balance sheets as of January 3, 2021 and December 29, 2019. The Company recorded the following pre-tax losses, which have been reported as a net loss on disposition of discontinued operations during the three fiscal years ended: January 3, December 29, December 30, (In thousands) Loss on disposition of the Medical Imaging business $ — $ — $ (793) Loss on disposition of Fluid Sciences business (76) — (66) Loss on disposition of discontinued operations before income taxes $ (76) $ — $ (859) During fiscal year 2018, the Company completed the sale of substantially all of the assets and liabilities related to its multispectral imaging business for aggregate consideration of $37.3 million, recognizing a pre-tax gain of $13.0 million. The pre-tax gain is included in interest and other expense, net in the consolidated statement of operations. The multispectral imaging business was a component of the Company's Discovery & Analytical Solutions segment. The divestiture of the multispectral imaging business has not been classified as a discontinued operation in this Form 10-K because the disposition does not represent a strategic shift that will have a major effect on the Company's operations and financial statements. The Company recorded a provision for (benefit from) income taxes of $0.1 million, $0.2 million and $(1.3) million on discontinued operations and dispositions in fiscal years 2020, 2019 and 2018, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Jan. 03, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position. The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended: January 3, December 29, December 30, (In thousands) Unrecognized tax benefits, beginning of year $ 35,547 $ 33,009 $ 30,308 Gross increases—tax positions in prior periods 4,974 4,433 6,931 Gross decreases—tax positions in prior periods (2,471) (2,183) (1,622) Gross increases—current-period tax positions 309 152 — Settlements — (45) (2,253) Lapse of statute of limitations — — (181) Foreign currency translation adjustments 414 181 (174) Unrecognized tax benefits, end of year $ 38,773 $ 35,547 $ 33,009 The Company classifies interest and penalties as a component of income tax expense. At January 3, 2021 and December 29, 2019, the Company had accrued interest and penalties of $5.8 million and $4.1 million, respectively. During fiscal years 2020, 2019 and 2018, the Company recognized a net expense of $4.7 million, $1.6 million and $0.4 million, respectively, for interest and penalties in its total tax provision which includes settlements and statutes of limitations that had lapsed. At January 3, 2021, the Company had gross tax effected unrecognized tax benefits of $38.8 million, of which $37.1 million, if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations. The Company believes that it is reasonably possible that approximately $0.2 million of its uncertain tax positions at January 3, 2021, including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2010 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as China, Finland, Germany, Luxembourg, The Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction. During fiscal year 2020, the Company recorded net discrete income tax expense of $10.8 million, which primarily consisted of a $15.2 million assessment related to foreign entities for which the Company had previously believed, in error, that the relevant tax authority had granted fiscal unity to consolidate in fiscal years 2019 and 2018. The Company determined that this is not material to any of the previous periods or the current fiscal year. The Company filed an appeal for relief on this matter with the foreign tax authority but cannot be assured of a favorable outcome and has therefore recorded the full impact in the current year’s tax provision as a result of not being granted fiscal unity in fiscal years 2019 and 2018. The Company also provided for interest on uncertain tax positions of $4.5 million, foreign tax rate changes of $2.5 million, return to provision adjustments of $1.2 million and other tax matters of $1.6 million, offset by recognition of excess tax benefits on stock compensation of $11.7 million and a valuation allowance reversal of $2.5 million. During fiscal years 2019 and 2018, the Company recorded net discrete income tax benefits of $23.4 million and $8.1 million, respectively. The $23.4 million tax benefits in fiscal year 2019 was primarily due to a valuation allowance reversal of $12.3 million, recognition of excess tax benefits on stock compensation of $4.9 million, return to provision adjustments of $6.7 million and benefits from tax elections made during fiscal year 2019 of $3.7 million, partially offset by a tax expense of $2.7 million related to the one-time transition tax under the Tax Cut and Jobs Act ("Tax Act") and additional discrete expense of $1.4 million expense related to other tax matters. The $8.1 million of tax benefits in fiscal year 2018 was primarily due to a discrete benefit of $7.2 million related to the recognition of excess tax benefits on stock compensation, along with an additional discrete benefit of $2.0 million as a result of the Tax Act, partially offset by discrete benefits of $1.1 million related to other tax matters. The components of income from continuing operations before income taxes were as follows for the fiscal years ended: January 3, December 29, December 30, (In thousands) U.S. $ 183,452 $ 29,252 $ 32,627 Non-U.S. 722,912 207,890 225,056 Total $ 906,364 $ 237,142 $ 257,683 On a U.S. income tax basis, the Company has reported significant taxable income over the three-year period ended January 3, 2021. The Company has utilized tax attributes to minimize cash taxes paid on that taxable income. The components of the provision for income taxes on continuing operations were as follows: Current Deferred Total (In thousands) Fiscal year ended January 3, 2021 Federal $ 21,262 $ 15,951 $ 37,213 State 13,688 (967) 12,721 Non-U.S. 172,437 (44,105) 128,332 Total $ 207,387 $ (29,121) $ 178,266 Fiscal year ended December 29, 2019 Federal $ 3,735 $ (267) $ 3,468 State 4,425 (1,574) 2,851 Non-U.S. 62,582 (59,512) 3,070 Total $ 70,742 $ (61,353) $ 9,389 Fiscal year ended December 30, 2018 Federal $ 7,938 $ (5,250) $ 2,688 State 2,345 2,572 4,917 Non-U.S. 61,028 (48,425) 12,603 Total $ 71,311 $ (51,103) $ 20,208 The total provision for (benefit from) income taxes included in the consolidated financial statements is as follows for the fiscal years ended: January 3, December 29, December 30, (In thousands) Continuing operations $ 178,266 $ 9,389 $ 20,208 Discontinued operations 135 195 (1,311) Total $ 178,401 $ 9,584 $ 18,897 A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended: January 3, December 29, December 30, (In thousands) Tax at statutory rate $ 190,339 $ 49,799 $ 54,114 Non-U.S. rate differential, net (40,216) (32,124) (27,281) U.S. taxation of multinational operations 9,050 4,251 7,047 State income taxes, net 13,306 1,941 2,028 Prior year tax matters 8,262 (5,103) 1,124 Effect of stock compensation (8,818) (2,053) (6,331) General business tax credits (4,136) (4,325) (3,738) Change in valuation allowance 10 (1,117) (759) Foreign consolidations 15,222 — — Tax elections — (3,700) — Impact of U.S. Tax Act — 2,718 (2,025) Others, net (4,753) (898) (3,971) Total $ 178,266 $ 9,389 $ 20,208 The variation in the Company's effective tax rate for each year is primarily a result of the recognition of earnings in foreign jurisdictions, predominantly Finland, Singapore and the United Kingdom in fiscal year 2020 and Finland, Singapore and The Netherlands in fiscal years 2019 and 2018, which are taxed at rates lower than the U.S. federal statutory rate, resulting in a benefit from income taxes of $42.5 million in fiscal year 2020 , $16.7 million in fiscal year 2019 and $18.7 million in fiscal year 2018. These amounts include $21.8 million in fiscal year 2020, $10.4 million in fiscal year 2019 and $10.3 million in fiscal year 2018 of benefits derived from tax holidays in China and Singapore. The effect of these benefits, derived from tax holidays, on basic and diluted earnings per s hare for fiscal year 2020 was $0.20 and $0.19, respectively, for fiscal year 2019 was $0.09 and $0.09, respectively, and for fiscal year 2018 was $0.09 and $0.09, respectively. The tax holiday in China is renewed every three years. The Company expects to renew the tax holiday for two of the Company's subsidiaries in China that expired in fiscal year 2020. The t ax holiday for one of the Company's subsidiaries in Singapore is scheduled to expire in fiscal year 2023. The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of January 3, 2021 and December 29, 2019 were as follows: January 3, December 29, (In thousands) Deferred tax assets: Inventory $ 4,788 $ 4,662 Reserves and accruals 51,107 46,817 Accrued compensation 20,881 18,953 Net operating loss and credit carryforwards 131,884 116,751 Accrued pension 34,192 35,890 Restructuring reserve 1,579 2,983 Deferred revenue 29,838 30,412 Operating lease liabilities 42,220 46,477 Unrealized foreign exchange loss 21,614 — Total deferred tax assets 338,103 302,945 Deferred tax liabilities: Postretirement health benefits (8,168) (4,106) Depreciation and amortization (355,876) (330,768) Operating lease right-of-use assets (38,598) (42,774) All other, net (4,160) (1,780) Total deferred tax liabilities (406,802) (379,428) Valuation allowance (99,740) (88,449) Net deferred tax liabilities $ (168,439) $ (164,932) The components of net deferred tax liabilities as of January 3, 2021 and December 29, 2019 were recognized in the consolidated balance sheets as follows: January 3, December 29, (In thousands) Other assets, net $ 65,518 $ 60,004 Long-term liabilities (233,957) (224,936) Total $ (168,439) $ (164,932) At January 3, 2021, for income tax return purposes, the Company had U.S. federal net operating loss carryforwards of $36.6 million , state net operating loss carryforw ards of $11.5 million, foreig n ne t operating loss carryforwards of $495.3 million, state tax credit carryforwards of $15.3 million, general business tax credit carryforwards of $0.3 million, and foreign tax credit carryforwards of $0.1 million. These are subject to expiration in years ranging from 2021 to 2038, and without expiration for certain foreign net operating loss carryforwards and certain state c redit carryforwards. Valuation allowances take into consideration limitations imposed upon the use of the tax attributes and reduce the value of such items to the likely net realizable amount. The Company regularly evaluates positive and negative evidence available to determine if valuation allowances are required or if existing valuation allowances are no longer required. Valuation allowances have been provided on state net operating loss and state tax credit carryforwards and on certain foreign tax attributes that the Company has determined are not more likely than not to be realized. The increase in the valuation allowance of $11.3 million in fiscal year 2020 is primarily due to a net build of tax attributes related to the generation and utilization of net operating loss carryforwards by some of the Company's non-U.S. subsidiaries, as well as realization of certain U.S. state tax credit carryforwards. The components of net deferred tax (liabilities) assets as of January 3, 2021 and December 29, 2019 were as follows: January 3, December 29, (In thousands) U.S. $ 50,302 $ 43,683 Non-U.S. (218,741) (208,615) Total $ (168,439) $ (164,932)

Earnings Per Share

Earnings Per Share	12 Months Ended
	Jan. 03, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended: January 3, December 29, December 30, (In thousands) Number of common shares—basic 111,514 110,827 110,561 Effect of dilutive securities: Stock options 466 541 761 Restricted stock awards 105 133 212 Number of common shares—diluted 112,085 111,501 111,534 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 220 364 349

Accounts Receivable, Net

Accounts Receivable, Net	12 Months Ended
	Jan. 03, 2021
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable, net as of January 3, 2021 and December 29, 2019 consisted of the following: January 3, December 29, (In thousands) Accounts receivable, net, current $ 1,155,109 $ 725,184 Long-term accounts receivable, net, included in Other assets 22,510 19,677 Total accounts receivable, net $ 1,177,619 $ 744,861 Accounts receivable were net of reserves for doubtful accounts of $47.6 million and $35.2 million as of January 3, 2021 and December 29, 2019, respectively.

Inventories, Net

Inventories, Net	12 Months Ended
	Jan. 03, 2021
Inventory Disclosure [Abstract]
Inventories, Net	Inventories Inventories as of January 3, 2021 and December 29, 2019 consisted of the following: January 3, December 29, (In thousands) Raw materials $ 205,022 $ 130,673 Work in progress 35,160 26,409 Finished goods 274,385 199,855 Total inventories $ 514,567 $ 356,937

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Jan. 03, 2021
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment as of January 3, 2021 and December 29, 2019, consisted of the following: January 3, December 29, (In thousands) At cost: Land $ 3,937 $ 5,272 Building and leasehold improvements 291,526 250,639 Machinery and equipment 522,734 445,669 Total property, plant and equipment 818,197 701,580 Accumulated depreciation (449,893) (383,357) Total property, plant and equipment, net $ 368,304 $ 318,223 Depreciation expense on property, plant and equipment for the fiscal years ended January 3, 2021, December 29, 2019 and December 30, 2018 was $54.0 million, $49.7 million and $44.7 million, respectively.

Marketable Securities and Inves

Marketable Securities and Investments	12 Months Ended
	Jan. 03, 2021
Marketable Securities [Abstract]
Marketable Securities and Investments	Marketable Securities and Investments Investments as of January 3, 2021 and December 29, 2019 consisted of the following: January 3, December 29, (In thousands) Marketable securities $ 2,154 $ 2,906 Equity investments 48,626 29,228 $ 50,780 $ 32,134 Marketable securities. Marketable securities include equity and fixed-income securities held to meet obligations associated with the Company’s supplemental executive retirement plan and other deferred compensation plans. The Company has, accordingly, classified these securities as long-term. The net unrealized holding gain and loss on marketable securities, net of deferred income taxes, reported as a component of other comprehensive income (loss) in the statements of stockholders’ equity, were not material in fiscal years 2020 and 2019. The proceeds from the sales of securities and the related gains and losses are not material for any period presented. Marketable securities classified as available for sale as of January 3, 2021 and December 29, 2019 consisted of the following: Market Value Gross Unrealized Holding Cost Gains (Losses) (In thousands) January 3, 2021 Equity securities $ 203 $ 584 $ — $ (381) Fixed-income securities 7 7 — — Other 1,944 2,007 — (63) $ 2,154 $ 2,598 $ — $ (444) December 29, 2019 Equity securities $ 752 $ 1,109 $ — $ (357) Fixed-income securities 7 7 — — Other 2,147 2,210 — (63) $ 2,906 $ 3,326 $ — $ (420) Equity investments. The Company has equity interests in privately-held entities over which the Company neither has significant influence nor control. Equity investments without readily determinable fair values as of January 3, 2021 and December 29, 2019 consisted of the following: January 3, December 29, (In thousands) Equity investments, carried at cost minus impairment, if any $ 27,438 $ 29,228 Equity investments, carried at fair value 21,188 — $ 48,626 $ 29,228 The amount of upward adjustments during fiscal years 2020 and 2019 were $35,000 and $8.2 million, respectively. The cumulative amount of upward adjustments as of each of January 3, 2021 and December 29, 2019 was $8.2 million. The amount of impairments and downward adjustments during fiscal year 2019 was $4.9 million. The cumulative amount of impairments and downward adjustments as of each of January 3, 2021 and December 29, 2019 was $4.9 million.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	12 Months Ended
	Jan. 03, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. The Company performed its annual impairment testing for its reporting units as of January 1, 2020, its annual impairment testing date for fiscal year 2020. The Company concluded based on the first step of the process that there was no goodwill impairment, and the fair value exceeded the carrying value by more than 20% for each reporting unit, except for the Meizheng Group reporting unit. The fair value of the Meizheng Group reporting unit approximated its carrying value given that the reporting unit was a relatively new acquisition. At January 4, 2021, the Tulip reporting unit, which had a goodwill balance of $77.8 million at January 3, 2021, had a fair value that was between 10% and 20% more than its carrying value. Tulip is at increased risk of an impairment charge given its ongoing weakness due to the impact of COVID-19. Despite the increased risk associated with this reporting unit, the Company does not believe there will be a significant change in the key estimates or assumptions driving the fair value of this reporting unit that would lead to a material impairment charge. While the Company believes that its estimates of current value are reasonable, if actual results differ from the estimates and judgments used, including such items as future cash flows and the volatility inherent in markets which the Company serves, impairment charges against the carrying value of those assets could be required in the future. Non-amortizing intangibles are also subject to an annual impairment test. The Company consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible asset. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of the amortizing intangible asset. In addition, the Company evaluates the remaining useful life of our non-amortizing intangible asset at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful life of our non-amortizing intangible asset is no longer indefinite, the asset will be tested for impairment. This intangible asset will then be amortized prospectively over its estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. The changes in the carrying amount of goodwill for fiscal years 2020 and 2019 are as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Balance at December 30, 2018 $ 1,334,992 $ 1,617,616 $ 2,952,608 Foreign currency translation (8,559) (9,725) (18,284) Acquisitions, earnouts and other 172,387 4,516 176,903 Balance at December 29, 2019 1,498,820 1,612,407 3,111,227 Foreign currency translation 58,086 62,596 120,682 Acquisitions, earnouts and other 198,981 16,224 215,205 Balance at January 3, 2021 $ 1,755,887 $ 1,691,227 $ 3,447,114 Identifiable intangible asset balances at January 3, 2021 by category and segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Patents $ 28,146 $ 2,709 $ 30,855 Less: Accumulated amortization (27,933) (507) (28,440) Net patents 213 2,202 2,415 Trade names and trademarks 51,143 47,518 98,661 Less: Accumulated amortization (31,859) (16,947) (48,806) Net trade names and trademarks 19,284 30,571 49,855 Licenses 50,468 8,232 58,700 Less: Accumulated amortization (49,317) (3,135) (52,452) Net licenses 1,151 5,097 6,248 Core technology 456,607 333,192 789,799 Less: Accumulated amortization (232,648) (166,344) (398,992) Net core technology 223,959 166,848 390,807 Customer relationships 475,748 881,912 1,357,660 Less: Accumulated amortization (239,428) (283,392) (522,820) Net customer relationships 236,320 598,520 834,840 IPR&D 10,944 — 10,944 Net amortizable intangible assets 491,871 803,238 1,295,109 Non-amortizing intangible asset: Trade name 70,584 — 70,584 Total $ 562,455 $ 803,238 $ 1,365,693 Identifiable intangible asset balances at December 29, 2019 by category and segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Patents $ 28,122 $ 2,709 $ 30,831 Less: Accumulated amortization (27,142) (281) (27,423) Net patents 980 2,428 3,408 Trade names and trademarks 39,859 48,138 87,997 Less: Accumulated amortization (23,632) (16,663) (40,295) Net trade names and trademarks 16,227 31,475 47,702 Licenses 50,393 8,103 58,496 Less: Accumulated amortization (47,607) (2,126) (49,733) Net licenses 2,786 5,977 8,763 Core technology 390,116 298,973 689,089 Less: Accumulated amortization (205,263) (115,663) (320,926) Net core technology 184,853 183,310 368,163 Customer relationships 313,898 847,628 1,161,526 Less: Accumulated amortization (156,967) (221,221) (378,188) Net customer relationships 156,931 626,407 783,338 IPR&D — 1,328 1,328 Net amortizable intangible assets 361,777 850,925 1,212,702 Non-amortizing intangible asset: Trade name 70,584 — 70,584 Total $ 432,361 $ 850,925 $ 1,283,286 Total amortization expense related to definite-lived intangible assets was $192.6 million in fiscal year 2020, $164.3 million in fiscal year 2019 and $135.9 million in fiscal year 2018. Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $211.0 million in fiscal year 2021, $191.4 million in fiscal year 2022, $164.0 million in fiscal year 2023, $139.9 million in fiscal year 2024, and $111.9 million in fiscal year 2025.

Debt

Debt	12 Months Ended
	Jan. 03, 2021
Debt Disclosure [Abstract]
Debt	Debt Senior Unsecured Revolving Credit Facility. The Company's senior unsecured revolving credit facility provides for $1.0 billion of revolving loans that may be either US Dollar Base Rate loans or Eurocurrency Rate loans, as those terms are defined in the credit agreement, and has an initial maturity of September 17, 2024. As of January 3, 2021, undrawn letters of credit in the aggregate amount of $11.0 million were treated as issued and outstanding when calculating the borrowing availability under the facility. As of January 3, 2021, the Company had $830.4 million available for additional borrowing under the facility. The Company plans to use the senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates on the Eurocurrency Rate loans are based on the Eurocurrency Rate at the time of borrowing, plus a percentage spread based on the credit rating of the Company's debt. The interest rates on the US Dollar Base Rate loans are based on the US Dollar Base Rate at the time of borrowing, plus a percentage spread based on the credit rating of the Company's debt. The base rate is the higher of (i) the Federal Funds Rate (as defined in the credit agreement) plus 50 basis points (ii) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its "prime rate," or (iii) the Eurocurrency Rate plus 1.00%. The Eurocurrency margin as of January 3, 2021 was 101.5 basis points. The weighted average Eurocurrency interest rate as of January 3, 2021 was 0.02%, resulting in a weighted average effective Eurocurrency Rate, including the margin, of 1.04%, which was the interest applicable to the borrowings outstanding as of January 3, 2021. As of January 3, 2021, the senior unsecured revolving credit facility had outstanding borrowings of $158.6 million, and $2.6 million of unamortized debt issuance costs. As of December 29, 2019, the senior unsecured revolving credit facility had $325.4 million of outstanding borrowings, and $3.4 million of unamortized debt issuance costs. The credit agreement for the facility contains affirmative, negative and financial covenants and events of default. The financial covenants include a debt-to-capital ratio that remains applicable for so long as the Company's debt is rated as investment grade. In the event that the Company's debt is not rated as investment grade, the debt-to-capital ratio covenant is replaced with a maximum consolidated leverage ratio covenant and a minimum consolidated interest coverage ratio covenant. 1.875% Senior Unsecured Notes due 2026. On July 19, 2016, the Company issued €500.0 million aggregate principal amount of senior unsecured notes due in 2026 (the “2026 Notes”) in a registered public offering and received approximately €492.3 million of net proceeds from the issuance. The 2026 Notes were issued at 99.118% of the principal amount, which resulted in a discount of €4.4 million. The 2026 Notes mature in July 2026 and bear interest at an annual rate of 1.875%. Interest on the 2026 Notes is payable annually on July 19th each year. The proceeds from the 2026 Notes were used to pay in full the outstanding balance of the Company's previous senior unsecured revolving credit facility. As of January 3, 2021, the 2026 Notes had an aggregate carrying value of $604.7 million, net of $3.3 million of unamortized original issue discount and $2.8 million of unamortized debt issuance costs. As of December 29, 2019, the 2026 Notes had an aggregate carrying value of $552.2 million, net of $3.5 million of unamortized original issue discount and $3.3 million of unamortized debt issuance costs. Prior to April 19, 2026 (three months prior to their maturity date), the Company may redeem the 2026 Notes in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2026 Notes to be redeemed, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2026 Notes being redeemed, discounted on an annual basis, at the applicable Comparable Government Bond Rate (as defined in the indenture governing the 2026 Notes) plus 35 basis points; plus, in each case, accrued and unpaid interest. In addition, at any time on or after April 19, 2026 (three months prior to their maturity date), the Company may redeem the 2026 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2026 Notes due to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2026 Notes) and a contemporaneous downgrade of the 2026 Notes below investment grade, the Company will, in certain circumstances, make an offer to purchase the 2026 Notes at a price equal to 101% of their principal amount plus any accrued and unpaid interest. 0.6% Senior Unsecured Notes due in 2021. On April 11, 2018, the Company issued €300.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “2021 Notes”) in a registered public offering and received approximately €298.7 million of net proceeds from the issuance. The 2021 Notes were issued at 99.95% of the principal amount, which resulted in a discount of €0.2 million. As of January 3, 2021, the 2021 Notes had an aggregate carrying value of $366.2 million, net of $16,200 of unamortized original issue discount and $0.2 million of unamortized debt issuance costs. As of December 29, 2019, the 2021 Notes had an aggregate carrying value of $334.2 million, net of $0.1 million of unamortized original issue discount and $1.1 million of unamortized debt issuance costs. The 2021 Notes mature in April 2021 and bear interest at an annual rate of 0.6%. Interest on the 2021 Notes is payable annually on April 9th each year. Prior to the maturity date of the 2021 Notes, the Company may redeem them in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2021 Notes being redeemed, discounted on an annual basis, at the applicable Comparable Government Bond Rate (as defined in the indenture governing the 2021 Notes) plus 15 basis points; plus, in each case, accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2021 Notes) and a contemporaneous downgrade of the 2021 Notes below investment grade, the Company will, in certain circumstances, make an offer to purchase the 2021 Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest. 3.3% Senior Unsecured Notes due in 2029. On September 12, 2019, the Company issued $850.0 million aggregate principal amount of senior unsecured notes due in 2029 (the "2029 Notes”) in a registered public offering and received $847.2 million of net proceeds from the issuance. The 2029 Notes were issued at 99.67% of the principal amount, which resulted in a discount of $2.8 million. As of January 3, 2021, the 2029 Notes had an aggregate carrying value of $840.6 million, net of $2.5 million of unamortized original issue discount and $6.9 million of unamortized debt issuance costs. As of December 29, 2019, the 2029 Notes had an aggregate carrying value of $839.9 million, net of $2.7 million of unamortized original issue discount and $7.4 million of unamortized debt issuance costs. The 2029 Notes mature in September 2029 and bear interest at an annual rate of 3.3%. Interest on the 2029 Notes is payable semi-annually on March 15th and September 15th each year. Proceeds from the 2029 Notes were used to repay all outstanding borrowings under the Company’s previous senior unsecured revolving credit facility with the remaining proceeds used in the redemption of the 5% senior unsecured notes that were due in November 2021. Prior to June 15, 2029 (three months prior to their maturity date), the Company may redeem the 2029 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2029 Notes to be redeemed, and (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2029 Notes being redeemed (not including any portion of such payments of interest accrued but unpaid as of the date of redemption) assuming that such 2029 Notes matured on June 15, 2029, discounted at the date of redemption on a semi-annual basis (assuming a 360-day year of twelve 30-day months), at the Treasury Rate (as defined in the indenture governing the 2029 Notes) plus 25 basis points, plus accrued and unpaid interest. At any time on or after June 15, 2029 (three months prior to their maturity date), the Company may redeem the 2029 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2029 Notes) and a contemporaneous downgrade of the 2029 Notes below investment grade, each holder of 2029 Notes will have the right to require the Company to repurchase such holder's 2029 Notes for 101% of their principal amount, plus accrued and unpaid interest. Other Debt Facilities. The Company's other debt facilities include Euro-denominated bank loans with an aggregate carrying value of $17.0 million (or €13.9 million) and $23.8 million (or €21.3 million) as of January 3, 2021 and December 29, 2019, respectively. These bank loans are primarily utilized for financing fixed assets and are required to be repaid in monthly or quarterly installments with maturity dates extending to 2028. Of these bank loans, loans in the aggregate amount of $17.0 million bear fixed interest rates between 1.1% and 4.3% and a loan in the amount of $0.1 million bears a variable interest rate based on the Euribor rate plus a margin of 1.5%. An aggregate amount of $4.8 million of the bank loans are secured by mortgages on real property and the remaining $12.2 million are unsecured. Certain credit agreements for the unsecured bank loans include financial covenants which are based on an equity ratio or an equity ratio and minimum interest coverage ratio. In addition, the Company had secured bank loans in the aggregate amount of $6.1 million and $1.9 million as of January 3, 2021 and December 29, 2019, respectively. The secured bank loans of $6.1 million bear fixed annual interest rates between 1.95% and 8.94% and are required to be repaid in monthly installments until 2027. The following table summarizes the maturities of the Company’s indebtedness as of January 3, 2021: Sr. Unsecured 2021 2026 Notes 2029 Notes Other Debt Facilities Total (In thousands) 2021 $ — $ 366,450 $ — $ — $ 14,743 $ 381,193 2022 — — — — 4,075 4,075 2023 — — — — 2,457 2,457 2024 158,595 — — — 1,372 159,967 2025 — — — — 230 230 2026 and thereafter — — 610,750 850,000 282 1,461,032 Total before unamortized discount and debt issuance costs 158,595 366,450 610,750 850,000 23,159 2,008,954 Unamortized discount and debt issuance costs (2,621) (245) (6,035) (9,404) — (18,305) Total $ 155,974 $ 366,205 $ 604,715 $ 840,596 $ 23,159 $ 1,990,649

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Jan. 03, 2021
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities as of January 3, 2021 and December 29, 2019 consisted of the following: January 3, December 29, (In thousands) Payroll and incentives $ 96,502 $ 77,892 Employee benefits 47,489 42,405 Deferred revenue 203,927 164,261 Federal, non-U.S. and state income taxes 97,406 29,876 Operating lease liabilities 40,330 36,573 Contract liabilities 189,718 — Other accrued operating expenses 261,655 152,325 Total accrued expenses and other current liabilities $ 937,027 $ 503,332

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Jan. 03, 2021
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit Plans Savings Plan: The Company has a 401(k) Savings Plan for the benefit of all qualified U.S. employees, with such employees receiving matching contributions in the amount equal to 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits. Savings plan expense was $14.1 million in fiscal year 2020, $13.6 million in fiscal year 2019, and $13.2 million in fiscal year 2018. Pension Plans: The Company has a defined benefit pension plan covering certain U.S. employees and non-U.S. pension plans for certain non-U.S. employees. The principal U.S. defined benefit pension plan was closed to new hires effective January 31, 2001, and benefits for those employed by the Company’s former Life Sciences business were frozen as of that date. Plan benefits were frozen as of March 2003 for those employed by the Company’s former Analytical Instruments business and corporate employees. Plan benefits were frozen as of January 31, 2011 for all remaining employees that were still actively accruing in the plan. The plans provide benefits that are based on an employee’s years of service and compensation near retirement. Net periodic pension cost for U.S. and non-U.S. plans included the following components for fiscal years ended: January 3, December 29, December 30, (In thousands) Service and administrative costs $ 7,414 $ 6,598 $ 6,853 Interest cost 12,876 16,546 16,146 Expected return on plan assets (21,786) (24,561) (28,939) Actuarial loss 20,291 27,134 17,146 Curtailment gain — (1,547) — Amortization of prior service (credit) cost — (152) 375 Net periodic pension cost $ 18,795 $ 24,018 $ 11,581 The Company recognizes actuarial gains and losses, unless an interim remeasurement is required, in the fourth quarter of the year in which the gains and losses occur, in accordance with the Company's accounting method for defined benefit pension plans and other postretirement benefits as described in Note 1, Nature of Operations and Accounting Policies . Such adjustments for gains and losses are primarily driven by events and circumstances beyond the Company's control, including changes in interest rates, the performance of the financial markets and mortality assumptions. Actuarial gains and losses, including other components of periodic pension cost, are recognized in the line item "Interest and other expense, net" in the consolidated statements of operations. The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of January 3, 2021 and December 29, 2019. January 3, 2021 December 29, 2019 Non-U.S. U.S. Non-U.S. U.S. (In thousands) Actuarial present value of benefit obligations: Accumulated benefit obligations $ 392,948 $ 317,679 $ 338,722 $ 304,710 Change in benefit obligations: Projected benefit obligations at beginning of year $ 341,455 $ 304,710 $ 311,168 $ 283,310 Service and administrative costs 5,314 2,100 4,248 2,350 Interest cost 3,991 8,885 5,448 11,098 Benefits paid and plan expenses (15,823) (20,510) (12,778) (21,162) Participants’ contributions 37 — 162 — Business acquisitions (120) — — — Plan curtailments — — (1,420) — Actuarial loss 35,910 22,494 34,602 29,114 Effect of exchange rate changes 24,575 — 25 — Projected benefit obligations at end of year $ 395,339 $ 317,679 $ 341,455 $ 304,710 Change in plan assets: Fair value of plan assets at beginning of year $ 179,860 $ 254,450 $ 159,163 $ 234,342 Actual return on plan assets 25,153 34,746 19,873 41,270 Benefits paid and plan expenses (15,823) (20,510) (12,778) (21,162) Employer’s contributions 7,506 — 8,200 — Participants’ contributions 37 — 162 — Effect of exchange rate changes 8,011 — 5,240 — Fair value of plan assets at end of year $ 204,744 $ 268,686 $ 179,860 $ 254,450 Net liabilities recognized in the consolidated balance sheets $ (190,595) $ (48,993) $ (161,595) $ (50,260) Net amounts recognized in the consolidated balance sheets consist of: Other assets $ 36,295 $ — $ 36,699 $ — Current liabilities (7,597) — (6,764) — Long-term liabilities (219,293) (48,993) (191,530) (50,260) Net liabilities recognized in the consolidated balance sheets $ (190,595) $ (48,993) $ (161,595) $ (50,260) Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — $ — $ — Actuarial assumptions as of the year-end measurement date: Discount rate 0.92 % 2.21 % 1.34 % 3.01 % Rate of compensation increase 2.78 % None 3.36 % None Actuarial assumptions used to determine net periodic pension cost during the year were as follows: January 3, 2021 December 29, 2019 December 30, 2018 Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Discount rate 1.34 % 3.01 % 2.07 % 4.05 % 1.99 % 3.56 % Rate of compensation increase 3.36 % None 3.48 % None 3.50 % None Expected rate of return on assets 2.20 % 7.25 % 5.30 % 7.25 % 5.90 % 7.25 % The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets: January 3, December 29, (In thousands) Pension Plans with Projected Benefit Obligations in Excess of Plan Assets Projected benefit obligations $ 226,890 $ 198,294 Fair value of plan assets — — Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets Accumulated benefit obligations $ 224,499 $ 195,657 Fair value of plan assets — — Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of January 3, 2021 and December 29, 2019, and target asset allocations for fiscal year 2021 are as follows: Target Allocation Percentage of Plan Assets at January 2, 2022 January 3, 2021 December 29, 2019 Asset Category Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Equity securities 0-5% 40-60% — % 45 % — % 41 % Debt securities 85-90% 40-60% 88 % 55 % 87 % 59 % Other 10-15% 0-10% 12 % — % 13 % — % Total 100 % 100 % 100 % 100 % 100 % 100 % The Company maintains target allocation percentages among various asset classes based on investment policies established for the pension plans which are designed to maximize the total rate of return (income and appreciation) after inflation within the limits of prudent risk taking, while providing for adequate near-term liquidity for benefit payments. The Company’s expected rate of return on assets assumptions are derived from management’s estimates, as well as other information compiled by management, including studies that utilize customary procedures and techniques. The studies include a review of anticipated future long-term performance of individual asset classes and consideration of the appropriate asset allocation strategy given the anticipated requirements of the plans to determine the average rate of earnings expected on the funds invested to provide for the pension plans benefits. While the study gives appropriate consideration to recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate. The Company's discount rate assumptions are derived from a range of factors, including a yield curve for certain plans, composed of the rates of return on high-quality fixed-income corporate bonds available at the measurement date and the related expected duration for the obligations, and a bond matching approach for certain plans. During fiscal year 2018, the Society of Actuaries issued an updated projection scale, MP-2018, which incorporated an additional year (2016) of U.S. population data and reduced the life expectancy used to determine the projected benefit obligation. The Company adopted MP-2018 as of December 30, 2018. The adoption of MP-2018 resulted in a $1.0 million decrease to the projected benefit obligation at December 30, 2018. During fiscal year 2019, the Society of Actuaries issued an updated projection scale, MP-2019, which incorporated an additional year (2017) of U.S. population data and reduced the life expectancy used to determine the projected benefit obligation. The Company adopted MP-2019 as of December 29, 2019. The adoption of MP-2019 resulted in a $4.4 million decrease to the projected benefit obligation at December 29, 2019. During fiscal year 2020, the Society of Actuaries issued an updated projection scale, MP-2020, which incorporated an additional year (2018) of U.S. population data and made a few adjustments to the long-term rate of mortality improvement assumed. The Company adopted MP-2020 as of January 3, 2021. The adoption of MP-2020 resulted in a $2.7 million decrease to the projected benefit obligation at January 3, 2021. The changes to the projected benefit obligations due to the adoption of the mortality base table and projection scale are included within "Actuarial loss (gain)" in the Change in Benefit Obligations for fiscal years 2020 and 2019 above. The target allocations for plan assets are listed in the above table. Equity securities primarily include investments in large-cap and mid-cap companies located in the United States and abroad, and equity index funds. Debt securities include corporate bonds of companies from diversified industries, high-yield bonds, and U.S. government securities. Other types of investments include investments in non-U.S. government index linked bonds, multi-strategy hedge funds and venture capital funds that follow several different strategies. The fair values of the Company’s pension plan assets as of January 3, 2021 and December 29, 2019 by asset category, classified in the three levels of inputs described in Note 22 to the consolidated financial statements are as follows: Fair Value Measurements at January 3, 2021 Using: Total Carrying Quoted Prices in Significant Other Significant (In thousands) Cash $ 6,363 $ 6,363 $ — $ — Equity securities: U.S. large-cap 78,234 78,234 — — International large-cap value 28,315 28,315 — — Emerging markets growth 13,594 13,594 — — Foreign real estate funds 23,259 — — 23,259 Fixed income securities: Non-U.S. treasury securities 106,315 — 106,315 — Corporate and U.S. debt instruments 140,349 43,500 96,849 — Corporate bonds 35,816 — 35,816 — High yield bond funds 2,954 2,954 — — Other types of investments: Non-U.S. government index linked bonds 38,231 — 38,231 — Total assets measured at fair value $ 473,430 $ 172,960 $ 277,211 $ 23,259 Fair Value Measurements at December 29, 2019 Using: Total Carrying Quoted Prices in Significant Other Significant (In thousands) Cash $ 6,177 $ 6,177 $ — $ — Equity Securities: U.S. large-cap 57,797 57,797 — — International large-cap value 26,914 26,914 — — U.S. small mid-cap 2,700 2,700 — — Emerging markets growth 12,853 12,853 — — Domestic real estate funds 2,010 2,010 — — Foreign real estate funds 22,688 — — 22,688 Fixed income securities: Non-U.S. Treasury Securities 93,473 — 93,473 — Corporate and U.S. debt instruments 139,300 47,104 92,196 — Corporate bonds 29,846 — 29,846 — High yield bond funds 5,734 5,734 — — Other types of investments: Multi-strategy hedge funds 1,721 — — 1,721 Non-U.S. government index linked bonds 33,097 — 33,097 — Total assets measured at fair value $ 434,310 $ 161,289 $ 248,612 $ 24,409 Valuation Techniques: Valuation techniques utilized need to maximize the use of observable inputs and minimize the use of unobservable inputs. There have been no changes in the methodologies utilized at January 3, 2021 compared to December 29, 2019. The following is a description of the valuation techniques utilized to measure the fair value of the assets shown in the table above. Equity Securities: Shares of registered investment companies that are publicly traded are categorized as Level 1 assets; they are valued at quoted market prices that represent the net asset value of the fund. These instruments have active markets. Equity index funds are mutual funds that are not publicly traded and are comprised primarily of underlying equity securities that are publicly traded on exchanges. Price quotes for the assets held by these funds are readily observable and available. Equity index funds are categorized as Level 2 assets. Fixed Income Securities: Fixed income mutual funds that are publicly traded are valued at quoted market prices that represent the net asset value of securities held by the fund and are categorized as Level 1 assets. Fixed income index funds that are not publicly traded are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments and are categorized as Level 2 assets. Individual fixed income bonds are categorized as Level 2 assets except where sufficient quoted prices exist in active markets, in which case such securities are categorized as Level 1 assets. These securities are valued using third-party pricing services. These services may use, for example, model-based pricing methods that utilize observable market data as inputs. Broker dealer bids or quotes of securities with similar characteristics may also be used. Other Types of Investments: Non-U.S. government index link bond funds are not publicly traded and are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments. Underlying investments consist of bonds in which payment of income on the principal is related to a specific price index and are categorized as Level 2 assets. Hedge funds, private equity funds, foreign real estate funds and venture capital funds are valued at fair value by using the net asset values provided by the investment managers and are updated, if necessary, using analytical procedures, appraisals, public market data and/or inquiry of the investment managers. The net asset values are determined based upon the fair values of the underlying investments in the funds. These other investments invest primarily in readily available marketable securities and allocate gains, losses, and expense to the investor based on the ownership percentage as described in the fund agreements. They are categorized as Level 3 assets. The Company's policy is to recognize significant transfers between levels at the actual date of the event. A reconciliation of the beginning and ending Level 3 assets for fiscal years 2020, 2019 and 2018 is as follows: Fair Value Measurements Using Foreign Multi-strategy Total (In thousands) Balance at December 31, 2017 $ — $ 16,789 $ 16,789 Unrealized gains — 145 145 Purchases 22,196 — 22,196 Balance at December 30, 2018 22,196 16,934 39,130 Sales — (15,586) (15,586) Realized gains — 4,175 4,175 Unrealized gains (losses) 492 (3,802) (3,310) Balance at December 29, 2019 22,688 1,721 24,409 Sales — (1,721) (1,721) Unrealized gains 571 — 571 Balance at January 3, 2021 $ 23,259 $ — $ 23,259 With respect to plans outside of the United States, the Company expects to contribute $7.6 million in the aggregate during fiscal year 2021. During fiscal years 2020, 2019 and 2018, the Company contributed $7.5 million, $8.2 million and $8.5 million in the aggregate, respectively, to pension plans outside of the United States. During fiscal year 2021, the Company contributed $20.0 million to its defined benefit pension plan in the United States for the plan year 2019. The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Non-U.S. U.S. (In thousands) 2021 $ 12,932 $ 19,373 2022 12,960 19,435 2023 13,349 19,504 2024 14,152 19,495 2025 14,206 19,390 2026-2030 72,747 92,258 The Company also sponsors a supplemental executive retirement plan to provide senior management with benefits in excess of normal pension benefits. Effective July 31, 2000, this plan was closed to new entrants. At January 3, 2021 and December 29, 2019, the projected benefit obligations were $25.9 million and $25.7 million, respectively. Assets with a fair value of $1.9 million and $2.1 million, segregated in a trust (which is included in marketable securities and investments on the consolidated balance sheets), were available to meet this obligation as of January 3, 2021 and December 29, 2019, respectively. Pension expenses and income for this plan netted to expense of $2.1 million in fiscal year 2020, expense of $4.8 million in fiscal year 2019 and income of $0.3 million in fiscal year 2018. Postretirement Medical Plans: The Company provides healthcare benefits for eligible retired U.S. employees under a comprehensive major medical plan or under health maintenance organizations where available. Eligible U.S. employees qualify for retiree health benefits if they retire directly from the Company and have at least ten years of service. Generally, the major medical plan pays stated percentages of covered expenses after a deductible is met and takes into consideration payments by other group coverage and by Medicare. The plan requires retiree contributions under most circumstances and has provisions for cost-sharing charges. Effective January 1, 2000, this plan was closed to new hires. For employees retiring after 1991, the Company has capped its medical premium contribution based on employees’ years of service. The Company funds the amount allowable under a 401(h) provision in the Company’s defined benefit pension plan. Assets of the plan are primarily equity and debt securities and are available only to pay retiree health benefits. Net periodic postretirement medical benefit (credit) cost included the following components for the fiscal years ended: January 3, December 29, December 30, (In thousands) Service cost $ 73 $ 87 $ 106 Interest cost 94 116 120 Expected return on plan assets (1,389) (1,175) (1,254) Actuarial (gain) loss (1,647) (1,776) 1,621 Net periodic postretirement medical benefit (credit) cost $ (2,869) $ (2,748) $ 593 The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of January 3, 2021 and December 29, 2019. January 3, December 29, (In thousands) Actuarial present value of benefit obligations: Retirees $ 611 $ 583 Active employees eligible to retire 420 362 Other active employees 2,069 1,966 Accumulated benefit obligations at beginning of year 3,100 2,911 Service cost 73 87 Interest cost 94 116 Benefits paid (101) (122) Actuarial (gain) loss (179) 108 Change in accumulated benefit obligations during the year (113) 189 Retirees 545 611 Active employees eligible to retire 1,232 420 Other active employees 1,211 2,069 Accumulated benefit obligations at end of year $ 2,988 $ 3,100 Change in plan assets: Fair value of plan assets at beginning of year $ 19,216 $ 16,279 Actual return on plan assets 2,756 2,937 Fair value of plan assets at end of year $ 21,972 $ 19,216 Net assets recognized in the consolidated balance sheets $ 18,984 $ 16,116 Net amounts recognized in the consolidated balance sheets consist of: Other assets $ 18,984 $ 16,116 Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — Actuarial assumptions as of the year-end measurement date: Discount rate 2.34 % 3.09 % Actuarial assumptions used to determine net cost during the year are as follows: January 3, December 29, December 30, Discount rate 3.09 % 4.09 % 3.60 % Expected rate of return on assets 7.25 % 7.25 % 7.25 % The Company maintains a master trust for plan assets related to the U.S. defined benefit plans and the U.S. postretirement medical plan. Accordingly, investment policies, target asset allocations and actual asset allocations are the same as those disclosed for the U.S. defined benefit plans. The fair values of the Company’s plan assets at January 3, 2021 and December 29, 2019 by asset category, classified in the three levels of inputs described in Note 22, are as follows: Fair Value Measurements at January 3, 2021 Using: Total Carrying Quoted Prices in Significant Other Significant (In thousands) Cash $ 428 $ 428 $ — $ — Equity securities: U.S. large-cap 6,398 6,398 — — International large-cap value 2,315 2,315 — — Emerging markets growth 1,112 1,112 — — Fixed income securities: Corporate and U.S. debt instruments 11,477 3,557 7,920 — High yield bond funds 242 242 — — Total assets measured at fair value $ 21,972 $ 14,052 $ 7,920 $ — Fair Value Measurements at December 29, 2019 Using: Total Carrying Quoted Prices in Significant Other Significant (In thousands) Cash $ 408 $ 408 $ — $ — Equity securities: U.S. large-cap 4,365 4,365 — — International large-cap value 2,033 2,033 — — U.S. small mid-cap 204 204 — — Emerging markets growth 971 971 — — Domestic real estate funds 152 152 — — Fixed income securities: Corporate debt instruments 10,520 3,557 6,963 — High yield bond funds 433 433 — — Other types of investments: Multi-strategy hedge funds 130 — — 130 Total assets measured at fair value $ 19,216 $ 12,123 $ 6,963 $ 130 Valuation Techniques: Valuation techniques are the same as those disclosed for the U.S. defined benefit plans above. A reconciliation of the beginning and ending Level 3 assets for fiscal years 2020, 2019 and 2018 is as follows: Fair Value Multi-strategy (In thousands) Balance at December 31, 2017 $ 1,151 Unrealized gains 25 Balance at December 30, 2018 1,176 Sales (1,074) Realized gains 315 Unrealized losses (287) Balance at December 29, 2019 130 Sales (130) Balance at January 3, 2021 $ — The Company does not expect to make any contributions to the postretirement medical plan during fiscal year 2021. The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Postretirement Medical Plan (In thousands) 2021 $ 119 2022 137 2023 150 2024 161 2025 172 2026-2030 883 Deferred Compensation Plans: During fiscal year 1998, the Company implemented a nonqualified deferred compensation plan that provides benefits payable to officers and certain key employees or their designated beneficiaries at specified future dates, or upon retirement or death. The plan was amended to eliminate deferral elections, with the exception of Company 401(k) excess contributions for eligible participants, for plan years beginning January 1, 2011. Benefit payments under the plan are funded by contributions from participants, and for certain participants, contributions by the Company. The obligations related to the deferred compensation plan totaled $0.6 million and $1.1 million as of January 3, 2021 and December 29, 2019, respectively.

Contingencies

Contingencies	12 Months Ended
	Jan. 03, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	ContingenciesThe Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company's responsibility is established and when the cost can be reasonably estimated. The Company has accrued $12.9 million and $7.7 million as of January 3, 2021 and December 29, 2019, respectively, in accrued expenses and other current liabilities, which represents its management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. The Company's environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded. The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these contingencies at January 3, 2021 should not have a material adverse effect on the Company’s consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

Warranty Reserves

Warranty Reserves	12 Months Ended
	Jan. 03, 2021
Product Warranties Disclosures [Abstract]
Warranty Reserves	Warranty Reserves The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the consolidated balance sheets. A summary of warranty reserve activity for the fiscal years ended January 3, 2021, December 29, 2019 and December 30, 2018 is as follows: (In thousands) Balance at December 31, 2017 $ 9,050 Provision charged to income 13,545 Payments (13,775) Adjustments to previously provided warranties, net (157) Foreign currency translation and acquisitions (270) Balance at December 30, 2018 8,393 Provision charged to income 12,199 Payments (14,613) Adjustments to previously provided warranties, net 2,889 Foreign currency translation and acquisitions (56) Balance at December 29, 2019 8,812 Provision charged to income 15,315 Payments (15,130) Adjustments to previously provided warranties, net 2,721 Foreign currency translation and acquisitions 355 Balance at January 3, 2021 $ 12,073

Stock Plans

Stock Plans	12 Months Ended
	Jan. 03, 2021
Share-based Payment Arrangement [Abstract]
Stock Plans	Stock Plans Stock-Based Compensation: The Company’s 2019 Incentive Plan (the “2019 Plan”) authorizes the issuance of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and cash awards as part of the Company’s compensation programs. The 2019 Plan was approved by the Company’s Board on January 24, 2019 and by the Company’s shareholders on April 23, 2019. The 2019 Plan replaced the Company’s 2009 Incentive Plan (the “2009 Plan”), under which the Company’s common stock was made available for stock option grants, restricted stock awards, performance restricted stock units, performance units and stock awards as part of the Company’s compensation programs. Upon shareholder approval of the 2019 Plan, 6.25 million shares of the Company’s common stock, as well as shares of the Company’s common stock previously granted under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price subject to a contractual repurchase right, became available for grant under the 2019 Plan. Awards granted under the 2009 Plan prior to its expiration remain outstanding. As part of the Company’s compensation programs, the Company also offers shares of its common stock under its Employee Stock Purchase Plan. The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units, performance units and stock grants, included in the Company’s consolidated statements of operations for fiscal years 2020, 2019 and 2018: January 3, December 29, December 30, (In thousands) Cost of product and service revenue $ 1,388 $ 1,620 $ 1,466 Research and development expenses 1,228 1,061 1,359 Selling, general and administrative expenses 26,510 28,833 25,942 Total stock-based compensation expense $ 29,126 $ 31,514 $ 28,767 The total income tax benefit recognized in the consolidated statements of operations for stock-based compensation was $17.2 million in fiscal year 2020, $11.6 million in fiscal year 2019 and $13.6 million in fiscal year 2018. Stock-based compensation costs capitalized as part of inventory were $0.4 million and $0.3 million as of January 3, 2021 and December 29, 2019, respectively. Stock compensation expense from acceleration of vesting of certain stock awards to the Company's former Chief Executive Officer was $7.7 million for fiscal year 2019. Stock Options: The Company has granted options to purchase common shares at prices equal to the market price of the common shares on the date the option is granted. Conditions of vesting are determined at the time of grant. Options are generally exercisable in equal annual installments over a period of three years, and will generally expire seven years after the date of grant. Options replaced in association with business combination transactions are generally issued with the same terms of the respective plans under which they were originally issued. The fair value of each option grant is estimated using the Black-Scholes option pricing model. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical and implied volatility of the Company’s stock. The average expected life was based on the contractual term of the option and historic exercise experience. The risk-free interest rate is based on United States Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended: January 3, December 29, December 30, Risk-free interest rate 0.9 % 2.5 % 3.0 % Expected dividend yield 0.3 % 0.3 % 0.4 % Expected lives 5 years 5 years 5 years Expected stock volatility 23.8 % 22.8 % 20.7 % The following table summarizes stock option activity for the fiscal year ended January 3, 2021: Number Weighted- (Shares in thousands) Outstanding at beginning of year 1,535 $ 60.42 Granted 266 86.87 Exercised (764) 49.31 Canceled (1) 95.74 Forfeited (75) 87.34 Outstanding at end of year 961 $ 74.40 Exercisable at end of year 562 $ 65.30 The aggregate intrinsic value for stock options outstanding at January 3, 2021 was $66.4 million with a weighted-average remaining contractual term of 3.9 years. The aggregate intrinsic value for stock options exercisable at January 3, 2021 was $43.9 million with a weighted-average remaining contractual term of 2.6 years. At January 3, 2021, there were 1.0 million stock options that were vested, and expected to vest in the future, with an aggregate intrinsic value of $66.4 million and a weighted-average remaining contractual term of 3.9 years. The weighted-average per-share grant-date fair value of options granted during fiscal years 2020, 2019 and 2018 was $18.98, $22.63, and $17.56, respectively. The total intrinsic value of options exercised during fiscal years 2020, 2019 and 2018 was $51.1 million, $19.1 million, and $35.0 million, respectively. Cash received from option exercises for fiscal years 2020, 2019 and 2018 was $37.7 million, $19.7 million, and $24.8 million, respectively. The total compensation expense recognized related to the Company’s outstanding options was $3.6 million in fiscal year 2020, $6.7 million in fiscal year 2019 and $5.4 million in fiscal year 2018. There was $4.7 million of total unrecognized compensation cost related to nonvested stock options granted as of January 3, 2021. This cost is expected to be recognized over a weighted-average period of 1.8 years. Restricted Stock Awards: The Company has awarded shares of restricted stock and restricted stock units to certain employees and non-employee directors at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units vest through the passage of time, assuming continued employment. The fair value of the award at the time of the grant is expensed on a straight line basis primarily in selling, general and administrative expenses over the vesting period, which is generally 3 years. These awards were granted under the Company’s 2009 Plan. Recipients of the restricted stock have the right to vote such shares and receive dividends. The following table summarizes restricted stock award activity for the fiscal year ended January 3, 2021: Number Weighted- (Shares in thousands) Nonvested at beginning of year 345 $ 78.69 Granted 184 84.83 Vested (193) 72.28 Forfeited (40) 86.32 Nonvested at end of year 296 $ 85.67 The fair value of restricted stock awards vested during fiscal years 2020, 2019 and 2018 was $14.0 million, $12.0 million, and $10.4 million, respectively. The total compensation expense recognized related to the restricted stock awards was $10.8 million in fiscal year 2020, $12.7 million in fiscal year 2019 and $11.7 million in fiscal year 2018. As of January 3, 2021, there was $14.3 million of total unrecognized compensation cost, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.4 years. Performance Restricted Stock Units: As part of the Company's executive compensation program, the Company granted 49,138 and 76,218 performance restricted stock units during fiscal years 2020 and 2019, respectively, that will vest based on performance of the Company. The weighted-average per-share grant date fair value of performance restricted stock units granted during fiscal years 2020 and 2019 was $95.43 and $92.95, respectively. During fiscal year 2020, 29,943 performance restricted stock units were forfeited. The total compensation expense recognized related to the performance restricted stock units was $7.9 million in fiscal year 2020 and $5.9 million in fiscal year 2019. As of January 3, 2021, there were 121,759 performance restricted stock units outstanding. Performance Units: The Company’s performance unit program provides a cash award based on the achievement of specific performance criteria. A target number of units are granted at the beginning of a three-year performance period. The number of units earned at the end of the performance period is determined by multiplying the number of units granted by a performance factor ranging from 0% to 200%. Awards are determined by multiplying the number of units earned by the stock price at the end of the performance period, and are paid in cash and accounted for as a liability based award. The compensation expense associated with these units is recognized over the period that the performance targets are expected to be achieved. No performance units were granted during the fiscal years 2020 and 2019. The Company granted 37,281 performance units during fiscal year 2018. The weighted-average per-share grant-date fair value of performance units granted during fiscal year 2018 was $73.23. During fiscal years 2020 and 2019, 1,948 performance units and 10,116 performance units, respectively, were forfeited. The total compensation expense related to performance units was $6.1 million, $5.6 million, and $7.7 million for fiscal years 2020, 2019 and 2018, respectively. As of January 3, 2021, there were 31,207 performance units outstanding subject to forfeiture, with a corresponding liability of $9.4 million recorded in accrued expenses and other current liabilities in the consolidated balance sheets. Stock Awards: The Company’s stock award program provides an annual equity award to non-employee directors. For fiscal years 2020, 2019 and 2018, the award equaled the number of shares of the Company’s common stock which has an aggregate fair market value of $100,000 on the date of the award. The stock award is prorated for non-employee directors who serve for only a portion of the year. The compensation expense associated with these stock awards is recognized when the stock award is granted. In fiscal years 2020, 2019 and 2018, the Company awarded 8,333 shares, 7,301 shares, and 11,088 shares, respectively, to non-employee directors. The weighted-average per-share grant-date fair value of stock awards granted during fiscal years 2020, 2019 and 2018 was $91.75, $95.84, and $72.17, respectively. The total compensation expense recognized related to these stock awards was $0.8 million, $0.7 million and $0.8 million in fiscal years 2020, 2019 and 2018, respectively. Employee Stock Purchase Plan: In April 1999, the Company’s shareholders approved the 1998 Employee Stock Purchase Plan. In April 2005, the Compensation and Benefits Committee of the Board voted to amend the Employee Stock Purchase Plan, effective July 1, 2005, whereby participating employees have the right to purchase common stock at a price equal to 95% of the closing price on the last day of each six-month offering period. The number of shares which an employee may purchase, subject to certain aggregate limits, is determined by the employee’s voluntary contribution, which may not exceed 10% of the employee’s base compensation. During fiscal year 2020, the Company issued 38,727 shares of common stock under the Company’s Employee Stock Purchase Plan at a weighted-average price of $105.23 per share. During fiscal year 2019, the Company issued 33,843 shares under this plan at a weighted-average price of $82.25 per share. During fiscal year 2018, the Company issued 21,321 shares under this plan at a weighted-average price of $69.57 per share. At January 3, 2021 there remains available for sale to employees an aggregate of 0.8 million shares of the Company’s common stock out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jan. 03, 2021
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Comprehensive Income: The components of accumulated other comprehensive (loss) income consisted of the following: Foreign Unrecognized Unrealized Accumulated (In thousands) Balance, December 31, 2017 $ (46,582) $ 322 $ (258) $ (46,518) Current year change (123,388) (77) (9) (123,474) Reclassification to retained earnings upon adoption of ASU 2018-02 (6,489) — — (6,489) Balance, December 30, 2018 (176,459) 245 (267) (176,481) Current year change (23,978) 807 6 (23,165) Balance, December 29, 2019 (200,437) 1,052 (261) (199,646) Current year change 169,500 (1,799) (16) 167,685 Balance, January 3, 2021 $ (30,937) $ (747) $ (277) $ (31,961) During fiscal years 2020, 2019 and 2018, pre-tax credit (cost) of $1.8 million, $0.8 million, and $(0.1) million, respectively, was reclassified from accumulated other comprehensive income into selling, general and administrative expenses as a component of net periodic pension cost. Stock Repurchases: On July 23, 2018, the Board of Directors (the "Board") authorized the Company to repurchase shares of common stock for an aggregate amount up to $250.0 million under a stock repurchase program (the "Repurchase Program"). The Repurchase Program expired on July 23, 2020, and no shares remain available for repurchase under the Repurchase Program due to its expiration. On July 31, 2020, the Board authorized the Company to repurchase shares of common stock for an aggregate amount up to $250.0 million under a new stock repurchase program (the "New Repurchase Program"). The New Repurchase Program will expire on July 27, 2022 unless terminated earlier by the Board and may be suspended or discontinued at any time. During fiscal year 2020, the Company had no stock repurchases under either the Repurchase Program or the New Repurchase Program. As of January 3, 2021, $250.0 million remained available for aggregate repurchases of shares under the New Repurchase Program. Subsequent to fiscal year 2020, the Company repurchased 233,000 shares of common stock under the New Repurchase Program at an aggregate cost of $33.6 million. In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During fiscal year 2020, the Company repurchased 72,251 shares of common stock for this purpose at an aggregate cost of $6.9 million. During fiscal year 2019, the Company repurchased 68,536 shares of common stock for this purpose at an aggregate cost of $6.3 million. During fiscal year 2018, the Company repurchased 66,506 shares of common stock for this purpose at an aggregate cost of $5.2 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value. Dividends: The Board declared a regular quarterly cash dividend of $0.07 per share in each quarter of fiscal years 2020 and 2019. At January 3, 2021, the Company had accrued $7.9 million for a dividend declared in October 2020 for the fourth quarter of fiscal year 2020 that was paid in February 2021. On January 28, 2021, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the first quarter of fiscal year 2021 that will be payable in May 2021. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Derivatives And Hedging Activit

Derivatives And Hedging Activities	12 Months Ended
	Jan. 03, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Derivatives and Hedging Activities The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 70% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business. In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s consolidated statements of cash flows. Principal hedged currencies include the Brazilian Real, British Pound, Chinese Yuan, Euro, Indian Rupee, Singapore Dollar and Swedish Krona. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $808.0 million at January 3, 2021, $277.6 million at December 29, 2019, and $223.3 million at December 30, 2018, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of fiscal years 2020, 2019 and 2018. In addition, in connection with certain intercompany loan agreements utilized to finance its acquisitions and stock repurchase program, the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s consolidated statements of cash flows. The outstanding forward exchange contracts designated as economic hedges, which were intended to hedge movements in foreign exchange rates prior to the settlement of certain intercompany loan agreements, included combined Euro notional amounts of €33.4 million and U.S. Dollar notional amounts of $499.0 million as of January 3, 2021, combined Euro notional amounts of €105.8 million and combined U.S. Dollar notional amounts of $5.6 million as of December 29, 2019, and combined Euro notional amounts of €37.3 million and combined U.S. Dollar notional amounts of $5.7 million as of December 30, 2018. The net gains and losses on these derivatives, combined with the gains and losses on the remeasurement of the hedged intercompany loans were not material for each of the fiscal years 2020 and 2019. The Company paid $4.6 million and $1.3 million during the fiscal years 2020 and 2019, respectively, from the settlement of these hedges. During fiscal year 2018, the Company designated a portion of the 2026 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of January 3, 2021, the total notional amount of the 2026 Notes that was designated to hedge investments in foreign subsidiaries was €497.2 million. The unrealized foreign exchange losses (gains) recorded in AOCI related to the net investment hedge were $49.6 million and $(4.9) million during the fiscal years 2020 and 2019, respectively. During fiscal year 2018, the Company designated the 2021 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from the 2021 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. During the second quarter of fiscal year 2020, the Company removed the hedging relationship of the first €100.0 million of the 2021 Notes and investments in certain foreign subsidiaries. During the third quarter of fiscal year 2020, the Company removed the hedging relationship of the remaining €200.0 million of the 2021 Notes and investments in certain foreign subsidiaries. The unrealized foreign exchange losses (gains) recorded in AOCI related to the net investment hedge were $1.8 million and $(8.0) million during the fiscal years 2020 and 2019, respectively. During fiscal year 2019, the Company entered into a cross-currency swap designated as a net investment hedge to hedge the Euro currency exposure of the Company’s net investment in certain foreign subsidiaries. This agreement is a contract to exchange fixed-rate payments in one currency for fixed-rate payments in another currency. Changes in the fair value of this swap are recorded in equity as a component of AOCI in the same manner as foreign currency translation adjustments. In assessing the effectiveness of this hedge, the Company uses a method based on changes in spot rates to measure the impact of the foreign currency exchange rate fluctuations on both its foreign subsidiary net investment and the related swap. Under this method, changes in the fair value of the hedging instrument other than those due to changes in the spot rate are initially recorded in AOCI as a translation adjustment, and then are amortized into other (income) expense, net in the condensed consolidated statement of operations using a systematic and rational method over the instrument’s term. Changes in the fair value associated with the effective portion (i.e. those changes due to the spot rate) are recorded in AOCI as a translation adjustment and are released and recognized in earnings only upon the sale or liquidation of the hedged net investment. The cross-currency swap has an initial notional value of €197.4 million or $220.0 million and matures on November 15, 2021. Interest on the cross-currency swap is payable semi-annually, in Euro, on May 15th and November 15th of each year based on the Euro notional value and a fixed rate of 2.47%. The Company receives interest in U.S. dollars on May 15th and November 15th of each year based on the U.S. dollar equivalent of the Euro notional value and a fixed rate of 5.00%. As of January 3, 2021, the fair value of the cross-currency swap was $(18.3) million, which was recorded in AOCI. The unrealized foreign exchange (losses) gains recorded in AOCI related to cross-currency swap were $(18.6) million and $0.3 million dur ing the fiscal years 2020 and 2019, respectively. During the second and third quarters of fiscal year 2020, the Company entered into forward foreign exchange contracts, designated as cash flow hedges, to hedge the 2021 Notes. The effective portion of the gain or loss of the cash flow hedges will be reported as a component of other comprehensive income and reclassified into earnings in the same period during which the hedged transaction affects earnings. As of January 3, 2021, the total notional amount of the forward foreign exchange contracts that were designated as cash flow hedges was €300.0 million. The unrealized foreign exchange gains recorded in earnings related to the cash flow hedges were $29.3 million during the fiscal year 2020. The Company does not expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive (loss) income into interest and other expense, net within the next twelve months.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jan. 03, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of January 3, 2021. The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during fiscal years 2020 and 2019. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of January 3, 2021 and December 29, 2019 classified in one of the three classifications described above: Fair Value Measurements at January 3, 2021 Using: Total Carrying Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 2,154 $ 2,154 $ — $ — Foreign exchange derivative assets 31,248 — 31,248 — Foreign exchange derivative liabilities (21,413) — (21,413) — Contingent consideration (2,953) — — (2,953) Fair Value Measurements at December 29, 2019 Using: Total Carrying Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 2,906 $ 2,906 $ — $ — Foreign exchange derivative assets 451 — 451 — Foreign exchange derivative liabilities (1,538) — (1,538) — Contingent consideration (35,481) — — (35,481) Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. Marketable securities: Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date. Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's consolidated balance sheet on a net basis and are recorded in other assets. As of both January 3, 2021 and December 29, 2019, none of the master netting arrangements involved collateral. Level 3 Valuation Techniques: The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities. Contingent consideration: Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model. During fiscal year 2015, the Company acquired all the shares of Vanadis Diagnostics AB ("Vanadis"). Under the terms of the acquisition, the initial purchase consideration was $32.0 million, net of cash and the Company was obligated to make potential future milestone payments, based on completion of a proof of concept, regulatory approvals and product sales, of up to $93.0 million ranging from 2016 to 2019. The fair value of the contingent consideration as of the acquisition date was estimated at $56.9 million. As of January 3, 2021, the Company has no remaining obligation to the previous owners of Vanadis. During the fiscal year 2019, the Company recorded a contingent consideration obligation relating to other acquisitions with an estimated fair value of $12.7 million. During the fiscal year 2020, the Company paid $23.7 million of contingent consideration, of which $10.4 million was included in financing activities and $13.3 million was included in operating activities in the consolidated statements of cash flows. During the fiscal year 2019, the Company paid $50.9 million of contingent consideration, of which $29.9 million was included in financing activities and $20.9 million was included in operating activities in the consolidated statements of cash flows. The fair values of contingent consideration are calculated on a quarterly basis based on a collaborative effort of the Company’s regulatory, research and development, operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving proof of concept, regulatory approvals and revenue targets as compared to initial projections, the impact of market competition and market landscape shifts from non-invasive prenatal testing products, with the impact of such adjustments being recorded in the consolidated statements of operations. As of January 3, 2021, the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $7.3 million. The expected maximum earnout period for acquisitions with open contingency period does not exceed 2.9 years from January 3, 2021, and the remaining weighted average expected earnout period at January 3, 2021 was 1.9 years. A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: (In thousands) Balance at December 31, 2017 $ (65,328) Amounts paid and foreign currency translation 16,506 Change in fair value (included within selling, general and administrative expenses) (14,639) Balance at December 30, 2018 (69,661) Additions (12,734) Amounts paid and foreign currency translation 50,795 Change in fair value (included within selling, general and administrative expenses) (3,881) Balance at December 29, 2019 (35,481) Amounts paid and foreign currency translation 23,701 Change in fair value (included within selling, general and administrative expenses) 8,827 Balance at January 3, 2021 $ (2,953) The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1. As of January 3, 2021, the Company’s senior unsecured revolving credit facility, which provides for $1.0 billion of revolving loans, had a carrying value of $156.0 million, net of $2.6 million of unamortized debt issuance costs. As of December 29, 2019, the Company's senior unsecured revolving credit facility had a carrying value of $322.0 million, net of $3.4 million of unamortized debt issuance costs. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during fiscal year 2020. Consequently, the carrying value approximates fair value and were classified as Level 2. The Company's 2026 Notes, with a face value of €500.0 million, had an aggregate carrying value of $604.7 million, net of $3.3 million of unamortized original issue discount and $2.8 million of unamortized debt issuance costs as of January 3, 2021. The 2026 Notes had an aggregate carrying value of $552.2 million, net of $3.5 million of unamortized original issue discount and $3.3 million of unamortized debt issuance costs as of December 29, 2019. The 2026 Notes had a fair value of €539.8 million (or $659.3 million) and €518.5 million (or $579.6 million) as of January 3, 2021 and December 29, 2019, respectively. The fair value of the 2026 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's 2021 Notes, with a face value of €300.0 million, had an aggregate carrying value of $366.2 million, net of $16,200 of unamortized original issue discount and $0.2 million of unamortized debt issuance costs as of January 3, 2021. The 2021 Notes had an aggregate carrying value of $334.2 million, net of $0.1 million of unamortized original issue discount and $1.1 million of unamortized debt issuance costs as of December 29, 2019. The 2021 Notes had a fair value of €300.5 million (or $367.1 million) and €301.9 million (or $337.4 million) as of January 3, 2021 and December 29, 2019. The fair value of the 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's 2029 Notes, with a face value of $850.0 million, had an aggregate carrying value of $840.6 million, net of $2.5 million of unamortized original issue discount and $6.9 million of unamortized debt issuance costs as of January 3, 2021. The 2029 Notes had an aggregate carrying value of $839.9 million, net of $2.7 million of unamortized original issue discount and $7.4 million of unamortized debt issuance costs as of December 29, 2019. The 2029 Notes had a fair value of $957.9 million and $872.3 million as of January 3, 2021 and December 29, 2019. The fair value of the 2029 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company’s other debt facilities had an aggregate carrying value of $23.2 million and $25.7 million as of January 3, 2021 and December 29, 2019, respectively. As of January 3, 2021, these consisted of bank loans in the aggregate amount of $23.1 million bearing fixed interest rates between 1.1% and 8.9% and a bank loan in the amount of $0.1 million bearing a variable interest rate based on the Euribor rate plus a margin of 1.5%. The Company had no change in credit standing during fiscal year 2020. Consequently, the carrying value approximates fair value. As of January 3, 2021, the 2021 Notes, 2026 Notes, 2029 Notes and other debt facilities were classified as Level 2. As of January 3, 2021, there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Leases (Notes)

Leases (Notes)	12 Months Ended
	Jan. 03, 2021
Disclosure Text Block [Abstract]
Leases [Text Block]	Leases Lessee Disclosures The Company leases certain property and equipment under operating and finance leases. The Company's leases have remaining lease terms of less than 1 year to 30 years, some of which include options to extend the lease for up to 5 years, and some of which include options to terminate the lease within 1 year. Finance leases are not material to the Company. The components of lease expense were as follows: January 3, December 29, (In thousands) Lease Cost: Operating lease cost $ 56,977 $ 61,205 Supplemental cash flow information related to leases was as follows: January 3, December 29, (In thousands) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 47,427 $ 50,155 Supplemental balance sheet information related to leases was as follows: January 3, December 29, (In thousands, except lease term and discount rate) Operating Leases: Operating lease right-of-use assets $ 207,236 $ 167,276 Operating lease liabilities included in Accrued expenses and other current liabilities $ 40,330 $ 36,573 Operating lease liabilities 188,402 146,399 Total operating liabilities $ 228,732 $ 182,972 Weighted Average Remaining Lease Term in Years Operating leases 8.1 Weighted Average Remaining Discount Rate Operating leases 2.9% Maturities of operating lease liabilities as of January 3, 2021 were as follows: (In thousands) 2021 $ 48,986 2022 40,097 2023 30,044 2024 26,667 2025 24,847 2026 and thereafter 90,518 Total lease payments 261,159 Less imputed interest (32,427) Total $ 228,732 Lessor Disclosures
Leases of Lessor Disclosure [Text Block]	Lessor DisclosuresCertain of the Company's contracts require that it place its instrument at the customer's site and sell reagents to the customer. As the predominant component in these contracts are the sales of reagents, the Company accounts for the combined component under ASC 606 only when both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. When only one of the criteria is met, the Company accounts for the non-lease component under ASC 606 and the lease component under ASC 842. Profit or loss, interest income and aggregate net investment in sales-type leases that did not qualify for the practical expedient are not material to the Company.

Industry Segment and Geographic

Industry Segment and Geographic Area Information	12 Months Ended
	Jan. 03, 2021
Segment Reporting [Abstract]
Industry Segment Information	Industry Segment and Geographic Area Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1. The principal products and services of the Company's two operating segments are: • Discovery & Analytical Solutions . Provides products and services targeted towards the life sciences and applied markets. • Diagnostics . Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, emerging market diagnostics and applied genomics markets. The Diagnostics segment serves the diagnostics market. The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments. Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended: January 3, December 29, December 30, (In thousands) Discovery & Analytical Solutions Product revenue $ 995,216 $ 1,054,862 $ 1,010,899 Service revenue 720,587 691,299 682,312 Total revenue 1,715,803 1,746,161 1,693,211 Operating income from continuing operations (1) 183,471 238,331 230,481 Diagnostics Product revenue 1,783,509 962,180 924,594 Service revenue 283,433 175,332 160,191 Total revenue 2,066,942 1,137,512 1,084,785 Operating income from continuing operations (1)(2) 874,206 189,330 153,196 Corporate Operating loss from continuing operations (3) (79,096) (65,688) (59,793) Continuing Operations Product revenue 2,778,725 2,017,042 1,935,493 Service revenue 1,004,020 866,631 842,503 Total revenue 3,782,745 2,883,673 2,777,996 Operating income from continuing operations 978,581 361,973 323,884 Interest and other expense, net (see Note 6) 72,217 124,831 66,201 Income from continuing operations before income taxes $ 906,364 $ 237,142 $ 257,683 ____________________________ (1) Legal costs for significant litigation matters and settlements in the Company's Discovery & Analytical Solutions segment were $5.9 million, $2.2 million and $5.3 million for fiscal years 2020, 2019 and 2018, respectively. Legal costs for significant litigation matters and settlements in the Company's Diagnostics segment were $1.2 million, $0.1 million and $0.2 million for fiscal years 2020, 2019 and 2018, respectively. (2) Asset impairment in the Company's Diagnostics segment was $7.9 million for fiscal year 2020. (3) Costs for significant environmental matters was $5.2 million for fiscal year 2020. Stock compensation expense from acceleration of executive compensation was $7.7 million for fiscal year 2019. Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended January 3, 2021: Depreciation and Amortization Expense Capital Expenditures January 3, December 29, December 30, January 3, December 29, December 30, (In thousands) (In thousands) Discovery & Analytical Solutions $ 93,516 $ 74,445 $ 70,362 $ 20,217 $ 27,778 $ 34,852 Diagnostics 149,738 136,476 107,434 55,236 46,863 54,737 Corporate 3,253 3,104 2,792 2,053 1,690 3,664 Continuing operations $ 246,507 $ 214,025 $ 180,588 $ 77,506 $ 76,331 $ 93,253 Total Assets January 3, December 29, December 30, (In thousands) Discovery & Analytical Solutions $ 3,600,860 $ 3,082,917 $ 2,567,054 Diagnostics 4,228,943 3,368,598 3,358,964 Corporate 130,512 87,049 49,504 Total assets $ 7,960,315 $ 6,538,564 $ 5,975,522 The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended January 3, 2021 and net long-lived assets based on physical location as of January 3, 2021 and December 29, 2019: Revenue January 3, December 29, December 30, (In thousands) U.S. $ 1,269,293 $ 974,187 $ 906,398 International: China 492,283 581,688 559,865 United Kingdom 362,591 70,703 72,124 Germany 200,294 146,577 142,411 Italy 163,056 101,461 95,908 France 148,898 96,994 97,990 Republic of Korea 114,846 71,069 60,126 India 103,785 97,423 92,327 Japan 88,473 82,478 79,238 Other international 839,226 661,093 671,609 Total international 2,513,452 1,909,486 1,871,598 Total sales $ 3,782,745 $ 2,883,673 $ 2,777,996 Net Long-Lived Assets* January 3, December 29, December 30, (In thousands) U.S. $ 197,755 $ 269,183 $ 201,649 International: Germany 149,105 119,612 99,181 China 75,199 71,216 61,261 Finland 60,559 29,052 16,211 United Kingdom 35,243 51,659 33,429 Singapore 24,291 23,063 14,942 India 21,975 19,691 14,636 Italy 17,051 14,152 11,324 France 13,325 12,940 3,210 Brazil 8,627 9,126 8,237 Poland 7,732 7,216 3,212 Canada 5,671 6,485 5,454 Other international 34,625 26,210 17,565 Total international 453,403 390,422 288,662 Total net long-lived assets $ 651,158 $ 659,605 $ 490,311 * Long-lived assets consist of property and equipment, net, operating lease right-of-use assets, rental equipment, software and other long-term assets.

Quarterly Financial Information

Quarterly Financial Information (Unaudited)	12 Months Ended
	Jan. 03, 2021
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (Unaudited)	Quarterly Financial Information (Unaudited) Selected quarterly financial information is as follows for the fiscal years ended: First Second Third Fourth Quarter (1) Year (In thousands, except per share data) January 3, 2021 Revenue $ 652,396 $ 811,718 $ 964,025 $ 1,354,606 $ 3,782,745 Gross profit 308,023 447,344 527,445 827,065 2,109,877 Restructuring and other costs, net 5,858 1,158 4,059 (3,062) 8,013 Operating income from continuing operations 44,682 175,639 248,006 510,254 978,581 Income from continuing operations before income taxes 34,689 164,827 233,757 473,091 906,364 Income from continuing operations 33,715 137,213 176,736 380,434 728,098 Loss from discontinued operations and dispositions (50) (51) (37) (73) (211) Net income 33,665 137,162 176,699 380,361 727,887 Basic earnings per share: Income from continuing operations $ 0.30 $ 1.23 $ 1.58 $ 3.40 $ 6.53 Loss from discontinued operations and dispositions (0.00) (0.00) (0.00) (0.00) (0.00) Net income 0.30 1.23 1.58 3.40 6.53 Diluted earnings per share: Income from continuing operations $ 0.30 $ 1.23 $ 1.57 $ 3.38 $ 6.50 Loss from discontinued operations and dispositions (0.00) (0.00) (0.00) (0.00) (0.00) Net income 0.30 1.23 1.57 3.38 6.49 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 December 29, 2019 Revenue $ 648,737 $ 722,517 $ 706,923 $ 805,496 $ 2,883,673 Gross profit 307,806 347,793 342,275 398,181 1,396,055 Restructuring and other costs, net 7,639 6,161 14,068 1,560 29,428 Operating income from continuing operations 53,330 91,735 78,660 138,248 361,973 Income from continuing operations before income taxes 36,765 71,827 63,254 65,296 237,142 Income from continuing operations 35,453 69,141 58,610 64,549 227,753 Loss from discontinued operations and dispositions (41) (54) (52) (48) (195) Net income 35,412 69,087 58,558 64,501 227,558 Basic earnings per share: Income from continuing operations $ 0.32 $ 0.62 $ 0.53 $ 0.58 $ 2.06 Loss from discontinued operations and dispositions (0.00) (0.00) (0.00) (0.00) (0.00) Net income 0.32 0.62 0.53 0.58 2.06 Diluted earnings per share: Income continuing operations $ 0.32 $ 0.62 $ 0.53 $ 0.58 $ 2.04 Loss from discontinued operations and dispositions (0.00) (0.00) (0.00) (0.00) (0.00) Net income 0.32 0.62 0.52 0.58 2.04 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 ____________________________ (1) The fourth quarter of fiscal year 2020 includes a pre-tax loss of $25.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.

Subsequent Events

Subsequent Events	12 Months Ended
	Jan. 03, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsSubsequent to fiscal year 2020, the Company reached an agreement with Oxford Immunotec Global PLC (“Oxford Immunotec”) on terms under which the Company has agreed to acquire Oxford Immunotec. It is intended that the acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the “Scheme”). Under the terms of the acquisition, Oxford Immunotec shareholders will be entitled to receive $22 in cash for each outstanding ordinary share. The terms of the acquisition value Oxford Immunotec’s entire issued and to be issued ordinary share capital at approximately $591.0 million. The Scheme has been approved by the shareholders of Oxford Immunotec. Subject to the satisfaction of other customary closing conditions, the Company currently anticipates that the transaction will close later this month. Oxford Immunotec is based in Abingdon, UK, has approximately 275 employees, and is widely recognized as a global leader of proprietary test kits for latent tuberculosis. Its Interferon Gamma Release Assay offering identifies individuals who are infected with tuberculosis.

Nature of Operations and Acco_2

Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Policies)	12 Months Ended
	Jan. 03, 2021
Accounting Policies [Abstract]
Consolidation [Policy Text Block]	The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation.
Fiscal Periods [Policy Text Block]	The Company's fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ended January 3, 2021 ("fiscal year 2020") included 53 weeks. Each of the fiscal years ended December 29, 2019 ("fiscal year 2019") and December 30, 2018 ("fiscal year 2018") included 52 weeks.
Accounting Policies and Estimates [Policy Text Block]	Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Revenue Recognition [Policy Text Block]	Revenue Recognition:
Warranty Costs [Policy Text Block]	Warranty Costs: The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period.
Inventories [Policy Text Block]	Inventories : Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements.
Income Taxes [Policy Text Block]	Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings. When the Company determines during the period that previously undistributed earnings of certain international subsidiaries no longer meet the requirements of indefinite reinvestment, the Company recognizes the income tax expense in that period.
Property, Plant and Equipment [Policy Text Block]	Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 8 years. Certain tooling costs are capitalized and amortized over a 3-year life, while repairs and maintenance costs are expensed.
Change in Accounting for Pension and Other Postretirement Benefits [Policy Text Block]	Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company's fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds.
Translation of Foreign Currencies [Policy Text Block]	Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in AOCI, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net
Business Combinations [Policy Text Block]	Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. Measurement period adjustments are made in the period in which the amounts are determined and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed.
Goodwill and Other Intangible Assets [Policy Text Block]	Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of a trade name that is not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships and purchased technologies, which are being amortized over their estimated useful lives. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of the amortizing intangible asset . In addition, the Company
Stock-Based Compensation [Policy Text Block]	Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 19 below.
Marketable Securities and Investments [Policy Text Block]	Marketable Securities and Investments: Investments in debt securities that are classified as available for sale are recorded at their fair values with unrealized gains and losses included in accumulated other comprehensive (loss) income until realized. Investments in equity securities are recorded at their fair values with unrealized holding gains and losses included in earnings. Investments in equity securities without a readily determinable fair value are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, with changes included in earnings.
Cash Flows [Policy Text Block]	Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments.
Environmental Matters [Policy Text Block]	Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted.
Research and Development Expense, Policy [Policy Text Block]	Research and Development: Research and development costs are expensed as incurred. The fair value of acquired IPR&D costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned.
Restructuring Charges [Policy Text Block]	Restructuring and Other Costs: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with its growth strategy, the integration of its business units and its productivity initiatives. In connection with these initiatives, the Company has recorded restructuring and other charges, as more fully described in Note 5 below, which include employee severance, other exit costs as well as costs of terminating certain lease agreements or contracts and other costs associated with relocating facilities. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Prior to adoption of Accounting Standards Codification ("ASC") 842, Leases , costs related to lease terminations were recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceased use.
New Accounting Pronouncement or Change in Accounting Principle, Description	Comprehensive Income: Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income.
Derivative Instruments and Hedging [Policy Text Block]	Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive (loss) income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements. The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of AOCI, as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. Leases: Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized based on the present value of the remaining lease payments over the lease term. When the Company's lease did not provide an implicit rate, the Company used its incremental borrowing rate in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component. Additionally, for certain equipment leases, the Company applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities. The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statement of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred. As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under ASC 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with ASC 842.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In March 2020, the FASB issued Accounting Standards Update No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting ("ASU 2020-04"). This update provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in ASU 2020-04 provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The following optional expedients for applying the requirements of certain Topics or Industry Subtopics in the FASB's ASC are permitted for contracts that are modified because of reference rate reform and that meet certain scope guidance: (1) modifications of contracts within the scope of Topic 310, Receivables , and Topic 470, Debt , should be accounted for by prospectively adjusting the effective interest rate; and (2) modifications of contracts within the scope of Topic 840, Leases , and Topic 842, Leases , should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of lease payments. For other Topics or Industry Subtopics in the ASC, the amendments also include a general principle that permits an entity to consider contract modification due to reference rate reform to be an event that does not require contract remeasurement at the modification date or reassessment of a previous accounting determination. When elected, the optional expedients for contract modifications must be applied consistently for all eligible contracts or eligible transactions within the relevant Topic or Industry Subtopic. ASU 2020-04 is effective for any contract modifications or hedging relationships as of March 12, 2020 through December 31, 2022. In accordance with ASU 2020-04, the Company adopted the guidance as of March 12, 2020. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In March 2020, the FASB issued Accounting Standards Update No. 2020-03, Codification Improvements to Financial Instruments ("ASU 2020-03"). This guidance clarifies various ASC Topics related to financial instruments, including the following, among others: (1) Fair Value Option Disclosures: all entities are required to provide the fair value option disclosures in paragraphs 825-10-50-24 through 50-32 of the ASC; (2) Cross-Reference to Line-of-Credit or Revolving-Debt Arrangements Guidance in Subtopic 470-50, Modifications and Extinguishments : the amendments improve the understandability of the guidance; (3) Interaction of Topic 842 and Topic 326: the contractual term of a net investment in a lease determined in accordance with Topic 842, Leases should be the contractual term used to measure expected credit losses under Topic 326, Financial Instruments - Credit Losses ; and (4) Interaction of Topic 326 and Subtopic 860-20: the amendments to Subtopic 860- 20 clarify that when an entity regains control of financial assets sold, an allowance for credit losses should be recorded in accordance with Topic 326. For Fair Value Option Disclosures and Cross-Reference to Line-of-Credit or Revolving-Debt Arrangements Guidance, the provisions are effective upon issuance of this guidance. For Interaction of Topic 842 and Topic 326 and Interaction of Topic 326 and 860-20, the effective dates and transition requirements for the amendments are the same as the effective dates and transition requirements in ASU 2016-13, as described below. In accordance with ASU 2020-03, the Company adopted the guidance as of April 5, 2020. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In January 2020, the FASB issued Accounting Standards Update No. 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 ("ASU 2020-01"). This guidance addresses the accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The amendments clarify that: (a) an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method; and (b) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The provisions of this guidance are to be applied prospectively upon their effective date. ASU 2020-01 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those years. The standard was effective for the Company beginning on January 4, 2021, the first day of fiscal year 2021. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASU 2019-12 eliminates certain exceptions and adds guidance to reduce complexity in accounting for income taxes. Specifically, this guidance: (1) removes the intraperiod tax allocation exception to the incremental approach; (2) removes the ownership changes in investments exception in determining when a deferred tax liability is recognized after an investor in a foreign entity transitions to or from the equity method of accounting and applies this provision on a modified retrospective basis through a cumulative-effect adjustment to retained earnings at the beginning of the period of adoption; and (3) removes the exception to using the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. ASU 2019-12 also simplifies accounting principles by making other changes, including requiring an entity to: (1) evaluate whether a step-up in tax basis of goodwill relates to a business combination or a separate transaction; (2) make a policy election to not allocate consolidated income taxes when a member of a consolidated tax return is not subject to income tax and to apply this provision retrospectively to all periods presented; and (3) recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and apply this provision either retrospectively for all periods presented or on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The provisions of this guidance (except as specifically mentioned above) are to be applied prospectively upon their effective date. ASU 2019-12 is effective for annual reporting periods beginning after December 15, 2020, and interim p eriods within those years. The standard was effective for the Company beginning on January 4, 2021, the first day of fiscal year 2021. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In April 2019, the FASB issued Accounting Standards Update No. 2019-04, Codification Impro vem ents to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ("ASU 2019-04"). ASU 2019-04 clarifies certain aspects of previously issued accounting standards related to: (1) ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements ("ASU 2016-13"), in areas of accrued interest receivable, transfers of loans and debt securities between classifications, recoveries and prepayments, (2) ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities ("ASU 2017-12"), in areas of partial-term fair value hedges, fair value hedge basis adjustments, certain disclosures and transition requirements and (3) ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"), in areas of remeasurement of equity securities under ASC 820, Fair Value Measurement , when using the measurement alternative and remeasurement of equity securities at historical exchange rates. The amendments related to ASU 2016-13 are required to be adopted in conjunction with that accounting standards update, as further described below. Since the Company has already adopted ASU 2017-12 and ASU 2016-01, the related amendments in ASU 2019-04 are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted in any interim period. The amendments to ASU 2017-12 can either be adopted retrospectively as of the date of adoption of ASU 2017-12 or they can be adopted prospectively. The amendments to ASU 2016-01 are required to be applied using a modified-retrospective adoption approach with a cumulative-effect adjustment to retained earnings as of the date of adoption of ASU 2016-01, except for those related to equity securities without readily determinable fair values that are measured using the measurement alternative, which are required to be applied prospectively. The standard was effective for the Company beginning on December 30, 2019, the first day of the Company's fiscal year 2020. The Company applied the provisions of this guidance prospectively. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-15, Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract ("ASU 2018-15"). ASU 2018-15 aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the guidance on capitalizing costs associated with developing or obtaining internal-use software (and hosting arrangements that include an internal-use software license). The provisions of this guidance are to be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The standard was effective for the Company beginning on December 30, 2019, the first day of the Company's fiscal year 2020. The Company applied the provisions of this guidance prospectively. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans ("ASU 2018-14"). ASU 2018-14 adds, removes, and clarifies disclosure requirements related to defined benefit pension and other postretirement plans. ASU 2018-14 adds requirements for an entity to disclose the weighted-average interest crediting rates used in the entity’s cash balance pension plans and other similar plans; and an explanation of the reasons for significant gains and losses related to changes in the benefit obligation for the period . Further, ASU 2018-14 removes guidance that currently requires the following disclosures: the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year; the amount and timing of plan assets expected to be returned to the employer; information about (1) benefits covered by related-party insurance and annuity contracts and (2) significant transactions between the plan and related parties; and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. ASU 2018-14 also clarifies the guidance in Compensation-Retirement Benefits (Topic 715-20-50-3) on defined benefit plans to require disclosure of (1) the projected benefit obligation ("PBO") and fair value of plan assets for pension plans with PBOs in excess of plan assets (the same disclosure with reference to the accumulated postretirement benefit obligation rather than the PBO is required for other postretirement benefit plans) and (2) the accumulated benefit obligation ("ABO") and fair value of plan assets for pension plans with ABOs in excess of plan assets. The provisions of this guidance are to be applied retrospectively to all periods presented upon their effective date. ASU 2018-14 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those years with early adoption permitted. The standard was effective for the Company beginning on January 4, 2021, the first day of fiscal year 2021. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"). ASU 2018-13 adds, removes, and modifies certain disclosures related to fair value measurements. ASU 2018-13 adds requirements for an entity to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. Further, ASU 2018-13 removes the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. ASU 2018-13 also modifies existing disclosure requirements related to measurement uncertainty. The amendments regarding changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments are to be applied retrospectively to all periods presented upon their effective date. The standard was effective for the Company beginning on December 30, 2019, the first day of the Company's fiscal year 2020. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments . ASU 2016-13 changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The standard requires entities to use the expected loss impairment model and will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance sheet credit exposures. Entities are required to estimate the lifetime “expected credit loss” for each applicable financial asset and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The standard also amends the impairment model for available-for-sale (“AFS”) debt securities and requires entities to determine whether all or a portion of the unrealized loss on an AFS debt security is a credit loss. An entity will recognize an allowance for credit losses on an AFS debt security as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment. The provisions of this guidance are to be applied using a modified-retrospective approach. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Subsequent to the issuance of ASU 2016-13, in November 2018, the FASB issued Accounting Standards Update No. 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses ("ASU 2018-19"), in April 2019, the FASB issued ASU 2019-04, and in May 2019, the FASB issued Accounting Standards Update No. 2019-05, Financial Instruments - Credit Losses (Topic 326), Targeted Transition Relief ("ASU 2019-05") . The amendments in ASU 2018-19 clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, Financial Instruments - Credit Losses - Measured at Amortized Cost . Instead, impairment of receivables arising from operating leases should be accounted for in accordance with Topic 842, Leases . The amendments in ASU 2019-04 clarify the measurement of allowance for credit losses on accrued interest receivable; the inclusion of expected recoveries in the allowance for credit losses; the permission of a prepayment-adjusted effective interest rate when determining the allowance for credit losses; and the steps entities should take when recording the transfer of loans or debt securities between measurement classifications. The amendments in ASU 2019-05 provide an option to irrevocably elect the fair value option in Subtopic 825-10, Financial Instruments-Overall , on an instrument-by-instrument basis, for eligible financial assets measured at amortized cost basis upon adoption of ASU 2016-13, but this fair value option election does not apply to held-to-maturity debt securities. The effective date and transition requirements for the amendments in ASU 2018-19, ASU 2019-04 and ASU 2019-05 are the same as the effective date and transition requirements of ASU 2016-13, which is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. The standards were effective for the Company beginning on December 30, 2019, the first day of the Company's fiscal year 2020. The Company adopted these standards using the modified-retrospective approach. The adoption of the standard resulted in a decrease in retained earnings at December 30, 2019 of approximately $1.3 million from the cumulative effect of initially applying the standards as of that date. In addition, the adoption of the standard resulted in an increase in reserve for doubtful accounts of $1.7 million and an increase in deferred tax assets of $0.4 million from the tax impact of the cumulative adjustments. The adoption did not have an impact on cash from or used in operating, investing or financing activities in the Company's consolidated statement of cash flows at December 30, 2019.

Business Combinations and Ass_2

Business Combinations and Asset Purchases (Tables)	12 Months Ended
	Jan. 03, 2021
Business Acquisition [Line Items]
Fair Values of the Business Combinations and Allocations for the Acquisitions Completed	The total purchase price for the acquisitions in fiscal year 2020 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Preliminary Horizon Other (In thousands) Fair value of business combination: Cash payments $ 399,005 $ 38,243 Other liability 396 1,263 Working capital and other adjustments — (176) Less: cash acquired (25,539) (1,300) Total $ 373,862 $ 38,030 Identifiable assets acquired and liabilities assumed: Current assets $ 29,762 $ 5,770 Property, plant and equipment 17,729 2,673 Other assets 17,743 371 Identifiable intangible assets: Core technology 60,000 5,730 Trade names 4,900 680 Customer relationships 96,600 10,923 IPR&D 10,800 — Goodwill 200,745 16,224 Deferred taxes (22,480) (1,132) Deferred revenue (2,031) — Debt assumed — (29) Liabilities assumed (39,906) (3,180) Total $ 373,862 $ 38,030 The total purchase price for the acquisitions in fiscal year 2019 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Cisbio Meizheng Group Other (In thousands) Fair value of business combination: Cash payments $ 219,795 $ 145,000 $ 45,042 Other liability — 6,446 638 Contingent consideration — 12,100 634 Working capital and other adjustments 138 2,961 302 Less: cash acquired (12,542) (2,108) (1,334) Total $ 207,391 $ 164,399 $ 45,282 Identifiable assets acquired and liabilities assumed: Current assets $ 43,554 $ 15,077 $ 4,125 Property, plant and equipment 4,835 6,278 727 Other assets 100 24 502 Identifiable intangible assets: Core technology 89,000 36,600 27,667 Trade names 5,000 4,900 1,310 Customer relationships 39,000 55,800 6,700 Goodwill 73,417 78,612 17,079 Deferred taxes (34,962) (21,548) (6,603) Debt assumed — (706) (2,698) Liabilities assumed (12,553) (10,638) (3,527) Total $ 207,391 $ 164,399 $ 45,282 The total purchase price for the acquisitions in fiscal year 2018 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: (In thousands) Fair value of business combination: Cash payments $ 95,950 Other liability 3,354 Contingent consideration 6,200 Working capital and other adjustments 261 Less: cash acquired (1,132) Total $ 104,633 Identifiable assets acquired and liabilities assumed: Current assets $ 4,905 Property, plant and equipment 1,166 Other assets 776 Identifiable intangible assets: Core technology 31,956 Trade names 1,070 GC Libraries 2,065 Customer relationships 10,200 Goodwill 65,886 Deferred taxes (9,049) Debt assumed (461) Liabilities assumed (3,881) Total $ 104,633

Revenue from Contract with Cu_2

Revenue from Contract with Customer (Tables)	12 Months Ended
	Jan. 03, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	In the following tables, revenue is disaggregated by primary geographical market, end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments revenue. Reportable Segments For the fiscal year ended January 3, 2021 December 29, 2019 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 695,960 $ 750,641 $ 1,446,601 $ 717,205 $ 401,591 $ 1,118,796 Europe 490,789 864,687 1,355,476 495,768 291,610 787,378 Asia 529,054 451,614 980,668 533,188 444,311 977,499 $ 1,715,803 $ 2,066,942 $ 3,782,745 $ 1,746,161 $ 1,137,512 $ 2,883,673 Primary end-markets Diagnostics $ — $ 2,066,942 $ 2,066,942 $ — $ 1,137,512 $ 1,137,512 Life sciences 1,032,209 — 1,032,209 977,200 — 977,200 Applied markets 683,594 — 683,594 768,961 — 768,961 $ 1,715,803 $ 2,066,942 $ 3,782,745 $ 1,746,161 $ 1,137,512 $ 2,883,673 Timing of revenue recognition Products and services transferred at a point in time $ 1,195,249 $ 1,891,482 $ 3,086,731 $ 1,276,499 $ 1,053,974 $ 2,330,473 Services transferred over time 520,554 175,460 696,014 469,662 83,538 553,200 $ 1,715,803 $ 2,066,942 $ 3,782,745 $ 1,746,161 $ 1,137,512 $ 2,883,673

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Jan. 03, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Gains and Losses on Disposition of Discontinued Operations [Table Text Block]	The Company recorded the following pre-tax losses, which have been reported as a net loss on disposition of discontinued operations during the three fiscal years ended: January 3, December 29, December 30, (In thousands) Loss on disposition of the Medical Imaging business $ — $ — $ (793) Loss on disposition of Fluid Sciences business (76) — (66) Loss on disposition of discontinued operations before income taxes $ (76) $ — $ (859)

Restructuring and Contract Term

Restructuring and Contract Terminaiton Charges, Net (Tables)	12 Months Ended
	Jan. 03, 2021
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions implemented during fiscal years 2020, 2019 and 2018 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Diagnostics Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Severance Excess Facility (In thousands, except headcount data) Q3 2020 Plan 23 $ 901 $ 2,080 $ — $ — $ 2,981 Q2 FY2021 — Q1 2020 Plan 32 1,134 2,312 682 92 4,220 Q4 FY2020 Q1 FY2022 Q4 2019 Plan 22 2,404 177 — — 2,581 Q3 FY2020 — Q3 2019 Plan 259 2,641 11,156 — — 13,797 Q2 FY2020 — Q2 2019 Plan 44 1,129 4,461 — — 5,590 Q1 FY2020 — Q1 2019 Plan 105 1,459 6,001 — — 7,460 Q4 FY2019 — Q4 2018 Plan 1 — 348 — — 348 Q1 FY2019 — Q3 2018 Plan 61 618 1,146 — — 1,764 Q4 FY2019 — Q1 2018 Plan 47 902 5,096 — — 5,998 Q4 FY2019 —
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the Company's restructuring accrual balances and related activity by restructuring plan, as well as other accrual balances and related activity, during fiscal years 2020, 2019 and 2018 in continuing operations: Balance at December 31, 2017 2018 Charges and Changes in Estimates, Net 2018 Amounts Paid Balance at December 30, 2018 2019 Charges and Changes in Estimates, Net 2019 Amounts Paid Balance at December 29, 2019 2020 Charges and Changes in Estimates, Net 2020 Amounts Paid Balance at January 3, 2021 Severance: Q3 2020 Plan $ — $ — $ — $ — $ — $ — $ — $ 2,981 $ (1,814) $ 1,167 Q1 2020 Plan — — — — — — — 3,446 (2,574) 872 Q4 2019 Plan (1) — — — — 2,581 (1,692) 889 (386) (454) 49 Q3 2019 Plan (2) — — — — 13,797 (7,486) 6,311 (2,025) (2,779) 1,507 Q2 2019 Plan (3) — — — — 5,590 (3,701) 1,889 (376) (1,241) 272 Q1 2019 Plan (4) — — — — 7,483 (5,354) 2,129 (867) (669) 593 Q4 2018 Plan — 348 — 348 3 (351) — — — — Q3 2018 Plan — 2,054 (639) 1,415 (77) (1,314) 24 — — 24 Q1 2018 Plan (5) — 5,998 (4,389) 1,609 (1,069) (282) 258 (255) — 3 Facility: Q1 2020 Plan — — — — — — — 774 (380) 394 Previous Plans (6) 10,921 (1,998) (6,252) 2,671 (159) (1,147) 1,365 219 (482) 1,102 Restructuring 10,921 6,402 (11,280) 6,043 28,149 (21,327) 12,865 3,511 (10,393) 5,983 Contract Termination 3,048 4,742 (7,653) 137 452 (401) 188 212 (82) 318 Other Costs — — — — 827 — 827 4,290 (3,119) 1,998 Total Restructuring and Other Liabilities $ 13,969 $ 11,144 $ (18,933) $ 6,180 $ 29,428 $ (21,728) $ 13,880 $ 8,013 $ (13,594) $ 8,299 ____________________________ (1) During fiscal year 2020, the Company recognized pre-tax restructuring reversals of $0.3 million in the Discovery & Analytical Solutions segment and $0.1 million in the Diagnostics segment related to lower than expected costs associated with workforce reductions for the Q4 2019 Plan. (2) During fiscal year 2020, the Company recognized pre-tax restructuring reversals of $1.9 million in the Discovery & Analytical Solutions segment and $0.1 million in the Diagnostics segment related to lower than expected costs associated with workforce reductions for the Q3 2019 Plan. (3) During fiscal year 2020, the Company recognized pre-tax restructuring reversals of $0.4 million in the Discovery & Analytical Solutions segment related to lower than expected costs associated with workforce reductions for the Q2 2019 Plan. (4) During fiscal year 2020, the Company recognized pre-tax restructuring reversals of $0.9 million in the Discovery & Analytical Solutions segment related to lower than expected costs associated with workforce reductions for the Q1 2019 Plan. (5) During fiscal year 2020, the Company recognized pre-tax restructuring reversals of $0.2 million in the Discovery & Analytical Solutions segment and $0.1 million in the Diagnostics segment related to lower than expected costs associated with workforce reductions for the Q1 2018 Plan. (6) During fiscal year 2020, the Company recognized pre-tax restructuring reversals of $0.1 million in each of the Discovery & Analytical Solutions and Diagnostics segments related to lower than expected costs associated with workforce reductions for the Previous Plans.

Income Taxes (Tables)

Income Taxes (Tables) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Income Tax Disclosure [Abstract]
Summary of Income Tax Contingencies [Table Text Block]	The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended: January 3, December 29, December 30, (In thousands) Unrecognized tax benefits, beginning of year $ 35,547 $ 33,009 $ 30,308 Gross increases—tax positions in prior periods 4,974 4,433 6,931 Gross decreases—tax positions in prior periods (2,471) (2,183) (1,622) Gross increases—current-period tax positions 309 152 — Settlements — (45) (2,253) Lapse of statute of limitations — — (181) Foreign currency translation adjustments 414 181 (174) Unrecognized tax benefits, end of year $ 38,773 $ 35,547 $ 33,009
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The components of income from continuing operations before income taxes were as follows for the fiscal years ended: January 3, December 29, December 30, (In thousands) U.S. $ 183,452 $ 29,252 $ 32,627 Non-U.S. 722,912 207,890 225,056 Total $ 906,364 $ 237,142 $ 257,683
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the provision for income taxes on continuing operations were as follows: Current Deferred Total (In thousands) Fiscal year ended January 3, 2021 Federal $ 21,262 $ 15,951 $ 37,213 State 13,688 (967) 12,721 Non-U.S. 172,437 (44,105) 128,332 Total $ 207,387 $ (29,121) $ 178,266 Fiscal year ended December 29, 2019 Federal $ 3,735 $ (267) $ 3,468 State 4,425 (1,574) 2,851 Non-U.S. 62,582 (59,512) 3,070 Total $ 70,742 $ (61,353) $ 9,389 Fiscal year ended December 30, 2018 Federal $ 7,938 $ (5,250) $ 2,688 State 2,345 2,572 4,917 Non-U.S. 61,028 (48,425) 12,603 Total $ 71,311 $ (51,103) $ 20,208
Schedule of Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations [Table Text Block]	The total provision for (benefit from) income taxes included in the consolidated financial statements is as follows for the fiscal years ended: January 3, December 29, December 30, (In thousands) Continuing operations $ 178,266 $ 9,389 $ 20,208 Discontinued operations 135 195 (1,311) Total $ 178,401 $ 9,584 $ 18,897
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended: January 3, December 29, December 30, (In thousands) Tax at statutory rate $ 190,339 $ 49,799 $ 54,114 Non-U.S. rate differential, net (40,216) (32,124) (27,281) U.S. taxation of multinational operations 9,050 4,251 7,047 State income taxes, net 13,306 1,941 2,028 Prior year tax matters 8,262 (5,103) 1,124 Effect of stock compensation (8,818) (2,053) (6,331) General business tax credits (4,136) (4,325) (3,738) Change in valuation allowance 10 (1,117) (759) Foreign consolidations 15,222 — — Tax elections — (3,700) — Impact of U.S. Tax Act — 2,718 (2,025) Others, net (4,753) (898) (3,971) Total $ 178,266 $ 9,389 $ 20,208
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of January 3, 2021 and December 29, 2019 were as follows: January 3, December 29, (In thousands) Deferred tax assets: Inventory $ 4,788 $ 4,662 Reserves and accruals 51,107 46,817 Accrued compensation 20,881 18,953 Net operating loss and credit carryforwards 131,884 116,751 Accrued pension 34,192 35,890 Restructuring reserve 1,579 2,983 Deferred revenue 29,838 30,412 Operating lease liabilities 42,220 46,477 Unrealized foreign exchange loss 21,614 — Total deferred tax assets 338,103 302,945 Deferred tax liabilities: Postretirement health benefits (8,168) (4,106) Depreciation and amortization (355,876) (330,768) Operating lease right-of-use assets (38,598) (42,774) All other, net (4,160) (1,780) Total deferred tax liabilities (406,802) (379,428) Valuation allowance (99,740) (88,449) Net deferred tax liabilities $ (168,439) $ (164,932)
Schedule of Deferred Income Taxes, Domestic and Foreign [Table Text Block]	The components of net deferred tax (liabilities) assets as of January 3, 2021 and December 29, 2019 were as follows: January 3, December 29, (In thousands) U.S. $ 50,302 $ 43,683 Non-U.S. (218,741) (208,615) Total $ (168,439) $ (164,932)
Components of net deferred tax asset recognized [Table Text Block]	The components of net deferred tax liabilities as of January 3, 2021 and December 29, 2019 were recognized in the consolidated balance sheets as follows: January 3, December 29, (In thousands) Other assets, net $ 65,518 $ 60,004 Long-term liabilities (233,957) (224,936) Total $ (168,439) $ (164,932)
Deferred tax assets, other assets, net	$ 65,518	$ 60,004
Deferred tax liabilities, Long-term liabilities	(233,957)	(224,936)
Deferred Tax Liabilities, Net	$ (168,439)	$ (164,932)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Jan. 03, 2021
Earnings Per Share [Abstract]
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations	The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended: January 3, December 29, December 30, (In thousands) Number of common shares—basic 111,514 110,827 110,561 Effect of dilutive securities: Stock options 466 541 761 Restricted stock awards 105 133 212 Number of common shares—diluted 112,085 111,501 111,534 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 220 364 349

Accounts Receivable, Net Accoun

Accounts Receivable, Net Accounts Receivable, Net (Tables)	12 Months Ended
	Jan. 03, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	Accounts receivable, net as of January 3, 2021 and December 29, 2019 consisted of the following: January 3, December 29, (In thousands) Accounts receivable, net, current $ 1,155,109 $ 725,184 Long-term accounts receivable, net, included in Other assets 22,510 19,677 Total accounts receivable, net $ 1,177,619 $ 744,861

Inventories, Net (Tables)

Inventories, Net (Tables)	12 Months Ended
	Jan. 03, 2021
Inventory Disclosure [Abstract]
Schedule of Net Inventories	Inventories as of January 3, 2021 and December 29, 2019 consisted of the following: January 3, December 29, (In thousands) Raw materials $ 205,022 $ 130,673 Work in progress 35,160 26,409 Finished goods 274,385 199,855 Total inventories $ 514,567 $ 356,937

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Jan. 03, 2021
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment [Table Text Block]	Property, plant and equipment as of January 3, 2021 and December 29, 2019, consisted of the following: January 3, December 29, (In thousands) At cost: Land $ 3,937 $ 5,272 Building and leasehold improvements 291,526 250,639 Machinery and equipment 522,734 445,669 Total property, plant and equipment 818,197 701,580 Accumulated depreciation (449,893) (383,357) Total property, plant and equipment, net $ 368,304 $ 318,223

Marketable Securities and Inv_2

Marketable Securities and Investments (Tables)	12 Months Ended
	Jan. 03, 2021
Marketable Securities [Abstract]
Schedule of Investments, Noncurrent [Table Text Block]	Investments as of January 3, 2021 and December 29, 2019 consisted of the following: January 3, December 29, (In thousands) Marketable securities $ 2,154 $ 2,906 Equity investments 48,626 29,228 $ 50,780 $ 32,134
Available-for-sale Securities [Table Text Block]	Marketable securities classified as available for sale as of January 3, 2021 and December 29, 2019 consisted of the following: Market Value Gross Unrealized Holding Cost Gains (Losses) (In thousands) January 3, 2021 Equity securities $ 203 $ 584 $ — $ (381) Fixed-income securities 7 7 — — Other 1,944 2,007 — (63) $ 2,154 $ 2,598 $ — $ (444) December 29, 2019 Equity securities $ 752 $ 1,109 $ — $ (357) Fixed-income securities 7 7 — — Other 2,147 2,210 — (63) $ 2,906 $ 3,326 $ — $ (420)
Equity Securities without Readily Determinable Fair Value	Equity investments without readily determinable fair values as of January 3, 2021 and December 29, 2019 consisted of the following: January 3, December 29, (In thousands) Equity investments, carried at cost minus impairment, if any $ 27,438 $ 29,228 Equity investments, carried at fair value 21,188 — $ 48,626 $ 29,228

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	12 Months Ended
	Jan. 03, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for fiscal years 2020 and 2019 are as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Balance at December 30, 2018 $ 1,334,992 $ 1,617,616 $ 2,952,608 Foreign currency translation (8,559) (9,725) (18,284) Acquisitions, earnouts and other 172,387 4,516 176,903 Balance at December 29, 2019 1,498,820 1,612,407 3,111,227 Foreign currency translation 58,086 62,596 120,682 Acquisitions, earnouts and other 198,981 16,224 215,205 Balance at January 3, 2021 $ 1,755,887 $ 1,691,227 $ 3,447,114
Identifiable Intangible Asset Balances	Identifiable intangible asset balances at January 3, 2021 by category and segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Patents $ 28,146 $ 2,709 $ 30,855 Less: Accumulated amortization (27,933) (507) (28,440) Net patents 213 2,202 2,415 Trade names and trademarks 51,143 47,518 98,661 Less: Accumulated amortization (31,859) (16,947) (48,806) Net trade names and trademarks 19,284 30,571 49,855 Licenses 50,468 8,232 58,700 Less: Accumulated amortization (49,317) (3,135) (52,452) Net licenses 1,151 5,097 6,248 Core technology 456,607 333,192 789,799 Less: Accumulated amortization (232,648) (166,344) (398,992) Net core technology 223,959 166,848 390,807 Customer relationships 475,748 881,912 1,357,660 Less: Accumulated amortization (239,428) (283,392) (522,820) Net customer relationships 236,320 598,520 834,840 IPR&D 10,944 — 10,944 Net amortizable intangible assets 491,871 803,238 1,295,109 Non-amortizing intangible asset: Trade name 70,584 — 70,584 Total $ 562,455 $ 803,238 $ 1,365,693 Identifiable intangible asset balances at December 29, 2019 by category and segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Patents $ 28,122 $ 2,709 $ 30,831 Less: Accumulated amortization (27,142) (281) (27,423) Net patents 980 2,428 3,408 Trade names and trademarks 39,859 48,138 87,997 Less: Accumulated amortization (23,632) (16,663) (40,295) Net trade names and trademarks 16,227 31,475 47,702 Licenses 50,393 8,103 58,496 Less: Accumulated amortization (47,607) (2,126) (49,733) Net licenses 2,786 5,977 8,763 Core technology 390,116 298,973 689,089 Less: Accumulated amortization (205,263) (115,663) (320,926) Net core technology 184,853 183,310 368,163 Customer relationships 313,898 847,628 1,161,526 Less: Accumulated amortization (156,967) (221,221) (378,188) Net customer relationships 156,931 626,407 783,338 IPR&D — 1,328 1,328 Net amortizable intangible assets 361,777 850,925 1,212,702 Non-amortizing intangible asset: Trade name 70,584 — 70,584 Total $ 432,361 $ 850,925 $ 1,283,286

Debt (Tables)

Debt (Tables)	12 Months Ended
	Jan. 03, 2021
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt [Table Text Block]	The following table summarizes the maturities of the Company’s indebtedness as of January 3, 2021: Sr. Unsecured 2021 2026 Notes 2029 Notes Other Debt Facilities Total (In thousands) 2021 $ — $ 366,450 $ — $ — $ 14,743 $ 381,193 2022 — — — — 4,075 4,075 2023 — — — — 2,457 2,457 2024 158,595 — — — 1,372 159,967 2025 — — — — 230 230 2026 and thereafter — — 610,750 850,000 282 1,461,032 Total before unamortized discount and debt issuance costs 158,595 366,450 610,750 850,000 23,159 2,008,954 Unamortized discount and debt issuance costs (2,621) (245) (6,035) (9,404) — (18,305) Total $ 155,974 $ 366,205 $ 604,715 $ 840,596 $ 23,159 $ 1,990,649

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Jan. 03, 2021
Accounts Payable and Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses and other current liabilities as of January 3, 2021 and December 29, 2019 consisted of the following: January 3, December 29, (In thousands) Payroll and incentives $ 96,502 $ 77,892 Employee benefits 47,489 42,405 Deferred revenue 203,927 164,261 Federal, non-U.S. and state income taxes 97,406 29,876 Operating lease liabilities 40,330 36,573 Contract liabilities 189,718 — Other accrued operating expenses 261,655 152,325 Total accrued expenses and other current liabilities $ 937,027 $ 503,332

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Jan. 03, 2021
Pension Plans, Defined Benefit
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Components of Net Periodic Benefit Cost (Credit)	Net periodic pension cost for U.S. and non-U.S. plans included the following components for fiscal years ended: January 3, December 29, December 30, (In thousands) Service and administrative costs $ 7,414 $ 6,598 $ 6,853 Interest cost 12,876 16,546 16,146 Expected return on plan assets (21,786) (24,561) (28,939) Actuarial loss 20,291 27,134 17,146 Curtailment gain — (1,547) — Amortization of prior service (credit) cost — (152) 375 Net periodic pension cost $ 18,795 $ 24,018 $ 11,581
Schedule of Net Funded Status	The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of January 3, 2021 and December 29, 2019. January 3, 2021 December 29, 2019 Non-U.S. U.S. Non-U.S. U.S. (In thousands) Actuarial present value of benefit obligations: Accumulated benefit obligations $ 392,948 $ 317,679 $ 338,722 $ 304,710 Change in benefit obligations: Projected benefit obligations at beginning of year $ 341,455 $ 304,710 $ 311,168 $ 283,310 Service and administrative costs 5,314 2,100 4,248 2,350 Interest cost 3,991 8,885 5,448 11,098 Benefits paid and plan expenses (15,823) (20,510) (12,778) (21,162) Participants’ contributions 37 — 162 — Business acquisitions (120) — — — Plan curtailments — — (1,420) — Actuarial loss 35,910 22,494 34,602 29,114 Effect of exchange rate changes 24,575 — 25 — Projected benefit obligations at end of year $ 395,339 $ 317,679 $ 341,455 $ 304,710 Change in plan assets: Fair value of plan assets at beginning of year $ 179,860 $ 254,450 $ 159,163 $ 234,342 Actual return on plan assets 25,153 34,746 19,873 41,270 Benefits paid and plan expenses (15,823) (20,510) (12,778) (21,162) Employer’s contributions 7,506 — 8,200 — Participants’ contributions 37 — 162 — Effect of exchange rate changes 8,011 — 5,240 — Fair value of plan assets at end of year $ 204,744 $ 268,686 $ 179,860 $ 254,450 Net liabilities recognized in the consolidated balance sheets $ (190,595) $ (48,993) $ (161,595) $ (50,260) Net amounts recognized in the consolidated balance sheets consist of: Other assets $ 36,295 $ — $ 36,699 $ — Current liabilities (7,597) — (6,764) — Long-term liabilities (219,293) (48,993) (191,530) (50,260) Net liabilities recognized in the consolidated balance sheets $ (190,595) $ (48,993) $ (161,595) $ (50,260) Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — $ — $ — Actuarial assumptions as of the year-end measurement date: Discount rate 0.92 % 2.21 % 1.34 % 3.01 % Rate of compensation increase 2.78 % None 3.36 % None Actuarial assumptions used to determine net periodic pension cost during the year were as follows: January 3, 2021 December 29, 2019 December 30, 2018 Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Discount rate 1.34 % 3.01 % 2.07 % 4.05 % 1.99 % 3.56 % Rate of compensation increase 3.36 % None 3.48 % None 3.50 % None Expected rate of return on assets 2.20 % 7.25 % 5.30 % 7.25 % 5.90 % 7.25 %
Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]	The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets: January 3, December 29, (In thousands) Pension Plans with Projected Benefit Obligations in Excess of Plan Assets Projected benefit obligations $ 226,890 $ 198,294 Fair value of plan assets — — Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets Accumulated benefit obligations $ 224,499 $ 195,657 Fair value of plan assets — —
Schedule of Allocation of Plan Assets	Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of January 3, 2021 and December 29, 2019, and target asset allocations for fiscal year 2021 are as follows: Target Allocation Percentage of Plan Assets at January 2, 2022 January 3, 2021 December 29, 2019 Asset Category Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Equity securities 0-5% 40-60% — % 45 % — % 41 % Debt securities 85-90% 40-60% 88 % 55 % 87 % 59 % Other 10-15% 0-10% 12 % — % 13 % — % Total 100 % 100 % 100 % 100 % 100 % 100 %
Schedule of Changes in Fair Value of Plan Assets	The fair values of the Company’s pension plan assets as of January 3, 2021 and December 29, 2019 by asset category, classified in the three levels of inputs described in Note 22 to the consolidated financial statements are as follows: Fair Value Measurements at January 3, 2021 Using: Total Carrying Quoted Prices in Significant Other Significant (In thousands) Cash $ 6,363 $ 6,363 $ — $ — Equity securities: U.S. large-cap 78,234 78,234 — — International large-cap value 28,315 28,315 — — Emerging markets growth 13,594 13,594 — — Foreign real estate funds 23,259 — — 23,259 Fixed income securities: Non-U.S. treasury securities 106,315 — 106,315 — Corporate and U.S. debt instruments 140,349 43,500 96,849 — Corporate bonds 35,816 — 35,816 — High yield bond funds 2,954 2,954 — — Other types of investments: Non-U.S. government index linked bonds 38,231 — 38,231 — Total assets measured at fair value $ 473,430 $ 172,960 $ 277,211 $ 23,259 Fair Value Measurements at December 29, 2019 Using: Total Carrying Quoted Prices in Significant Other Significant (In thousands) Cash $ 6,177 $ 6,177 $ — $ — Equity Securities: U.S. large-cap 57,797 57,797 — — International large-cap value 26,914 26,914 — — U.S. small mid-cap 2,700 2,700 — — Emerging markets growth 12,853 12,853 — — Domestic real estate funds 2,010 2,010 — — Foreign real estate funds 22,688 — — 22,688 Fixed income securities: Non-U.S. Treasury Securities 93,473 — 93,473 — Corporate and U.S. debt instruments 139,300 47,104 92,196 — Corporate bonds 29,846 — 29,846 — High yield bond funds 5,734 5,734 — — Other types of investments: Multi-strategy hedge funds 1,721 — — 1,721 Non-U.S. government index linked bonds 33,097 — 33,097 — Total assets measured at fair value $ 434,310 $ 161,289 $ 248,612 $ 24,409
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets	A reconciliation of the beginning and ending Level 3 assets for fiscal years 2020, 2019 and 2018 is as follows: Fair Value Measurements Using Foreign Multi-strategy Total (In thousands) Balance at December 31, 2017 $ — $ 16,789 $ 16,789 Unrealized gains — 145 145 Purchases 22,196 — 22,196 Balance at December 30, 2018 22,196 16,934 39,130 Sales — (15,586) (15,586) Realized gains — 4,175 4,175 Unrealized gains (losses) 492 (3,802) (3,310) Balance at December 29, 2019 22,688 1,721 24,409 Sales — (1,721) (1,721) Unrealized gains 571 — 571 Balance at January 3, 2021 $ 23,259 $ — $ 23,259
Schedule of Expected Benefit Payments	The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Non-U.S. U.S. (In thousands) 2021 $ 12,932 $ 19,373 2022 12,960 19,435 2023 13,349 19,504 2024 14,152 19,495 2025 14,206 19,390 2026-2030 72,747 92,258
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Components of Net Periodic Benefit Cost (Credit)	Net periodic postretirement medical benefit (credit) cost included the following components for the fiscal years ended: January 3, December 29, December 30, (In thousands) Service cost $ 73 $ 87 $ 106 Interest cost 94 116 120 Expected return on plan assets (1,389) (1,175) (1,254) Actuarial (gain) loss (1,647) (1,776) 1,621 Net periodic postretirement medical benefit (credit) cost $ (2,869) $ (2,748) $ 593
Schedule of Net Funded Status	The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of January 3, 2021 and December 29, 2019. January 3, December 29, (In thousands) Actuarial present value of benefit obligations: Retirees $ 611 $ 583 Active employees eligible to retire 420 362 Other active employees 2,069 1,966 Accumulated benefit obligations at beginning of year 3,100 2,911 Service cost 73 87 Interest cost 94 116 Benefits paid (101) (122) Actuarial (gain) loss (179) 108 Change in accumulated benefit obligations during the year (113) 189 Retirees 545 611 Active employees eligible to retire 1,232 420 Other active employees 1,211 2,069 Accumulated benefit obligations at end of year $ 2,988 $ 3,100 Change in plan assets: Fair value of plan assets at beginning of year $ 19,216 $ 16,279 Actual return on plan assets 2,756 2,937 Fair value of plan assets at end of year $ 21,972 $ 19,216 Net assets recognized in the consolidated balance sheets $ 18,984 $ 16,116 Net amounts recognized in the consolidated balance sheets consist of: Other assets $ 18,984 $ 16,116 Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — Actuarial assumptions as of the year-end measurement date: Discount rate 2.34 % 3.09 % Actuarial assumptions used to determine net cost during the year are as follows: January 3, December 29, December 30, Discount rate 3.09 % 4.09 % 3.60 % Expected rate of return on assets 7.25 % 7.25 % 7.25 %
Schedule of Changes in Fair Value of Plan Assets	The fair values of the Company’s plan assets at January 3, 2021 and December 29, 2019 by asset category, classified in the three levels of inputs described in Note 22, are as follows: Fair Value Measurements at January 3, 2021 Using: Total Carrying Quoted Prices in Significant Other Significant (In thousands) Cash $ 428 $ 428 $ — $ — Equity securities: U.S. large-cap 6,398 6,398 — — International large-cap value 2,315 2,315 — — Emerging markets growth 1,112 1,112 — — Fixed income securities: Corporate and U.S. debt instruments 11,477 3,557 7,920 — High yield bond funds 242 242 — — Total assets measured at fair value $ 21,972 $ 14,052 $ 7,920 $ — Fair Value Measurements at December 29, 2019 Using: Total Carrying Quoted Prices in Significant Other Significant (In thousands) Cash $ 408 $ 408 $ — $ — Equity securities: U.S. large-cap 4,365 4,365 — — International large-cap value 2,033 2,033 — — U.S. small mid-cap 204 204 — — Emerging markets growth 971 971 — — Domestic real estate funds 152 152 — — Fixed income securities: Corporate debt instruments 10,520 3,557 6,963 — High yield bond funds 433 433 — — Other types of investments: Multi-strategy hedge funds 130 — — 130 Total assets measured at fair value $ 19,216 $ 12,123 $ 6,963 $ 130
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets	A reconciliation of the beginning and ending Level 3 assets for fiscal years 2020, 2019 and 2018 is as follows: Fair Value Multi-strategy (In thousands) Balance at December 31, 2017 $ 1,151 Unrealized gains 25 Balance at December 30, 2018 1,176 Sales (1,074) Realized gains 315 Unrealized losses (287) Balance at December 29, 2019 130 Sales (130) Balance at January 3, 2021 $ —
Schedule of Expected Benefit Payments	The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Postretirement Medical Plan (In thousands) 2021 $ 119 2022 137 2023 150 2024 161 2025 172 2026-2030 883

Warranty Reserves (Tables)

Warranty Reserves (Tables)	12 Months Ended
	Jan. 03, 2021
Product Warranties Disclosures [Abstract]
Warranty Reserve Activity	A summary of warranty reserve activity for the fiscal years ended January 3, 2021, December 29, 2019 and December 30, 2018 is as follows: (In thousands) Balance at December 31, 2017 $ 9,050 Provision charged to income 13,545 Payments (13,775) Adjustments to previously provided warranties, net (157) Foreign currency translation and acquisitions (270) Balance at December 30, 2018 8,393 Provision charged to income 12,199 Payments (14,613) Adjustments to previously provided warranties, net 2,889 Foreign currency translation and acquisitions (56) Balance at December 29, 2019 8,812 Provision charged to income 15,315 Payments (15,130) Adjustments to previously provided warranties, net 2,721 Foreign currency translation and acquisitions 355 Balance at January 3, 2021 $ 12,073

Stock Plans (Tables)

Stock Plans (Tables)	12 Months Ended
	Jan. 03, 2021
Share-based Payment Arrangement [Abstract]
Summary of Total Compensation Recognized Related to Outstanding Equity Awards	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units, performance units and stock grants, included in the Company’s consolidated statements of operations for fiscal years 2020, 2019 and 2018: January 3, December 29, December 30, (In thousands) Cost of product and service revenue $ 1,388 $ 1,620 $ 1,466 Research and development expenses 1,228 1,061 1,359 Selling, general and administrative expenses 26,510 28,833 25,942 Total stock-based compensation expense $ 29,126 $ 31,514 $ 28,767
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model	The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended: January 3, December 29, December 30, Risk-free interest rate 0.9 % 2.5 % 3.0 % Expected dividend yield 0.3 % 0.3 % 0.4 % Expected lives 5 years 5 years 5 years Expected stock volatility 23.8 % 22.8 % 20.7 %
Summary of Stock Option Activity	The following table summarizes stock option activity for the fiscal year ended January 3, 2021: Number Weighted- (Shares in thousands) Outstanding at beginning of year 1,535 $ 60.42 Granted 266 86.87 Exercised (764) 49.31 Canceled (1) 95.74 Forfeited (75) 87.34 Outstanding at end of year 961 $ 74.40 Exercisable at end of year 562 $ 65.30
Summary of Restricted Stock Award Activity	The following table summarizes restricted stock award activity for the fiscal year ended January 3, 2021: Number Weighted- (Shares in thousands) Nonvested at beginning of year 345 $ 78.69 Granted 184 84.83 Vested (193) 72.28 Forfeited (40) 86.32 Nonvested at end of year 296 $ 85.67

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Jan. 03, 2021
Stockholders' Equity Note [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive (loss) income consisted of the following: Foreign Unrecognized Unrealized Accumulated (In thousands) Balance, December 31, 2017 $ (46,582) $ 322 $ (258) $ (46,518) Current year change (123,388) (77) (9) (123,474) Reclassification to retained earnings upon adoption of ASU 2018-02 (6,489) — — (6,489) Balance, December 30, 2018 (176,459) 245 (267) (176,481) Current year change (23,978) 807 6 (23,165) Balance, December 29, 2019 (200,437) 1,052 (261) (199,646) Current year change 169,500 (1,799) (16) 167,685 Balance, January 3, 2021 $ (30,937) $ (747) $ (277) $ (31,961)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jan. 03, 2021
Fair Value Disclosures [Abstract]
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of January 3, 2021 and December 29, 2019 classified in one of the three classifications described above: Fair Value Measurements at January 3, 2021 Using: Total Carrying Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 2,154 $ 2,154 $ — $ — Foreign exchange derivative assets 31,248 — 31,248 — Foreign exchange derivative liabilities (21,413) — (21,413) — Contingent consideration (2,953) — — (2,953) Fair Value Measurements at December 29, 2019 Using: Total Carrying Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 2,906 $ 2,906 $ — $ — Foreign exchange derivative assets 451 — 451 — Foreign exchange derivative liabilities (1,538) — (1,538) — Contingent consideration (35,481) — — (35,481)
Reconciliation of Beginning and Ending Level 3 Net Liabilities	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: (In thousands) Balance at December 31, 2017 $ (65,328) Amounts paid and foreign currency translation 16,506 Change in fair value (included within selling, general and administrative expenses) (14,639) Balance at December 30, 2018 (69,661) Additions (12,734) Amounts paid and foreign currency translation 50,795 Change in fair value (included within selling, general and administrative expenses) (3,881) Balance at December 29, 2019 (35,481) Amounts paid and foreign currency translation 23,701 Change in fair value (included within selling, general and administrative expenses) 8,827 Balance at January 3, 2021 $ (2,953)

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jan. 03, 2021
Leases [Abstract]
Lease, Cost [Table Text Block]	The components of lease expense were as follows: January 3, December 29, (In thousands) Lease Cost: Operating lease cost $ 56,977 $ 61,205
Supplemental Cash Flow Information Related To Leases [Table Text Block]	Supplemental cash flow information related to leases was as follows: January 3, December 29, (In thousands) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 47,427 $ 50,155
Supplemental Balance Sheet Information Related To Leases [Table Text Block]	Supplemental balance sheet information related to leases was as follows: January 3, December 29, (In thousands, except lease term and discount rate) Operating Leases: Operating lease right-of-use assets $ 207,236 $ 167,276 Operating lease liabilities included in Accrued expenses and other current liabilities $ 40,330 $ 36,573 Operating lease liabilities 188,402 146,399 Total operating liabilities $ 228,732 $ 182,972 Weighted Average Remaining Lease Term in Years Operating leases 8.1 Weighted Average Remaining Discount Rate Operating leases 2.9%
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturities of operating lease liabilities as of January 3, 2021 were as follows: (In thousands) 2021 $ 48,986 2022 40,097 2023 30,044 2024 26,667 2025 24,847 2026 and thereafter 90,518 Total lease payments 261,159 Less imputed interest (32,427) Total $ 228,732

Industry Segment and Geograph_2

Industry Segment and Geographic Area Information (Tables)	12 Months Ended
	Jan. 03, 2021
Segment Reporting [Abstract]
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations	Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended: January 3, December 29, December 30, (In thousands) Discovery & Analytical Solutions Product revenue $ 995,216 $ 1,054,862 $ 1,010,899 Service revenue 720,587 691,299 682,312 Total revenue 1,715,803 1,746,161 1,693,211 Operating income from continuing operations (1) 183,471 238,331 230,481 Diagnostics Product revenue 1,783,509 962,180 924,594 Service revenue 283,433 175,332 160,191 Total revenue 2,066,942 1,137,512 1,084,785 Operating income from continuing operations (1)(2) 874,206 189,330 153,196 Corporate Operating loss from continuing operations (3) (79,096) (65,688) (59,793) Continuing Operations Product revenue 2,778,725 2,017,042 1,935,493 Service revenue 1,004,020 866,631 842,503 Total revenue 3,782,745 2,883,673 2,777,996 Operating income from continuing operations 978,581 361,973 323,884 Interest and other expense, net (see Note 6) 72,217 124,831 66,201 Income from continuing operations before income taxes $ 906,364 $ 237,142 $ 257,683 ____________________________ (1) Legal costs for significant litigation matters and settlements in the Company's Discovery & Analytical Solutions segment were $5.9 million, $2.2 million and $5.3 million for fiscal years 2020, 2019 and 2018, respectively. Legal costs for significant litigation matters and settlements in the Company's Diagnostics segment were $1.2 million, $0.1 million and $0.2 million for fiscal years 2020, 2019 and 2018, respectively. (2) Asset impairment in the Company's Diagnostics segment was $7.9 million for fiscal year 2020. (3) Costs for significant environmental matters was $5.2 million for fiscal year 2020. Stock compensation expense from acceleration of executive compensation was $7.7 million for fiscal year 2019.
Schedule of Depreciation, Amortization and Capital Expenditures	Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended January 3, 2021: Depreciation and Amortization Expense Capital Expenditures January 3, December 29, December 30, January 3, December 29, December 30, (In thousands) (In thousands) Discovery & Analytical Solutions $ 93,516 $ 74,445 $ 70,362 $ 20,217 $ 27,778 $ 34,852 Diagnostics 149,738 136,476 107,434 55,236 46,863 54,737 Corporate 3,253 3,104 2,792 2,053 1,690 3,664 Continuing operations $ 246,507 $ 214,025 $ 180,588 $ 77,506 $ 76,331 $ 93,253
Schedule of Total Assets by Segment	Total Assets January 3, December 29, December 30, (In thousands) Discovery & Analytical Solutions $ 3,600,860 $ 3,082,917 $ 2,567,054 Diagnostics 4,228,943 3,368,598 3,358,964 Corporate 130,512 87,049 49,504 Total assets $ 7,960,315 $ 6,538,564 $ 5,975,522
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended January 3, 2021 and net long-lived assets based on physical location as of January 3, 2021 and December 29, 2019: Revenue January 3, December 29, December 30, (In thousands) U.S. $ 1,269,293 $ 974,187 $ 906,398 International: China 492,283 581,688 559,865 United Kingdom 362,591 70,703 72,124 Germany 200,294 146,577 142,411 Italy 163,056 101,461 95,908 France 148,898 96,994 97,990 Republic of Korea 114,846 71,069 60,126 India 103,785 97,423 92,327 Japan 88,473 82,478 79,238 Other international 839,226 661,093 671,609 Total international 2,513,452 1,909,486 1,871,598 Total sales $ 3,782,745 $ 2,883,673 $ 2,777,996 Net Long-Lived Assets* January 3, December 29, December 30, (In thousands) U.S. $ 197,755 $ 269,183 $ 201,649 International: Germany 149,105 119,612 99,181 China 75,199 71,216 61,261 Finland 60,559 29,052 16,211 United Kingdom 35,243 51,659 33,429 Singapore 24,291 23,063 14,942 India 21,975 19,691 14,636 Italy 17,051 14,152 11,324 France 13,325 12,940 3,210 Brazil 8,627 9,126 8,237 Poland 7,732 7,216 3,212 Canada 5,671 6,485 5,454 Other international 34,625 26,210 17,565 Total international 453,403 390,422 288,662 Total net long-lived assets $ 651,158 $ 659,605 $ 490,311

Quarterly Financial Informati_2

Quarterly Financial Information (Unaudited) Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Jan. 03, 2021
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	Selected quarterly financial information is as follows for the fiscal years ended: First Second Third Fourth Quarter (1) Year (In thousands, except per share data) January 3, 2021 Revenue $ 652,396 $ 811,718 $ 964,025 $ 1,354,606 $ 3,782,745 Gross profit 308,023 447,344 527,445 827,065 2,109,877 Restructuring and other costs, net 5,858 1,158 4,059 (3,062) 8,013 Operating income from continuing operations 44,682 175,639 248,006 510,254 978,581 Income from continuing operations before income taxes 34,689 164,827 233,757 473,091 906,364 Income from continuing operations 33,715 137,213 176,736 380,434 728,098 Loss from discontinued operations and dispositions (50) (51) (37) (73) (211) Net income 33,665 137,162 176,699 380,361 727,887 Basic earnings per share: Income from continuing operations $ 0.30 $ 1.23 $ 1.58 $ 3.40 $ 6.53 Loss from discontinued operations and dispositions (0.00) (0.00) (0.00) (0.00) (0.00) Net income 0.30 1.23 1.58 3.40 6.53 Diluted earnings per share: Income from continuing operations $ 0.30 $ 1.23 $ 1.57 $ 3.38 $ 6.50 Loss from discontinued operations and dispositions (0.00) (0.00) (0.00) (0.00) (0.00) Net income 0.30 1.23 1.57 3.38 6.49 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 December 29, 2019 Revenue $ 648,737 $ 722,517 $ 706,923 $ 805,496 $ 2,883,673 Gross profit 307,806 347,793 342,275 398,181 1,396,055 Restructuring and other costs, net 7,639 6,161 14,068 1,560 29,428 Operating income from continuing operations 53,330 91,735 78,660 138,248 361,973 Income from continuing operations before income taxes 36,765 71,827 63,254 65,296 237,142 Income from continuing operations 35,453 69,141 58,610 64,549 227,753 Loss from discontinued operations and dispositions (41) (54) (52) (48) (195) Net income 35,412 69,087 58,558 64,501 227,558 Basic earnings per share: Income from continuing operations $ 0.32 $ 0.62 $ 0.53 $ 0.58 $ 2.06 Loss from discontinued operations and dispositions (0.00) (0.00) (0.00) (0.00) (0.00) Net income 0.32 0.62 0.53 0.58 2.06 Diluted earnings per share: Income continuing operations $ 0.32 $ 0.62 $ 0.53 $ 0.58 $ 2.04 Loss from discontinued operations and dispositions (0.00) (0.00) (0.00) (0.00) (0.00) Net income 0.32 0.62 0.52 0.58 2.04 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 ____________________________ (1) The fourth quarter of fiscal year 2020 includes a pre-tax loss of $25.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.

Business Combinations and Ass_3

Business Combinations and Asset Purchases (Narrative) (Details)	3 Months Ended								12 Months Ended
	Jan. 03, 2021USD ($)employees	Oct. 04, 2020USD ($)	Jul. 05, 2020USD ($)	Apr. 05, 2020USD ($)	Dec. 29, 2019USD ($)	Sep. 29, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Jan. 03, 2021USD ($)employees	Dec. 29, 2019USD ($)	Dec. 30, 2018USD ($)	Jan. 01, 2017USD ($)
Business Acquisition [Line Items]
Revenue	$ 1,354,606,000	$ 964,025,000	$ 811,718,000	$ 652,396,000	$ 805,496,000	$ 706,923,000	$ 722,517,000	$ 648,737,000	$ 3,782,745,000	$ 2,883,673,000
Business Combination, Contingent Consideration, Liability, Current	(2,900,000)				(20,800,000)				(2,900,000)	(20,800,000)
Business Combination, Contingent Consideration, Liability, Noncurrent	100,000				14,700,000				100,000	14,700,000
Business Combination, Contingent Consideration, Liability, Total	(3,000,000)				(35,500,000)				$ (3,000,000)	(35,500,000)
Business Combination, Contingent Consideration Arrangements, Maximum Period									2 years 10 months 24 days
Business Combination, Contingent Consideration Arrangements, Description									Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). The expected maximum earnout period for an acquisition with open contingency period do not exceed 2.9 years from January 3, 2021, and the remaining weighted average expected earnout period at January 3, 2021 was 1.9 years.
Goodwill	3,447,114,000				3,111,227,000				$ 3,447,114,000	3,111,227,000	$ 2,952,608,000
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions									1 year
Business Combination, Contingent Consideration Arrangements, Weighted Average Period									1 year 10 months 24 days
Business Combination, Acquisition Related Costs									$ 9,300,000	6,600,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	7,300,000								7,300,000
Foreign Currency Transaction Gain (Loss), before Tax									2,700,000	(6,500,000)	9,400,000
Interest Expense									49,712,000	63,627,000	66,976,000
Fiscal Year 2020 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	5,770,000								5,770,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(29,000)								(29,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	2,673,000								2,673,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	371,000								371,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	38,030,000								38,030,000
Business Acquisition, Cost of Acquired Entity, Cash Paid									38,243,000
Business Combination, Consideration Transferred, Liabilities Incurred									1,263,000
Goodwill	16,224,000								16,224,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(1,132,000)								(1,132,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue	0								0
Working capital and other adjustments									(176,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(3,180,000)								(3,180,000)
Cash Acquired									(1,300,000)
Business Combination, Consideration Transferred									38,030,000
Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	29,762,000								29,762,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	0								0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	17,729,000								17,729,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	17,743,000								17,743,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	$ 373,862,000								373,862,000
Business Acquisition, Cost of Acquired Entity, Cash Paid									399,005,000
Business Combination, Consideration Transferred, Liabilities Incurred									$ 396,000
Entity Number of Employees | employees	400								400
Goodwill	$ 200,745,000								$ 200,745,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(22,480,000)								(22,480,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue	2,031,000								2,031,000
Working capital and other adjustments									0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(39,906,000)								(39,906,000)
Cash Acquired									(25,539,000)
Business Combination, Consideration Transferred									373,862,000
Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Operating Income (Loss) From Immaterial Acquisitions									$ 0
Weighted average amortization period (in years)									11 years
Interest Expense									$ 500,000
Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Operating Income (Loss) From Immaterial Acquisitions										$ 0
Weighted average amortization period (in years)										11 years
Business Combination, Increase (Decrease) in Liabilities Assumed									(400,000)
Business Combination, Increase (Decrease) in Deferred Tax Liabilities									400,000
Goodwill, Purchase Accounting Adjustments									(1,800,000)
Business Combination, Increase (Decrease) in Intangible Assets									1,900,000
Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	4,125,000								4,125,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities					(2,698,000)					$ (2,698,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					727,000					727,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		502,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					45,282,000					45,282,000
Business Acquisition, Cost of Acquired Entity, Cash Paid										45,042,000
Business Combination, Consideration Transferred, Liabilities Incurred										638,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value										(634,000)
Goodwill					17,079,000					17,079,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(6,603,000)								(6,603,000)
Working capital and other adjustments										302,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(3,527,000)								(3,527,000)
Cash Acquired										(1,334,000)
Business Combination, Consideration Transferred										45,282,000
Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	15,077,000								15,077,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities					(706,000)					(706,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					6,278,000					6,278,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		$ 24,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					164,399,000					164,399,000
Business Acquisition, Cost of Acquired Entity, Cash Paid										145,000,000
Business Combination, Consideration Transferred, Liabilities Incurred										6,446,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value										(12,100,000)
Goodwill	78,612,000								78,612,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(21,548,000)								(21,548,000)
Working capital and other adjustments										2,961,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(10,638,000)								(10,638,000)
Cash Acquired										(2,108,000)
Business Combination, Consideration Transferred										164,399,000
Compensation Expense, Excluding Cost of Good and Service Sold									4,700,000
Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets					43,554,000					43,554,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities					0					0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					4,835,000					4,835,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets					100,000					100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					207,391,000					207,391,000
Business Acquisition, Cost of Acquired Entity, Cash Paid										219,795,000
Business Combination, Consideration Transferred, Liabilities Incurred										0
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value										0
Goodwill			73,417,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total			$ (34,962,000)
Working capital and other adjustments										138,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt					(12,553,000)					(12,553,000)
Cash Acquired										(12,542,000)
Business Combination, Consideration Transferred										207,391,000
Foreign Currency Transaction Gain (Loss), before Tax										2,600,000
Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Operating Income (Loss) From Immaterial Acquisitions											0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets					4,905,000					4,905,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities											(461,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					1,166,000					1,166,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets					776,000					776,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net											104,633,000
Business Acquisition, Cost of Acquired Entity, Cash Paid											95,950,000
Business Combination, Consideration Transferred, Liabilities Incurred											$ 3,354,000
Weighted average amortization period (in years)											11 years 2 months 12 days
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value											$ (6,200,000)
Goodwill											65,886,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total											(9,049,000)
Working capital and other adjustments											261,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt											(3,881,000)
Cash Acquired											(1,132,000)
Business Combination, Consideration Transferred											104,633,000
Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Compensation Expense, Excluding Cost of Good and Service Sold										500,000
Vanadis Diagnostics AB [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value												$ 56,900,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High												$ 93,000,000
Core Technology [Member] | Fiscal Year 2020 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	5,730,000								5,730,000
Core Technology [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	60,000,000								60,000,000
Core Technology [Member] | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					27,667,000					27,667,000
Core Technology [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				36,600,000
Core Technology [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				89,000,000
Core Technology [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											31,956,000
Trade Names [Member] | Fiscal Year 2020 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	680,000								680,000
Trade Names [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	4,900,000								4,900,000
Trade Names [Member] | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					1,310,000					1,310,000
Trade Names [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					4,900,000					4,900,000
Trade Names [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					5,000,000					5,000,000
Trade Names [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											1,070,000
Customer Relationships [Member] | Fiscal Year 2020 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	10,923,000								10,923,000
Customer Relationships [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	96,600,000								96,600,000
Customer Relationships [Member] | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					6,700,000					6,700,000
Customer Relationships [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				$ 55,800,000
Customer Relationships [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					39,000,000					39,000,000
Customer Relationships [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											10,200,000
In Process Research and Development [Member] | Fiscal Year 2020 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	0								0
In Process Research and Development [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	10,800,000								10,800,000
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,691,227,000				1,612,407,000				1,691,227,000	1,612,407,000	1,617,616,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	$ 1,755,887,000				1,498,820,000				1,755,887,000	1,498,820,000	1,334,992,000
United States of America, Dollars | Fiscal Year 2020 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									39,300,000
United States of America, Dollars | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									399,400,000
United States of America, Dollars | Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									438,700,000
United States of America, Dollars | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments										433,100,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High					$ 31,800,000					31,800,000
United States of America, Dollars | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments										46,600,000
United States of America, Dollars | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments										166,500,000
United States of America, Dollars | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments										$ 219,900,000
United States of America, Dollars | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments											$ 105,800,000
United Kingdom, Pounds | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									$ 296,000,000

Business Combinations and Ass_4

Business Combinations and Asset Purchases (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($)	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Oct. 04, 2020	Jul. 05, 2020	Apr. 05, 2020
Business Acquisition [Line Items]
Goodwill	$ 3,447,114,000	$ 3,111,227,000	$ 2,952,608,000
Fiscal Year 2020 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	38,243,000
Working capital and other adjustments	(176,000)
Less: cash acquired	1,300,000
Business Combination, Consideration Transferred	38,030,000
Current assets	5,770,000
Property, plant and equipment	2,673,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	371,000
Goodwill	16,224,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(1,132,000)
Liabilities assumed	(29,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(3,180,000)
Total	38,030,000
Business Combination, Consideration Transferred, Liabilities Incurred	1,263,000
Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	399,005,000
Working capital and other adjustments	0
Less: cash acquired	25,539,000
Business Combination, Consideration Transferred	373,862,000
Current assets	29,762,000
Property, plant and equipment	17,729,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	17,743,000
Goodwill	200,745,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(22,480,000)
Liabilities assumed	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(39,906,000)
Total	373,862,000
Business Combination, Consideration Transferred, Liabilities Incurred	396,000
Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		45,042,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value		634,000
Working capital and other adjustments		302,000
Less: cash acquired		1,334,000
Business Combination, Consideration Transferred		45,282,000
Current assets	4,125,000
Property, plant and equipment		727,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets				$ 502,000
Goodwill		17,079,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(6,603,000)
Liabilities assumed		(2,698,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(3,527,000)
Total		45,282,000
Business Combination, Consideration Transferred, Liabilities Incurred		638,000
Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		145,000,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value		12,100,000
Working capital and other adjustments		2,961,000
Less: cash acquired		2,108,000
Business Combination, Consideration Transferred		164,399,000
Current assets	15,077,000
Property, plant and equipment		6,278,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets				$ 24,000
Goodwill	78,612,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(21,548,000)
Liabilities assumed		(706,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(10,638,000)
Total		164,399,000
Business Combination, Consideration Transferred, Liabilities Incurred		6,446,000
Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		219,795,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value		0
Working capital and other adjustments		138,000
Less: cash acquired		12,542,000
Business Combination, Consideration Transferred		207,391,000
Current assets		43,554,000
Property, plant and equipment		4,835,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		100,000
Goodwill					$ 73,417,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total					$ (34,962,000)
Liabilities assumed		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt		(12,553,000)
Total		207,391,000
Business Combination, Consideration Transferred, Liabilities Incurred		0
Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid			95,950,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value			6,200,000
Working capital and other adjustments			261,000
Less: cash acquired			1,132,000
Business Combination, Consideration Transferred			104,633,000
Current assets		4,905,000
Property, plant and equipment		1,166,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		776,000
Goodwill			65,886,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total			(9,049,000)
Liabilities assumed			(461,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			(3,881,000)
Total			104,633,000
Business Combination, Consideration Transferred, Liabilities Incurred			3,354,000
Core Technology [Member] | Fiscal Year 2020 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	5,730,000
Core Technology [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	60,000,000
Core Technology [Member] | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		27,667,000
Core Technology [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						$ 36,600,000
Core Technology [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						89,000,000
Core Technology [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			31,956,000
Trade Names [Member] | Fiscal Year 2020 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	680,000
Trade Names [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	4,900,000
Trade Names [Member] | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		1,310,000
Trade Names [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		4,900,000
Trade Names [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		5,000,000
Trade Names [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			1,070,000
Customer Relationships [Member] | Fiscal Year 2020 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	10,923,000
Customer Relationships [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	96,600,000
Customer Relationships [Member] | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		6,700,000
Customer Relationships [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						$ 55,800,000
Customer Relationships [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		39,000,000
Customer Relationships [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			10,200,000
In Process Research and Development [Member] | Fiscal Year 2020 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	0
In Process Research and Development [Member] | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	10,800,000
GC Libraries [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			2,065,000
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,691,227,000	1,612,407,000	1,617,616,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	$ 1,755,887,000	$ 1,498,820,000	$ 1,334,992,000

Nature of Operations and Acco_3

Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Narrative) (Details) (Details) $ in Thousands	12 Months Ended
	Jan. 03, 2021USD ($)segmentsplan	Dec. 29, 2019USD ($)	Dec. 30, 2018USD ($)	Dec. 30, 2019USD ($)
Number of Stock-based Compensation Plans | plan	1
Number of Operating Segments | segments	2
Defined Benefit Plan, Other Cost (Credit)	$ 18,800	$ 25,300	$ 11,500
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	25,913	(447)	(8,004)
Restricted Cash	$ 578	$ 17	$ 3,204
Accounting Standards Update 2016-13 [Member]
Impact of New Accounting Principles, Deferred Tax Assets				$ 400
Impact of New Accounting Principles, Reserve for Doubtful Accounts				(1,700)
Cumulative Effect of New Accounting Pronouncement, Period of Adoption				$ 1,300
Minimum [Member] | Building [Member]
Property, Plant and Equipment, Useful Life, Maximum	10 years
Minimum [Member] | Tools, Dies and Molds [Member]
Property, Plant and Equipment, Useful Life, Maximum	3 years
Maximum [Member] | Building [Member]
Property, Plant and Equipment, Useful Life, Maximum	40 years
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment, Useful Life, Maximum	8 years

Revenue from Contract with Cu_3

Revenue from Contract with Customer (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 3,782,745	$ 2,883,673	$ 2,777,996
Contract with Customer, Asset and Liability [Abstract]
Contract with Customer, Asset, Net, Current	59,500	37,000
Contract with Customer, Liability, Current	238,100	29,900
Contract with Customer, Liability, Revenue Recognized	(27,300)	(21,200)
Increase (Decrease) in Contract with Customer, Asset	55,700	22,400
Increase (Decrease) in Contract with Customer, Liability	235,500	20,400
Unbilled Receivables Transferred To Accounts Receivables	(33,200)	(17,300)
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	3,086,731	2,330,473
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	696,014	553,200
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,446,601	1,118,796
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,355,476	787,378
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	980,668	977,499
Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,715,803	1,746,161	1,693,211
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,195,249	1,276,499
Discovery & Analytical Solutions [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	520,554	469,662
Discovery & Analytical Solutions [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	695,960	717,205
Discovery & Analytical Solutions [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	490,789	495,768
Discovery & Analytical Solutions [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	529,054	533,188
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	2,066,942	1,137,512	$ 1,084,785
Diagnostics [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,891,482	1,053,974
Diagnostics [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	175,460	83,538
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	750,641	401,591
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	864,687	291,610
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	451,614	444,311
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,032,209	977,200
Life Sciences [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,032,209	977,200
Life Sciences [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	2,066,942	1,137,512
Diagnostics [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	2,066,942	1,137,512
Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	683,594	768,961
Applied Markets [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	683,594	768,961
Applied Markets [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0

Changes in Accounting Policies

Changes in Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended									12 Months Ended
	Jan. 03, 2021		Oct. 04, 2020	Jul. 05, 2020	Apr. 05, 2020	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax										$ (3,782,745)	$ (2,883,673)	$ (2,777,996)
Selling, general and administrative expenses										917,894	815,318	811,913
Research and development expenses										205,389	189,336	193,998
Restructuring and other costs, net	$ (3,062)		$ 4,059	$ 1,158	$ 5,858	$ 1,560	$ 14,068	$ 6,161	$ 7,639	8,013	29,428	11,144
Interest and other expense, net										72,217	124,831	66,201
Restructuring and contract termination charges, net										(8,013)	(29,428)	(11,144)
Operating income from continuing operations	510,254	[1]	248,006	175,639	44,682	138,248	78,660	91,735	53,330	978,581	361,973	323,884
Nonoperating Income (Expense)										72,217	124,831	66,201
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	473,091	[1]	233,757	164,827	34,689	65,296	63,254	71,827	36,765	906,364	237,142	257,683
Provision for income taxes										178,266	9,389	20,208
Operating income from continuing operations	380,434	[1]	176,736	137,213	33,715	64,549	58,610	69,141	35,453	728,098	227,753	237,475
(Loss) gain on disposition of discontinued operations before income taxes										(76)	0	(859)
Cash and cash equivalents	402,036					191,877				402,036	191,877	163,111
Accounts receivable, net	(1,155,109)					(725,184)				(1,155,109)	(725,184)
Inventories	514,567					356,937				514,567	356,937
Other current assets	(167,208)					(100,381)				(167,208)	(100,381)
Property, plant and equipment, net	368,304					318,223				368,304	318,223
Intangible assets, net	1,365,693					1,283,286				1,365,693	1,283,286
Goodwill	3,447,114					3,111,227				3,447,114	3,111,227	2,952,608
Other assets, net	333,048					284,173				333,048	284,173
Current portion of long-term debt	380,948					9,974				380,948	9,974
Assets	(7,960,315)					(6,538,564)				(7,960,315)	(6,538,564)
Accounts payable	327,325					235,855				327,325	235,855
Accrued restructuring and contract termination costs	4,716					11,559				4,716	11,559
Accrued expenses and other current liabilities	937,027					503,332				937,027	503,332
Current liabilities of discontinued operations	2,173					2,112				2,173	2,112
Long-term debt	1,609,701					2,064,041				1,609,701	2,064,041
Long-term liabilities	774,531					751,468				774,531	751,468
Liabilities	4,224,823					3,724,740				4,224,823	3,724,740
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0					0				0	0
Common Stock, Value, Issued	112,090					111,140				112,090	111,140
Capital in excess of par value	148,101					90,357				148,101	90,357
Retained earnings	3,507,262					2,811,973				3,507,262	2,811,973
Accumulated other comprehensive loss	(31,961)					(199,646)				(31,961)	(199,646)	(176,481)	$ (46,518)
Stockholders' Equity Attributable to Parent	3,735,492					2,813,824				3,735,492	2,813,824	2,584,955	$ 2,503,188
Liabilities and Equity	(7,960,315)					(6,538,564)				(7,960,315)	(6,538,564)
Net income	380,361	[1]	176,699	137,162	33,665	64,501	58,558	69,087	35,412	727,887	227,558	237,927
Provision For Income Taxes On Discontinued Operations And Dispositions										135	(195)	1,311
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	$ (73)		$ (37)	$ (51)	$ (50)	$ (48)	$ (52)	$ (54)	$ (41)	(211)	(195)	452
Product [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax										(2,778,725)	(2,017,042)	(1,935,493)
Cost of Goods and Services Sold										(1,105,614)	(956,398)	(908,228)
Service [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax										(1,004,020)	(866,631)	(842,503)
Cost of Goods and Services Sold										$ (567,254)	$ (531,220)	$ (528,829)
[1]	The fourth quarter of fiscal year 2020 includes a pre-tax loss of $25.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy

Discontinued Operations Narrati

Discontinued Operations Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	$ (76)	$ 0	$ (859)
(Benefit from) provision for income taxes on discontinued operations and dispositions	135	195	(1,311)
Disposal Group, Including Discontinued Operation, Liabilities, Current	2,173	2,112
Fluid Sciences Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	(76)	0	(66)
Medical Imaging Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	$ 0	$ 0	(793)
Multispectral Imaging Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes			13,000
Disposal Group, Including Discontinued Operation, Consideration			$ 37,300

Restructuring and Contract Te_2

Restructuring and Contract Termination Charges, Net (Narrative) (Details) - USD ($)	3 Months Ended										12 Months Ended
	Jan. 03, 2021	Oct. 04, 2020	Jul. 05, 2020	Apr. 05, 2020	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Apr. 01, 2018	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net	$ (3,062,000)	$ 4,059,000	$ 1,158,000	$ 5,858,000	$ 1,560,000	$ 14,068,000	$ 6,161,000	$ 7,639,000			$ 8,013,000	$ 29,428,000	$ 11,144,000
Accrued restructuring and contract termination costs	4,716,000				11,559,000						4,716,000	11,559,000
Restructuring Reserve1	8,300,000				13,900,000						8,300,000	13,900,000
Restructuring Charges and Changes in Estimates											8,013,000	29,428,000	11,144,000
Accrued restructuring and contract termination costs	8,299,000				13,880,000						8,299,000	13,880,000	6,180,000	$ 13,969,000
Short-term accrued restructuring and other costs [Member]
Restructuring Cost and Reserve [Line Items]
Accrued restructuring and contract termination costs	4,700,000				11,600,000						4,700,000	11,600,000
Accrued expenses and other current liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Accrued restructuring and contract termination costs	2,000,000				400,000						2,000,000	400,000
Long-term liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Noncurrent					800,000							800,000
Operating lease liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Noncurrent	1,300,000				1,100,000						1,300,000	1,100,000
Operating lease right-of-use assets [Member]
Restructuring Cost and Reserve [Line Items]
Accrued restructuring and contract termination costs	300,000										300,000
Q3 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net									$ 1,764,000
Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net										$ 5,998,000
Q1 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net								7,460,000
Q2 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net							5,590,000
Q3 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net						13,797,000
Q4 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net					2,581,000
Previous restructuring and integration plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges and Changes in Estimates											219,000	(159,000)	(1,998,000)
Accrued restructuring and contract termination costs	1,102,000				1,365,000						1,102,000	1,365,000	2,671,000	10,921,000
Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges and Changes in Estimates											212,000	452,000	4,742,000
Accrued restructuring and contract termination costs	318,000				188,000						318,000	188,000	137,000	3,048,000
Facility Relocation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges and Changes in Estimates											4,290,000	827,000	0
Accrued restructuring and contract termination costs	1,998,000				827,000						1,998,000	827,000	0	0
Severance [Member] | Q3 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges and Changes in Estimates											0	(77,000)	2,054,000
Accrued restructuring and contract termination costs	24,000				24,000						24,000	24,000	1,415,000	0
Severance [Member] | Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges and Changes in Estimates											(255,000)	(1,069,000)	5,998,000
Accrued restructuring and contract termination costs	3,000				258,000						3,000	258,000	1,609,000	0
Severance [Member] | Q1 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges and Changes in Estimates											(867,000)	7,483,000	0
Accrued restructuring and contract termination costs	593,000				2,129,000						593,000	2,129,000	0	0
Severance [Member] | Q2 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges and Changes in Estimates											(376,000)	5,590,000	0
Accrued restructuring and contract termination costs	272,000				1,889,000						272,000	1,889,000	0	0
Severance [Member] | Q3 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges and Changes in Estimates											(2,025,000)	13,797,000	0
Accrued restructuring and contract termination costs	1,507,000				6,311,000						1,507,000	6,311,000	0	0
Severance [Member] | Q4 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges and Changes in Estimates											(386,000)	2,581,000	0
Accrued restructuring and contract termination costs	$ 49,000				889,000						49,000	889,000	0	$ 0
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | 2020 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net											200,000
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | 2019 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net												200,000
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | 2018 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net													$ 5,000,000
Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net									1,146,000
Discovery & Analytical Solutions [Member] | Severance [Member] | Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net										5,096,000
Discovery & Analytical Solutions [Member] | Severance [Member] | Q1 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net								6,001,000
Change in estimates											(900,000)
Discovery & Analytical Solutions [Member] | Severance [Member] | Q2 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net							4,461,000
Change in estimates											(400,000)
Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net						11,156,000
Change in estimates											(1,900,000)
Discovery & Analytical Solutions [Member] | Severance [Member] | Q4 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net					177,000
Change in estimates											(300,000)
Discovery & Analytical Solutions [Member] | Severance [Member] | Previous restructuring and integration plans [Member]
Restructuring Cost and Reserve [Line Items]
Change in estimates											100,000
Diagnostics [Member] | Contract Termination [Member] | 2020 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net											100,000
Diagnostics [Member] | Contract Termination [Member] | 2019 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net												$ 200,000
Diagnostics [Member] | Severance [Member] | Q3 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net									$ 618,000
Diagnostics [Member] | Severance [Member] | Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net										$ 902,000
Diagnostics [Member] | Severance [Member] | Q1 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net								$ 1,459,000
Diagnostics [Member] | Severance [Member] | Q2 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net							$ 1,129,000
Diagnostics [Member] | Severance [Member] | Q3 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net						$ 2,641,000
Change in estimates											(100,000)
Diagnostics [Member] | Severance [Member] | Q4 2019 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net					$ 2,404,000
Change in estimates											$ (100,000)

Restructuring and Contract Te_3

Restructuring and Contract Termination Charges, Net Restructuring and Contract Termination Charges, Net (Schedule of Initial Charges) (Details) $ in Thousands

3 Months Ended

12 Months Ended

Jan. 03, 2021USD ($)

Oct. 04, 2020USD ($)employees

Jul. 05, 2020USD ($)

Apr. 05, 2020USD ($)employees

Dec. 29, 2019USD ($)employees

Sep. 29, 2019USD ($)employees

Jun. 30, 2019USD ($)employees

Mar. 31, 2019USD ($)employees

Dec. 30, 2018USD ($)employees

Sep. 30, 2018USD ($)employees

Apr. 01, 2018USD ($)employees

Jan. 03, 2021USD ($)

Dec. 29, 2019USD ($)

Dec. 30, 2018USD ($)

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ (3,062)

$ 4,059

$ 1,158

$ 5,858

$ 1,560

$ 14,068

$ 6,161

$ 7,639

$ 8,013

$ 29,428

$ 11,144

Q3 2020 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

23

Restructuring and other costs, net

$ 2,981

Q1 2020 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

32

Restructuring and other costs, net

$ 4,220

Q4 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

22

Restructuring and other costs, net

$ 2,581

Q3 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

259

Restructuring and other costs, net

$ 13,797

Q2 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

44

Restructuring and other costs, net

$ 5,590

Q1 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

105

Restructuring and other costs, net

$ 7,460

Q4 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

1

Restructuring and other costs, net

$ 348

Q3 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

61

Restructuring and other costs, net

$ 1,764

Q1 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

47

Restructuring and other costs, net

$ 5,998

Diagnostics [Member] | Severance [Member] | Q3 2020 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

901

Diagnostics [Member] | Severance [Member] | Q1 2020 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

1,134

Diagnostics [Member] | Severance [Member] | Q4 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

2,404

Diagnostics [Member] | Severance [Member] | Q3 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

2,641

Diagnostics [Member] | Severance [Member] | Q2 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

1,129

Diagnostics [Member] | Severance [Member] | Q1 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

1,459

Diagnostics [Member] | Severance [Member] | Q4 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Severance [Member] | Q3 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

618

Diagnostics [Member] | Severance [Member] | Q1 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

902

Diagnostics [Member] | Facility Closing [Member] | Q3 2020 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q1 2020 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

682

Diagnostics [Member] | Facility Closing [Member] | Q4 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q3 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q2 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q1 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q4 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q3 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q1 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2020 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

2,080

Discovery & Analytical Solutions [Member] | Severance [Member] | Q1 2020 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

2,312

Discovery & Analytical Solutions [Member] | Severance [Member] | Q4 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

177

Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

11,156

Discovery & Analytical Solutions [Member] | Severance [Member] | Q2 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

4,461

Discovery & Analytical Solutions [Member] | Severance [Member] | Q1 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

6,001

Discovery & Analytical Solutions [Member] | Severance [Member] | Q4 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

348

Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

1,146

Discovery & Analytical Solutions [Member] | Severance [Member] | Q1 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

5,096

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2020 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2020 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 92

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q4 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q2 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q4 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Restructuring and Contract Te_4

Restructuring and Contract Termination Charges, Net (Schedule of Restructuring Plan Activity) (Details) - USD ($)	3 Months Ended											12 Months Ended
	Jan. 03, 2021	Oct. 04, 2020	Jul. 05, 2020	Apr. 05, 2020	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Apr. 01, 2018	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Restructuring Reserve [Roll Forward]
Beginning balance				$ 13,880,000				$ 6,180,000			$ 13,969,000	$ 13,880,000	$ 6,180,000	$ 13,969,000
Restructuring Charges and Changes in Estimates												8,013,000	29,428,000	11,144,000
Amounts paid and foreign currency translation												(13,594,000)	(21,728,000)	(18,933,000)
Ending balance	$ 8,299,000				$ 13,880,000				$ 6,180,000			8,299,000	13,880,000	6,180,000
Restructuring and other costs, net	(3,062,000)	$ 4,059,000	$ 1,158,000	5,858,000	1,560,000	$ 14,068,000	$ 6,161,000	7,639,000				8,013,000	29,428,000	11,144,000
Employee Severance and Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				12,865,000				6,043,000			10,921,000	12,865,000	6,043,000	10,921,000
Restructuring Charges and Changes in Estimates												3,511,000	28,149,000	6,402,000
Amounts paid and foreign currency translation												(10,393,000)	(21,327,000)	(11,280,000)
Ending balance	5,983,000				12,865,000				6,043,000			5,983,000	12,865,000	6,043,000
Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				188,000				137,000			3,048,000	188,000	137,000	3,048,000
Restructuring Charges and Changes in Estimates												212,000	452,000	4,742,000
Amounts paid and foreign currency translation												(82,000)	(401,000)	(7,653,000)
Ending balance	318,000				188,000				137,000			318,000	188,000	137,000
Facility Relocation [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				827,000				0			0	827,000	0	0
Restructuring Charges and Changes in Estimates												4,290,000	827,000	0
Amounts paid and foreign currency translation												(3,119,000)	0	0
Ending balance	1,998,000				827,000				0			1,998,000	827,000	0
Q3 2020 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net		2,981,000
Q3 2020 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				0			0	0	0	0
Restructuring Charges and Changes in Estimates												2,981,000	0	0
Amounts paid and foreign currency translation												(1,814,000)	0	0
Ending balance	1,167,000				0				0			1,167,000	0	0
Q1 2020 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net				4,220,000
Q1 2020 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				0			0	0	0	0
Restructuring Charges and Changes in Estimates												3,446,000	0	0
Amounts paid and foreign currency translation												(2,574,000)	0	0
Ending balance	872,000				0				0			872,000	0	0
Q4 2019 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net					2,581,000
Q4 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				889,000				0			0	889,000	0	0
Restructuring Charges and Changes in Estimates												(386,000)	2,581,000	0
Amounts paid and foreign currency translation												(454,000)	(1,692,000)	0
Ending balance	49,000				889,000				0			49,000	889,000	0
Q3 2019 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net						13,797,000
Q3 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				6,311,000				0			0	6,311,000	0	0
Restructuring Charges and Changes in Estimates												(2,025,000)	13,797,000	0
Amounts paid and foreign currency translation												(2,779,000)	(7,486,000)	0
Ending balance	1,507,000				6,311,000				0			1,507,000	6,311,000	0
Q2 2019 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net							5,590,000
Q2 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				1,889,000				0			0	1,889,000	0	0
Restructuring Charges and Changes in Estimates												(376,000)	5,590,000	0
Amounts paid and foreign currency translation												(1,241,000)	(3,701,000)	0
Ending balance	272,000				1,889,000				0			272,000	1,889,000	0
Q1 2019 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net								7,460,000
Q1 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				2,129,000				0			0	2,129,000	0	0
Restructuring Charges and Changes in Estimates												(867,000)	7,483,000	0
Amounts paid and foreign currency translation												(669,000)	(5,354,000)	0
Ending balance	593,000				2,129,000				0			593,000	2,129,000	0
Q4 2018 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net									348,000
Q4 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				348,000			0	0	348,000	0
Restructuring Charges and Changes in Estimates												0	3,000	348,000
Amounts paid and foreign currency translation												0	(351,000)	0
Ending balance	0				0				348,000			0	0	348,000
Previous restructuring and integration plans [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				1,365,000				2,671,000			10,921,000	1,365,000	2,671,000	10,921,000
Restructuring Charges and Changes in Estimates												219,000	(159,000)	(1,998,000)
Amounts paid and foreign currency translation												(482,000)	(1,147,000)	(6,252,000)
Ending balance	1,102,000				1,365,000				2,671,000			1,102,000	1,365,000	2,671,000
Q3 2018 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net										$ 1,764,000
Q3 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				24,000				1,415,000			0	24,000	1,415,000	0
Restructuring Charges and Changes in Estimates												0	(77,000)	2,054,000
Amounts paid and foreign currency translation												0	(1,314,000)	(639,000)
Ending balance	24,000				24,000				1,415,000			24,000	24,000	1,415,000
Q1 2018 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net											5,998,000
Q1 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				258,000				1,609,000			0	258,000	1,609,000	0
Restructuring Charges and Changes in Estimates												(255,000)	(1,069,000)	5,998,000
Amounts paid and foreign currency translation												0	(282,000)	(4,389,000)
Ending balance	3,000				258,000				1,609,000			3,000	258,000	1,609,000
Q1 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				0			0	0	0	0
Restructuring Charges and Changes in Estimates												774,000	0	0
Amounts paid and foreign currency translation												(380,000)	0
Ending balance	$ 394,000				0				0			394,000	$ 0	$ 0
Diagnostics [Member] | Q3 2020 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net		901,000
Diagnostics [Member] | Q3 2020 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net		0
Diagnostics [Member] | Q1 2020 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net				1,134,000
Diagnostics [Member] | Q1 2020 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net				682,000
Diagnostics [Member] | Q4 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												(100,000)
Restructuring and other costs, net					2,404,000
Diagnostics [Member] | Q4 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net					0
Diagnostics [Member] | Q3 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												(100,000)
Restructuring and other costs, net						2,641,000
Diagnostics [Member] | Q3 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net						0
Diagnostics [Member] | Q2 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net							1,129,000
Diagnostics [Member] | Q2 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net							0
Diagnostics [Member] | Q1 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net								1,459,000
Diagnostics [Member] | Q1 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net								0
Diagnostics [Member] | Q4 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net									0
Diagnostics [Member] | Q4 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net									0
Diagnostics [Member] | Q3 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net										618,000
Diagnostics [Member] | Q3 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net										0
Diagnostics [Member] | Q1 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net											902,000
Diagnostics [Member] | Q1 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net											0
Discovery & Analytical Solutions [Member] | Q3 2020 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net		2,080,000
Discovery & Analytical Solutions [Member] | Q3 2020 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net		$ 0
Discovery & Analytical Solutions [Member] | Q1 2020 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net				2,312,000
Discovery & Analytical Solutions [Member] | Q1 2020 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net				$ 92,000
Discovery & Analytical Solutions [Member] | Q4 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												(300,000)
Restructuring and other costs, net					177,000
Discovery & Analytical Solutions [Member] | Q4 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net					$ 0
Discovery & Analytical Solutions [Member] | Q3 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												(1,900,000)
Restructuring and other costs, net						11,156,000
Discovery & Analytical Solutions [Member] | Q3 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net						$ 0
Discovery & Analytical Solutions [Member] | Q2 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												(400,000)
Restructuring and other costs, net							4,461,000
Discovery & Analytical Solutions [Member] | Q2 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net							$ 0
Discovery & Analytical Solutions [Member] | Q1 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												(900,000)
Restructuring and other costs, net								6,001,000
Discovery & Analytical Solutions [Member] | Q1 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net								$ 0
Discovery & Analytical Solutions [Member] | Q4 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net									348,000
Discovery & Analytical Solutions [Member] | Q4 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net									$ 0
Discovery & Analytical Solutions [Member] | Previous restructuring and integration plans [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												$ 100,000
Discovery & Analytical Solutions [Member] | Q3 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net										1,146,000
Discovery & Analytical Solutions [Member] | Q3 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net										$ 0
Discovery & Analytical Solutions [Member] | Q1 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net											5,096,000
Discovery & Analytical Solutions [Member] | Q1 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net											$ 0

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Income Tax Contingency [Line Items]
Income Tax Holiday, Aggregate Dollar Amount	$ (21,800)	$ (10,400)	$ (10,300)
Impact of benefits derived from tax holidays on earnings per share, basic	$ 0.20	$ (0.09)	$ (0.09)
Impact of benefits derived from tax holidays on earnings per share, diluted	$ (0.19)	$ (0.09)	$ (0.09)
Valuation Allowance, Amount	$ 99,740	$ 88,449
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning of period	35,547	33,009	$ 30,308
Gross increases - tax positions in prior period	4,974	4,433	6,931
Gross decreases - tax positions in prior period	(2,471)	(2,183)	(1,622)
Gross increases - current-period tax positions	309	152	0
Settlements	0	(45)	(2,253)
Lapse of statute of limitations	0	0	(181)
Foreign currency translation adjustments	414	181	(174)
Unrecognized tax benefits, end of period	38,773	35,547	33,009	$ 30,308
Income Tax Penalties and Interest Accrued	5,800	4,100
Income Tax Penalties and Interest Expense	4,700	1,600	400
Unrecognized Tax Benefits, Ending Balance	38,800
Uncertain tax benefits if recognized that could affect the continuing operations effective tax rate	37,100
Unrecognized Tax Benefits Expected To Be Resolved With In A Year	200
Income Tax Expense (Benefits) on Undistributed Foreign Earnings		1,600
Foreign earnings invested outside U.S.	$ 1,500,000
Open Tax Years by Major Tax Jurisdiction, Begin Date	2010
Tax Adjustments, Settlements, and Unusual Provisions	$ 10,800	(23,400)	(8,100)
2017 Tax Cuts and Jobs Act [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense		2,700	(4,600)	$ 85,000
Tax Adjustments, Settlements, and Unusual Provisions		2,700
Discrete Income Tax Expense (Benefit), Tax Reform Trueup			(2,000)
Other Tax Matters [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	1,600	1,400	1,100
Excess tax benefits on stock compensation [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	(11,700)	(4,900)	$ (7,200)
Valuation allowance adjustments [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	(2,500)	(12,300)
Foreign tax rate changes
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	2,500
Interest on uncertain tax positions
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	4,500
Tax elections adjustments [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions		(3,700)
True-up of Return-to-Provision [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	1,200	$ (6,700)
Foreign fiscal unity adjustments
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	15,200
General Business [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Credit Carryforward, Amount	300
State and Local Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	11,500
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Credit Carryforward, Amount	15,300
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	495,300
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Credit Carryforward, Amount	100
Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	$ 36,600
Singapore [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Income Tax Holiday, Termination Date	2023

Income Taxes Income Before Inco

Income Taxes Income Before Income taxes (Details) - USD ($) $ in Thousands	3 Months Ended									12 Months Ended
	Jan. 03, 2021	[1]	Oct. 04, 2020	Jul. 05, 2020	Apr. 05, 2020	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Income Tax Contingency [Line Items]
U.S.										$ 183,452	$ 29,252	$ 32,627
Non-U.S.										722,912	207,890	225,056
Income from continuing operations before income taxes	$ 473,091		$ 233,757	$ 164,827	$ 34,689	$ 65,296	$ 63,254	$ 71,827	$ 36,765	$ 906,364	$ 237,142	$ 257,683
[1]	The fourth quarter of fiscal year 2020 includes a pre-tax loss of $25.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy

Income Taxes Components of the

Income Taxes Components of the Provision (Benefits from) Income Tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Income Tax Contingency [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount	$ (40,216)	$ (32,124)	$ (27,281)
Federal current	21,262	3,735	7,938
Federal deferred expense (benefit)	15,951	(267)	(5,250)
Federal total	37,213	3,468	2,688
State current	13,688	4,425	2,345
State deferred expense (benefit)	(967)	(1,574)	2,572
State total	12,721	2,851	4,917
Non-U.S. current	172,437	62,582	61,028
Non-U.S.deferred expense benefit	(44,105)	(59,512)	(48,425)
Non-U.S. total	128,332	3,070	12,603
Total current	207,387	70,742	71,311
Total deferred expense (benefit)	(29,121)	(61,353)	(51,103)
Total	178,266	9,389	20,208
Discontinued operations	135	195	(1,311)
Total provision for income taxes	178,401	9,584	18,897
Singapore, Finland, Netherlands and China [Member]
Income Tax Contingency [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount		$ 16,700	$ 18,700
Singapore, Finland, and The Netherlands [Member]
Income Tax Contingency [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount	$ 42,500

Income Taxes Reconciliation of

Income Taxes Reconciliation of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Income Tax Contingency [Line Items]
Tax at statutory rate	$ 190,339	$ 49,799	$ 54,114
Non-U.S. rate differential, net	(40,216)	(32,124)	(27,281)
U.S. taxation of multinational operations	9,050	4,251	7,047
State income taxes, net	13,306	1,941	2,028
Prior year tax matters	8,262	(5,103)	1,124
Effect of Stock Compensation	(8,818)	(2,053)	(6,331)
Federal tax credits	(4,136)	(4,325)	(3,738)
Change in valuation allowance	10	(1,117)	(759)
Effective Income Tax Rate Reconciliation, Foreign Fiscal Unity Adj., Amount	15,222	0	0
Tax Elections	0	(3,700)	0
Tax Adjustments, Settlements, and Unusual Provisions	10,800	(23,400)	(8,100)
Other, net	(4,753)	(898)	(3,971)
Total	178,266	9,389	20,208
Singapore, Finland, Netherlands and China [Member]
Income Tax Contingency [Line Items]
Non-U.S. rate differential, net		16,700	18,700
Singapore, Finland, and The Netherlands [Member]
Income Tax Contingency [Line Items]
Non-U.S. rate differential, net	42,500
2017 Tax Cuts and Jobs Act [Member]
Income Tax Contingency [Line Items]
Tax Adjustments, Settlements, and Unusual Provisions		2,700
Impact of U.S. Tax Act	$ 0	$ 2,718	$ (2,025)

Income Taxes Components of Defe

Income Taxes Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Income Tax Contingency [Line Items]
Inventory	$ 4,788	$ 4,662
Reserves and accruals	51,107	46,817
Accrued compensation	20,881	18,953
Net operating loss and credit carryforwards	131,884	116,751
Accrued pension	34,192	35,890
Restructuring reserve	1,579	2,983
Deferred revenue	29,838	30,412
Deferred Tax Assets, Unrealized Foreign Exchange Losses	21,614	0
Deferred tax assets, operating lease liabilities	42,220	46,477
Deferred Tax Assets, Gross	338,103	302,945
Postretirement health benefits	(8,168)	(4,106)
Depreciation and amortization	(355,876)	(330,768)
Deferred Tax Liabilities, Other	(4,160)	(1,780)
Deferred tax liabilities, operating lease right-of-use assets	(38,598)	42,774
Total deferred tax liabilities	(406,802)	(379,428)
Valuation allowance	(99,740)	(88,449)
Deferred Tax Liabilities, Net	(168,439)	(164,932)
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(11,300)
Domestic Country [Member]
Income Tax Contingency [Line Items]
Net deferred tax liabilities	(50,302)	(43,683)
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Deferred Tax Liabilities, Net	$ (218,741)	$ (208,615)

Income Taxes Summary of Loss an

Income Taxes Summary of Loss and Tax Credit Carryforwards (Details) - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019
Income Tax Contingency [Line Items]
Valuation Allowance, Amount	$ 99,740	$ 88,449
State and Local Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	11,500
Tax Credit Carryforward, Amount	15,300
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	495,300
Tax Credit Carryforward, Amount	100
Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	36,600
General Business [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Amount	$ 300

Earnings Per Share (Schedule of

Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares shares in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Earnings Per Share [Abstract]
Number of common shares-basic	111,514	110,827	110,561
Effect of dilutive securities, Stock options	466	541	761
Effect of dilutive securities, Restricted stock	105	133	212
Number of common shares-diluted	112,085	111,501	111,534
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	220	364	349

Accounts Receivable, Net (Detai

Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	$ 1,155,109	$ 725,184
Accounts Receivable, after Allowance for Credit Loss, Noncurrent	22,510	19,677
Accounts Receivable, after Allowance for Credit Loss	1,177,619	744,861
Reserves for doubtful accounts	$ 47,600	$ 35,200

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 205,022	$ 130,673
Work in progress	35,160	26,409
Finished goods	274,385	199,855
Total inventories	$ 514,567	$ 356,937

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 818,197	$ 701,580
Accumulated depreciation	(449,893)	(383,357)
Total property, plant and equipment, net	368,304	318,223
Depreciation expense	54,000	49,700	$ 44,700
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,937	5,272
Building and leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	291,526	250,639
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 522,734	$ 445,669

Investments, Debt and Equity Se

Investments, Debt and Equity Securities (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Equity Securities without Readily Determinable Fair Value [Line Items]
Equity Securities without Readily Determinable Fair Value, Amount	$ 48,626	$ 29,228
Equity investments, carried at cost minus impairment, if any	27,438	29,228
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount	8,200
Equity Securities, FV-NI and without Readily Determinable Fair Value	21,188	0
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount	35	8,200
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount		$ 4,900
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount	$ 4,900

Marketable Securities and Inv_3

Marketable Securities and Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Debt Securities, Available-for-sale [Line Items]
Unrealized (losses) gains on securities, net of tax	$ (16)	$ 6	$ (9)
Marketable securities	2,154	2,906
Marketable Securities and Investments	50,780	32,134
Equity Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost	584	1,109
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	203	752
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(381)	(357)
Fixed Income Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost	7	7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	7	7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0	0
Available-for-sale Securities, Other [Member]
Debt Securities, Available-for-sale [Line Items]
Cost	2,007	2,210
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	1,944	2,147
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(63)	(63)
Available-for-sale Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost	2,598	3,326
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	2,154	2,906
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	$ (444)	$ (420)

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Goodwill and Intangible Assets Net [Line Items]
Total amortization expense related to finite-lived intangible assets	$ 192,600	$ 164,300	$ 135,900
Future Amortization Expense, Year One	211,000
Future Amortization Expense, Year Two	191,400
Future Amortization Expense, Year Three	164,000
Future Amortization Expense, Year Four	139,900
Future Amortization Expense, Year Five	111,900
Finite-Lived Intangible Assets, Net	1,295,109	1,212,702
Goodwill	$ 3,447,114	3,111,227	2,952,608
Impairment Testing Date	January 1, 2020
Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	$ 49,855	47,702
Licenses [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	6,248	8,763
Discovery & Analytical Solutions [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	491,871	361,777
Goodwill	1,755,887	1,498,820	1,334,992
Discovery & Analytical Solutions [Member] | Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	19,284	16,227
Discovery & Analytical Solutions [Member] | Licenses [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	1,151	2,786
Diagnostics [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	803,238	850,925
Goodwill	1,691,227	1,612,407	$ 1,617,616
Diagnostics [Member] | Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	30,571	31,475
Diagnostics [Member] | Licenses [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	5,097	$ 5,977
Tulip Diagnostics Private Limited [Member]
Goodwill and Intangible Assets Net [Line Items]
Goodwill	$ 77,800

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Changes in the carrying amount of goodwill
Foreign currency translation	$ 120,682	$ (18,284)
Acquisitions, earn outs and other	215,205	176,903
Ending balance	3,447,114	3,111,227
Diagnostics [Member]
Changes in the carrying amount of goodwill
Foreign currency translation	62,596	(9,725)
Acquisitions, earn outs and other	16,224	4,516
Ending balance	1,691,227	1,612,407
Discovery & Analytical Solutions [Member]
Changes in the carrying amount of goodwill
Foreign currency translation	58,086	(8,559)
Acquisitions, earn outs and other	198,981	172,387
Ending balance	$ 1,755,887	$ 1,498,820

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	$ 1,295,109	$ 1,212,702
Totals	1,365,693	1,283,286
Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	30,855	30,831
Less: Accumulated amortization	(28,440)	(27,423)
Net amortizable intangible assets	2,415	3,408
Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	98,661	87,997
Less: Accumulated amortization	(48,806)	(40,295)
Net amortizable intangible assets	49,855	47,702
Non-amortizing intangible assets	70,584	70,584
Licenses [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	58,700	58,496
Less: Accumulated amortization	(52,452)	(49,733)
Net amortizable intangible assets	6,248	8,763
Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	789,799	689,089
Less: Accumulated amortization	(398,992)	(320,926)
Net amortizable intangible assets	390,807	368,163
Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	1,357,660	1,161,526
Less: Accumulated amortization	(522,820)	(378,188)
Net amortizable intangible assets	834,840	783,338
In Process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	10,944	1,328
Diagnostics [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	803,238	850,925
Totals	803,238	850,925
Diagnostics [Member] | Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	2,709	2,709
Less: Accumulated amortization	(507)	(281)
Net amortizable intangible assets	2,202	2,428
Diagnostics [Member] | Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	47,518	48,138
Less: Accumulated amortization	(16,947)	(16,663)
Net amortizable intangible assets	30,571	31,475
Non-amortizing intangible assets	0	0
Diagnostics [Member] | Licenses [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	8,232	8,103
Less: Accumulated amortization	(3,135)	(2,126)
Net amortizable intangible assets	5,097	5,977
Diagnostics [Member] | Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	333,192	298,973
Less: Accumulated amortization	(166,344)	(115,663)
Net amortizable intangible assets	166,848	183,310
Diagnostics [Member] | Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	881,912	847,628
Less: Accumulated amortization	(283,392)	(221,221)
Net amortizable intangible assets	598,520	626,407
Diagnostics [Member] | In Process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	0	1,328
Discovery & Analytical Solutions [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	491,871	361,777
Totals	562,455	432,361
Discovery & Analytical Solutions [Member] | Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	28,146	28,122
Less: Accumulated amortization	(27,933)	(27,142)
Net amortizable intangible assets	213	980
Discovery & Analytical Solutions [Member] | Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	51,143	39,859
Less: Accumulated amortization	(31,859)	(23,632)
Net amortizable intangible assets	19,284	16,227
Non-amortizing intangible assets	70,584	70,584
Discovery & Analytical Solutions [Member] | Licenses [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	50,468	50,393
Less: Accumulated amortization	(49,317)	(47,607)
Net amortizable intangible assets	1,151	2,786
Discovery & Analytical Solutions [Member] | Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	456,607	390,116
Less: Accumulated amortization	(232,648)	(205,263)
Net amortizable intangible assets	223,959	184,853
Discovery & Analytical Solutions [Member] | Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	475,748	313,898
Less: Accumulated amortization	(239,428)	(156,967)
Net amortizable intangible assets	236,320	156,931
Discovery & Analytical Solutions [Member] | In Process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	$ 10,944	$ 0

Debt (Details)

Debt (Details) € in Millions	Sep. 12, 2019USD ($)	Apr. 11, 2018USD ($)	Jul. 19, 2016USD ($)	Jan. 03, 2021USD ($)	Jan. 03, 2021EUR (€)	Dec. 29, 2019USD ($)	Dec. 29, 2019EUR (€)	Sep. 17, 2019USD ($)	Jul. 19, 2016EUR (€)
Unamortized discount and debt issuance costs				$ (18,305,000)
Maturities of Long-term Debt [Abstract]
2017				381,193,000
2018				4,075,000
2019				2,457,000
2020				159,967,000
2021				230,000
Thereafter				1,461,032,000
Long-term Debt Before Unamortized Discount				2,008,954,000
Total				1,990,649,000
Other Long-term Debt, Current				380,948,000		$ 9,974,000
Line of Credit, Maturing August 11, 2021 [Member]
Aggregate borrowings under the amended facility						325,400,000
Unamortized Debt Issuance Expense						3,400,000
Maturities of Long-term Debt [Abstract]
Total						322,000,000
Line of Credit, Maturing September 17, 2024 [Member]
Unsecured revolving credit facility, amount								$ 1,000,000,000
Line of Credit Facility, Remaining Borrowing Capacity				830,400,000
Letters of credit issued and outstanding				$ 11,000,000
Interest rate terms under amended senior unsecured revolving credit facility				The interest rates on the Eurocurrency Rate loans are based on the Eurocurrency Rate at the time of borrowing, plus a percentage spread based on the credit rating of the Company's debt. The interest rates on the US Dollar Base Rate loans are based on the US Dollar Base Rate at the time of borrowing, plus a percentage spread based on the credit rating of the Company's debt. The base rate is the higher of (i) the Federal Funds Rate (as defined in the credit agreement) plus 50 basis points (ii) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its "prime rate," or (iii) the Eurocurrency Rate plus 1.00%. The Eurocurrency margin as of 44199 was 101.5 basis points.
Weighted average interest rates under amended senior unsecured revolving credit facility				The weighted average Eurocurrency interest rate as of 44199 was 1.16%, which was the interest applicable to the borrowings outstanding as of 44199.
Aggregate borrowings under the amended facility				$ 158,600,000
Unamortized discount and debt issuance costs				(2,621,000)
Unamortized Debt Issuance Expense				2,600,000
Maturities of Long-term Debt [Abstract]
2017				0
2018				0
2019				0
2020				158,595,000
2021				0
Thereafter				0
Long-term Debt Before Unamortized Discount				158,595,000
Total				$ 155,974,000
Line of Credit, Maturing September 17, 2024 [Member] | Base Rate Option Three [Member] | Line of Credit [Member]
Basis spread on variable rate				1.00%
Line of Credit, Maturing September 17, 2024 [Member] | Eurocurrency Rate [Member]
Basis spread on variable rate				1.02%
Line of Credit, Maturing September 17, 2024 [Member] | Base Rate Option Two [Member] | Line of Credit [Member]
Basis spread on variable rate				0.50%
Line of Credit, Maturing December 16, 2016 [Member] | Eurocurrency Rate [Member]
Description of variable rate basis				Eurocurrency margin
Line of Credit, Maturing December 16, 2016 [Member] | Base Rate Option Two [Member]
Description of variable rate basis				Federal Funds
Other Debt Facilities - EUROIMMUN [Member]
Maturities of Long-term Debt [Abstract]
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €					€ 23.1
Long-term Debt, Percentage Bearing Variable Interest, Amount | €					0.1
Other Debt Facilities - EUROIMMUN [Member] | Fair Value, Inputs, Level 2 [Member]
Maturities of Long-term Debt [Abstract]
Other Long-term Debt | €					€ 23.2		€ 25.7
Other Debt Facilities - EUROIMMUN [Member] | Minimum [Member]
Unsecured senior notes, interest rate percent				1.10%	1.10%
Other Debt Facilities - EUROIMMUN [Member] | Maximum [Member]
Unsecured senior notes, interest rate percent				8.90%	8.90%
Other Debt Facilities - EUROIMMUN [Member] | Euribor Rate [Member]
Basis spread on variable rate				1.50%
Other Debt Facilities [Member]
Unamortized discount and debt issuance costs				$ 0
Maturities of Long-term Debt [Abstract]
2017				14,743,000
2018				4,075,000
2019				2,457,000
2020				1,372,000
2021				230,000
Thereafter				282,000
Long-term Debt Before Unamortized Discount				23,159,000
Total				$ 23,159,000
Other Secured Bank Loan [Member]
Maturities of Long-term Debt [Abstract]
Secured Debt | €					€ 6.1		1.9
Other Secured Bank Loan [Member] | Minimum [Member]
Unsecured senior notes, interest rate percent				1.95%	1.95%
Other Secured Bank Loan [Member] | Maximum [Member]
Unsecured senior notes, interest rate percent				8.94%	8.94%
0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Interest rate terms under amended senior unsecured revolving credit facility				Interest on the April 2021 Notes is payable annually on April 9th each year.
Unsecured senior notes, interest rate percent		0.60%
Gross proceeds from the issuance of debt instrument		$ 298,700,000
Senior unsecured notes issuance as percentage of principal amount		99.95%
Unamortized discount and debt issuance costs				$ (245,000)
Unamortized Debt Issuance Expense						1,100,000
Debt Instrument, Redemption Percentage Upon Change of Control and Downgrade of Debt Instrument		101.00%
Maturities of Long-term Debt [Abstract]
2017				366,450,000
2018				0
2019				0
2020				0
2021				0
Thereafter				0
Long-term Debt Before Unamortized Discount				366,450,000
Total				366,205,000
Debt Instrument, Unamortized Discount		$ 200,000		16,200		100,000
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Fair Value, Inputs, Level 2 [Member]
Maturities of Long-term Debt [Abstract]
Total				$ 366,200,000		334,200,000
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Treasury Rate [Member]
Basis spread on variable rate				0.15%
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Interest rate terms under amended senior unsecured revolving credit facility				The 2029 Notes mature in September 2029 and bear interest at an annual rate of 3.3%. Interest on the 2029 Notes is payable semi-annually on March 15th and September 15th each year.
Unsecured senior notes, interest rate percent	3.30%
Unsecured senior notes, face value	$ 850,000,000
Gross proceeds from the issuance of debt instrument	$ 847,200,000
Senior unsecured notes issuance as percentage of principal amount	99.67%
Unamortized discount and debt issuance costs				$ (9,404,000)
Unamortized Debt Issuance Expense				6,900,000		7,400,000
Debt Instrument, Redemption Percentage Upon Change of Control and Downgrade of Debt Instrument	101.00%
Maturities of Long-term Debt [Abstract]
2017				0
2018				0
2019				0
2020				0
2021				0
Thereafter				850,000,000
Long-term Debt Before Unamortized Discount				850,000,000
Total				840,596,000
Debt Instrument, Unamortized Discount	$ 2,800,000			2,500,000		2,700,000
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Fair Value, Inputs, Level 2 [Member]
Maturities of Long-term Debt [Abstract]
Total				$ 840,600,000		839,900,000
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Treasury Rate [Member]
Basis spread on variable rate				0.25%
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Unsecured senior notes, interest rate percent			1.875%						1.875%
Gross proceeds from the issuance of debt instrument			$ 492,300,000
Senior unsecured notes issuance as percentage of principal amount			99.118%						99.118%
Unamortized discount and debt issuance costs				$ (6,035,000)
Unamortized Debt Issuance Expense				2,800,000		3,300,000
Debt Instrument, Redemption Percentage Upon Change of Control and Downgrade of Debt Instrument			101.00%
Maturities of Long-term Debt [Abstract]
2017				0
2018				0
2019				0
2020				0
2021				0
Thereafter				610,750,000
Long-term Debt Before Unamortized Discount				610,750,000
Total				604,715,000		552,200,000
Debt Instrument, Unamortized Discount			$ 4,400,000	$ 3,300,000		$ 3,500,000
Euro Member Countries, Euro | Other Debt Facilities - EUROIMMUN [Member]
Maturities of Long-term Debt [Abstract]
Other Long-term Debt | €					€ 13.9		21.3
Euro Member Countries, Euro | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Unsecured senior notes, face value		$ 300,000,000
Euro Member Countries, Euro | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Unsecured senior notes, face value | €									€ 500
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member]
Maturities of Long-term Debt [Abstract]
Other Long-term Debt | €					17		€ 23.8
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €					17
Secured Debt | €					4.8
Unsecured Debt | €					€ 12.2
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member] | Minimum [Member]
Unsecured senior notes, interest rate percent				1.10%	1.10%
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member] | Maximum [Member]
Unsecured senior notes, interest rate percent				4.30%	4.30%

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019
Accounts Payable and Accrued Liabilities, Current [Abstract]
Payroll and incentives	$ 96,502	$ 77,892
Employee benefits	47,489	42,405
Deferred revenue	203,927	164,261
Federal, non-U.S. and state income taxes	97,406	29,876
Operating Lease liabilities, Accrued, Current	40,330	36,573
Contract with Customer, Liability, Current	238,100	29,900
Contract Liability, Accrued, Current	189,718	0
Other accrued operating expenses	261,655	152,325
Total accrued expenses and other current liabilities	$ 937,027	$ 503,332

Employee Benefit Plans (Schedul

Employee Benefit Plans (Schedule of Net Benefit Costs, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 7,414	$ 6,598	$ 6,853
Interest cost	12,876	16,546	16,146
Expected return on plan assets	(21,786)	(24,561)	(28,939)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment	0	1,547	0
Actuarial loss (gain)	20,291	27,134	17,146
Amortization of prior service cost	0	(152)	375
Net periodic benefit cost	$ 18,795	$ 24,018	$ 11,581

Employee Benefit Plans (Sched_2

Employee Benefit Plans (Schedule of Net Funded Status, Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Change in benefit obligations:
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change	$ (2,700)	$ (4,400)	$ (1,000)
Actuarial assumptions as of the year-end measurement date:
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Projected Benefit Obligation	224,499	195,657
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets	0	0
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation	226,890	198,294
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets	0	0
Foreign Plan [Member]
Change in plan assets:
Employer's contributions	7,500	8,200	8,500
UNITED STATES
Change in plan assets:
Employer's contributions		$ 20,000
Other Pension Plan [Member]
Actuarial assumptions as of the year-end measurement date:
Rate of compensation increase		3.36%
Foreign Plan [Member]
Actuarial present value of benefit obligations: [Abstract]
Accumulated benefit obligations	392,948	$ 338,722
Change in benefit obligations:
Projected benefit obligations at beginning of year	341,455	311,168
Service cost	5,314	4,248
Interest cost	3,991	5,448
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	37	162
Defined Benefit Plan, Benefit Obligation, Business Combination	(120)	0
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	0	(1,420)
Actuarial loss (gain)	35,910	34,602
Effect of exchange rate changes	24,575	25
Projected benefit obligations at end of year	395,339	341,455	311,168
Change in plan assets:
Fair value of plan assets at beginning of year	179,860	159,163
Actual return on plan assets	25,153	19,873
Benefits paid and plan expenses	(15,823)	(12,778)
Employer's contributions	7,506	8,200
Participant's contributions	37	162
Effect of exchange rate changes	8,011	5,240
Fair value of plan assets at end of year	204,744	179,860	$ 159,163
Net amounts recognized in the consolidated balance sheets consist of:
Net amounts recognized in the consolidated balance sheets	(190,595)	(161,595)
Assets for Plan Benefits, Defined Benefit Plan	36,295	36,699
Current liabilities	(7,597)	(6,764)
Noncurrent liabilities	(219,293)	(191,530)
Net amounts recognized in accumulated other comprehensive income consist of:
Prior service cost	$ 0	$ 0
Actuarial assumptions as of the year-end measurement date:
Discount rate	0.92%	1.34%	2.07%	1.99%
Rate of compensation increase	2.78%	3.36%	3.48%	3.50%
Expected rate of return on assets		2.20%	5.30%	5.90%
Defined Benefit Plan, Benefit Obligation, Benefits Paid	$ 15,823	$ 12,778
UNITED STATES
Actuarial present value of benefit obligations: [Abstract]
Accumulated benefit obligations	317,679	304,710
Change in benefit obligations:
Projected benefit obligations at beginning of year	304,710	283,310
Service cost	2,100	2,350
Interest cost	8,885	11,098
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Defined Benefit Plan, Benefit Obligation, Business Combination	0	0
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	0	0
Actuarial loss (gain)	22,494	29,114
Effect of exchange rate changes	0	0
Projected benefit obligations at end of year	317,679	304,710	$ 283,310
Change in plan assets:
Fair value of plan assets at beginning of year	254,450	234,342
Actual return on plan assets	34,746	41,270
Benefits paid and plan expenses	(20,510)	(21,162)
Employer's contributions	0	0
Participant's contributions	0	0
Effect of exchange rate changes	0	0
Fair value of plan assets at end of year	268,686	254,450	$ 234,342
Net amounts recognized in the consolidated balance sheets consist of:
Net amounts recognized in the consolidated balance sheets	(48,993)	(50,260)
Assets for Plan Benefits, Defined Benefit Plan	0	0
Current liabilities	0	0
Noncurrent liabilities	(48,993)	(50,260)
Net amounts recognized in accumulated other comprehensive income consist of:
Prior service cost	$ 0	$ 0
Actuarial assumptions as of the year-end measurement date:
Discount rate	2.21%	3.01%	4.05%	3.56%
Rate of compensation increase	0.00%	0.00%	0.00%	0.00%
Expected rate of return on assets		7.25%	7.25%	7.25%
Defined Benefit Plan, Benefit Obligation, Benefits Paid	$ 20,510	$ 21,162

Employee Benefit Plans (Sched_3

Employee Benefit Plans (Schedule of Allocation of Plan Assets, Pension Plans) (Details)	12 Months Ended
	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		100.00%	100.00%
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		100.00%	100.00%
Other Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		12.00%	13.00%
Other Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		0.00%	0.00%
Debt Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		88.00%	87.00%
Debt Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		55.00%	59.00%
Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		0.00%	0.00%
Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		45.00%	41.00%
Forecast [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities	100.00%
Forecast [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities	100.00%
Forecast [Member] | Minimum [Member] | Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	0.00%
Forecast [Member] | Minimum [Member] | Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	40.00%
Forecast [Member] | Minimum [Member] | Debt Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	85.00%
Forecast [Member] | Minimum [Member] | Debt Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	40.00%
Forecast [Member] | Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	10.00%
Forecast [Member] | Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	0.00%
Forecast [Member] | Maximum [Member] | Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	5.00%
Forecast [Member] | Maximum [Member] | Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	60.00%
Forecast [Member] | Maximum [Member] | Debt Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	90.00%
Forecast [Member] | Maximum [Member] | Debt Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	60.00%
Forecast [Member] | Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	15.00%
Forecast [Member] | Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	10.00%

Employee Benefit Plans (Sched_4

Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 473,430	$ 434,310
Equity Securities, U.S. Small-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		2,700
Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,363	6,177
Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	78,234	57,797
Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28,315	26,914
Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	13,594	12,853
Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		2,010
Equity Securities, Foreign Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	23,259	22,688
Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	106,315	93,473
Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	140,349	139,300
Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	35,816	29,846
Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,954	5,734
Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		1,721
Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	38,231	33,097
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	172,960	161,289
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Small-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		2,700
Fair Value, Inputs, Level 1 [Member] | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,363	6,177
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	78,234	57,797
Fair Value, Inputs, Level 1 [Member] | Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28,315	26,914
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	13,594	12,853
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		2,010
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Foreign Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	43,500	47,104
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,954	5,734
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	277,211	248,612
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Small-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fair Value, Inputs, Level 2 [Member] | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Foreign Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	106,315	93,473
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	96,849	92,196
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	35,816	29,846
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	38,231	33,097
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	23,259	24,409	$ 39,130	$ 16,789
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Small-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fair Value, Inputs, Level 3 [Member] | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Foreign Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	23,259	22,688
Fair Value, Inputs, Level 3 [Member] | Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	1,721	$ 16,934	$ 16,789
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	$ 0

Employee Benefit Plans (Sched_5

Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Other Postretirement Benefits Plan [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	$ 19,216	$ 16,279
Realized gains (losses)	1,647	1,776	$ (1,621)
Fair value of plan assets at end of year	21,972	19,216	16,279
Other Postretirement Benefits Plan [Member] | Multi-strategy hedge funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	130
Fair value of plan assets at end of year		130
Pension Plans, Defined Benefit
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	434,310
Fair value of plan assets at end of year	473,430	434,310
Pension Plans, Defined Benefit | Multi-strategy hedge funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,721
Fair value of plan assets at end of year		1,721
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefits Plan [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	130
Fair value of plan assets at end of year	0	130
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefits Plan [Member] | Multi-strategy hedge funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	130	1,176	1,151
Realized gains (losses)		315
Unrealized gains (losses)		(287)	25
Fair value of plan assets at end of year	0	130	1,176
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale	(1,721)	(15,586)
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase			22,196
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	24,409	39,130	16,789
Realized gains (losses)		4,175
Unrealized gains (losses)	571	(3,310)	145
Fair value of plan assets at end of year	23,259	24,409	39,130
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | Foreign Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale	0	0
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase			22,196
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	22,688	22,196	0
Realized gains (losses)		0
Unrealized gains (losses)	571	492	0
Fair value of plan assets at end of year	23,259	22,688	22,196
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale	(1,721)	(15,586)
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase			0
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,721	16,934	16,789
Realized gains (losses)		4,175
Unrealized gains (losses)	0	(3,802)	145
Fair value of plan assets at end of year	$ 0	$ 1,721	$ 16,934

Employee Benefit Plans (Sched_6

Employee Benefit Plans (Schedule of Expected Benefit Payments, Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Jan. 02, 2022
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
2018	$ 12,932
2019	12,960
2020	13,349
2021	14,152
2022	14,206
2023-2026	72,747
Defined Benefit Plan, Plan Assets, Contributions by Employer	7,500	$ 8,200	$ 8,500
Foreign Plan [Member] | Forecast [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in next fiscal year				$ 7,600
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
2018	19,373
2019	19,435
2020	19,504
2021	19,495
2022	19,390
2023-2026	$ 92,258
Defined Benefit Plan, Plan Assets, Contributions by Employer		$ 20,000

Employee Benefit Plans (Sched_7

Employee Benefit Plans (Schedule of Net Benefit Costs, Other Postretirement Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 7,414	$ 6,598	$ 6,853
Interest cost	12,876	16,546	16,146
Expected return on plan assets	(21,786)	(24,561)	(28,939)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment	0	1,547	0
Actuarial loss (gain)	(20,291)	(27,134)	(17,146)
Amortization of prior service cost	0	(152)	375
Net periodic benefit cost	18,795	24,018	11,581
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	73	87	106
Interest cost	94	116	120
Expected return on plan assets	(1,389)	(1,175)	(1,254)
Defined Benefit Plan, Amortization of Gain (Loss)	(1,647)	(1,776)	1,621
Actuarial loss (gain)	(179)	108
Net periodic benefit cost	$ (2,869)	$ (2,748)	$ 593

Employee Benefit Plans (Sched_8

Employee Benefit Plans (Schedule of Net Funded Status, Other Postretirement Benefit Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	3.09%	4.09%	3.60%
Change in benefit obligations:
Projected benefit obligations at beginning of year	$ 3,100	$ 2,911
Service cost	73	87	$ 106
Interest cost	94	116	120
Defined Benefit Plan, Benefit Obligation, Benefits Paid	101	122
Actuarial loss (gain)	(179)	108
Change in accumulated benefit obligations during the year	(113)	189
Projected benefit obligations at end of year	2,988	3,100	2,911
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	19,216	16,279
Actual return on plan assets	2,756	2,937
Fair value of plan assets at end of year	21,972	19,216	$ 16,279
Net amounts recognized in the consolidated balance sheets	18,984	16,116
Assets for Plan Benefits, Defined Benefit Plan	18,984	16,116
Prior service cost	$ 0	$ 0
Discount rate	2.34%	3.09%
Expected rate of return on assets	7.25%	7.25%	7.25%
Retirees [Member]
Change in benefit obligations:
Projected benefit obligations at beginning of year	$ 611	$ 583
Projected benefit obligations at end of year	545	611	$ 583
Active Employees Eligible to Retire [Member]
Change in benefit obligations:
Projected benefit obligations at beginning of year	420	362
Projected benefit obligations at end of year	1,232	420	362
Other Active Employees [Member]
Change in benefit obligations:
Projected benefit obligations at beginning of year	2,069	1,966
Projected benefit obligations at end of year	$ 1,211	$ 2,069	$ 1,966

Employee Benefit Plans (Sched_9

Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Other Postretirement Benefit Plans) (Details) - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 473,430	$ 434,310
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	21,972	19,216	$ 16,279
Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	172,960	161,289
Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14,052	12,123
Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	277,211	248,612
Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,920	6,963
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	23,259	24,409	39,130	$ 16,789
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	130
Cash [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,363	6,177
Cash [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	428	408
Cash [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,363	6,177
Cash [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	428	408
Cash [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Cash [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Cash [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Cash [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	78,234	57,797
Equity Securities, U.S. Large-cap [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,398	4,365
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	78,234	57,797
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,398	4,365
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28,315	26,914
Equity Securities, International large-cap value[Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,315	2,033
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28,315	26,914
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,315	2,033
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Equity Index Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,112	971
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,112	971
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Domestic Real Estate Funds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		2,010
Equity Securities, Domestic Real Estate Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		152
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		2,010
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		152
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Equity Securities, Foreign Real Estate Funds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	23,259	22,688
Equity Securities, Foreign Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Foreign Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Foreign Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	23,259	22,688
Fixed Income Funds, Corporate Debt Instruments [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	140,349	139,300
Fixed Income Funds, Corporate Debt Instruments [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		10,520
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	43,500	47,104
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		3,557
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	96,849	92,196
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		6,963
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fixed Income Funds, Corporate Bonds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	35,816	29,846
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	35,816	29,846
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,954	5,734
Fixed Income Funds, High Yield Bonds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	242	433
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,954	5,734
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	242	433
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		1,721
Other Types of Investments, Multi-strategy hedge funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		130
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	1,721	16,934	16,789
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	130	$ 1,176	$ 1,151
Equity Securities, U.S. Small-cap [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		2,700
Equity Securities, U.S. Small-cap [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		204
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		2,700
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		204
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		$ 0
Fixed Income Funds, Corporate and U.S. Debt Instruments [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	11,477
Fixed Income Funds, Corporate and U.S. Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,557
Fixed Income Funds, Corporate and U.S. Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,920
Fixed Income Funds, Corporate and U.S. Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0

Employee Benefit Plans (Sche_10

Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Other Postretirement Benefit Plans) (Details) - Other Postretirement Benefits Plan [Member] - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	$ 19,216	$ 16,279
Realized gains (losses)	1,647	1,776	$ (1,621)
Fair value of plan assets at end of year	21,972	19,216	16,279
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	130
Fair value of plan assets at end of year	0	130
Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	130
Fair value of plan assets at end of year		130
Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement	130	1,074
Fair value of plan assets at beginning of year	130	1,176	1,151
Realized gains (losses)		315
Unrealized gains (losses)		(287)	25
Fair value of plan assets at end of year	$ 0	$ 130	$ 1,176

Employee Benefit Plans (Sche_11

Employee Benefit Plans (Schedule of Expected Benefit Payments, Other Postretirement Benefits) (Details) - USD ($) $ in Thousands	Jan. 02, 2022	Jan. 03, 2021
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
2018		$ 12,932
2019		12,960
2020		13,349
2021		14,152
2022		14,206
2023-2026		72,747
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
2018		19,373
2019		19,435
2020		19,504
2021		19,495
2022		19,390
2023-2026		92,258
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
2018		119
2019		137
2020		150
2021		161
2022		172
2023-2026		$ 883
Forecast [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	$ 7,600

Employee Benefit Plans (Savings

Employee Benefit Plans (Savings Plan) (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, 401(k) Savings Plan, Employer Contribution Match of Employees Eligible Compensation	100.00%
Defined Benefit Plan, 401(k) Savings Plan, Maximum Employee Match Percent for Employer Match	5.00%
Defined Benefit, 401(k) Savings Plan Expense	$ 14.1	$ 13.6	$ 13.2

Employee Benefit Plans (Supplem

Employee Benefit Plans (Supplemental Executive Retirement Plan) (Details) - Supplemental Employee Retirement Plans, Defined Benefit [Member] - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	$ 25.9	$ 25.7
Fair value of plan assets	1.9	2.1
Pension expense	$ 2.1	$ 4.8	$ (0.3)

Employee Benefit Plans (Nonqual

Employee Benefit Plans (Nonqualified Deferred Compensation Plans) (Details) - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019
Management [Member]
Defined Benefit Plan Disclosure [Line Items]
Deferred Compensation Arrangement with Individual, Recorded Liability	$ 0.6	$ 1.1

Contingencies (Details)

Contingencies (Details) $ in Millions	12 Months Ended
	Jan. 03, 2021USD ($)years	Dec. 29, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Management's estimate of total cost of ultimate disposition of known environmental matters | $	$ 12.9	$ 7.7
Number of years over which estimated environmental cost will be paid | years	10

Warranty Reserves (Details)

Warranty Reserves (Details) $ in Thousands	12 Months Ended
	Jan. 03, 2021USD ($)years	Dec. 29, 2019USD ($)	Dec. 30, 2018USD ($)
Warranty reserve activity
Period of warranty protection beyond date of sale (in years) | years	1
Balance beginning of period	$ 8,812	$ 8,393	$ 9,050
Provision charged to income	15,315	12,199	13,545
Payments	(15,130)	(14,613)	(13,775)
Adjustments to previously provided warranties, net	2,721	2,889	(157)
Foreign currency and acquisitions	355	(56)	(270)
Balance end of period	$ 12,073	$ 8,812	$ 8,393

Stock Plans (Narrative) (Detail

Stock Plans (Narrative) (Details)	12 Months Ended
	Jan. 03, 2021USD ($)plan$ / sharesshares	Dec. 29, 2019USD ($)$ / sharesshares	Dec. 30, 2018USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock-based Compensation Plans | plan	1
Total income tax benefit recognized for stock-based compensation	$ 17,200,000	$ 11,600,000	$ 13,600,000
Stock-based compensation costs capitalized as part of inventory	400,000	300,000
Aggregate intrinsic value for stock options outstanding	$ 66,400,000
Weighted average remaining contractual term of options (in years)	3 years 10 months 24 days
Aggregate intrinsic value for stock options exercisable	$ 43,900,000
Weighted average remaining contractual term of options exercisable (in years)	2 years 7 months 6 days
Number of shares vested and expected to vest in the future | shares	1,000,000
Aggregate intrinsic value of vested and expected to vest stock options	$ 66,400,000
Weighted average remaining contractual term for options vested and expected to vest	3 years 10 months 24 days
Total pre-tax stock-based compensation expense	$ 29,126,000	31,514,000	$ 28,767,000
Deferred compensation liability	$ 9,400,000
Acceleration of executive compensation		$ 7,700,000
Performance Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share) | $ / shares			$ 73.23
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares	1,948	10,116
Total pre-tax stock-based compensation expense	$ 6,100,000	$ 5,600,000	$ 7,700,000
Shares/units granted | shares	0		37,281
Awards/units outstanding | shares	31,207
Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 91.75	$ 95.84	$ 72.17
Total pre-tax stock-based compensation expense	$ 800,000	$ 700,000	$ 800,000
Shares/units granted | shares	8,333	7,301	11,088
Stock award program for non-employees Directors, fair market value	$ 100,000
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 84.83
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares	40,000
Fair value of restricted stock awards vested	$ 14,000,000	$ 12,000,000	$ 10,400,000
Total pre-tax stock-based compensation expense	10,800,000	$ 12,700,000	$ 11,700,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$ 14,300,000
Shares/units granted | shares	184,000
Awards/units outstanding | shares	296,000	345,000
Weighted-average period for recognition of unrecognized compensation cost, years	1 year 4 months 24 days
Option vesting period (in years)	3 years
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan | shares	5,000,000
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 105.23	$ 82.25	$ 69.57
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date	95.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate	10.00%
Shares/units granted | shares	38,727	33,843	21,321
Shares available for grant under employee stock purchase plan | shares	800,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of options | $ / shares	$ 18.98	$ 22.63	$ 17.56
Total intrinsic value of options exercised	$ 51,100,000	$ 19,100,000	$ 35,000,000
Cash received from option exercises	37,700,000	19,700,000	24,800,000
Total pre-tax stock-based compensation expense	3,600,000	$ 6,700,000	$ 5,400,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$ 4,700,000
Weighted-average period for recognition of unrecognized compensation cost, years	1 year 9 months 18 days
Option vesting period (in years)		3 years
Stock Options Expiration Period After Date of Grant		7 years
Performance Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 95.43	$ 92.95
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares	29,943
Total pre-tax stock-based compensation expense	$ 7,900,000	$ 5,900,000
Shares/units granted | shares	49,138	76,218
Awards/units outstanding | shares	121,759

Stock Plans (Summary of Total C

Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 29,126	$ 31,514	$ 28,767
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,388	1,620	1,466
Research and development expenses [Member ]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,228	1,061	1,359
Selling, general and administrative and other expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 26,510	$ 28,833	$ 25,942

Stock Plans (Weighted-Average A

Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	0.90%	2.50%	3.00%
Expected dividend yield	0.30%	0.30%	0.40%
Expected lives, years	5 years	5 years	5 years
Expected stock volatility	23.80%	22.80%	20.70%

Stock Plans (Summary of Stock O

Stock Plans (Summary of Stock Option Activity) (Details) - $ / shares shares in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Stock option activity
Shares outstanding at beginning of the year	1,535
Shares granted	266
Shares exercised	(764)
Shares canceled		(1)
Shares forfeited	(75)
Shares outstanding at end of year	961	1,535
Shares exercisable at end of year	562
Number of shares vested and expected to vest in the future	1,000
Weighted-average price, outstanding at beginning of year (per share)	$ 60.42
Weighted-average price, granted (per share)	86.87
Weighted-average price, exercised (per share)	49.31
Weighted-average price, canceled (per share)		$ 95.74
Weighted-average price, forfeited (per share)	87.34
Weighted-average price, outstanding at end of year (per share)	74.40	$ 60.42
Weighted-average price, exercisable at end of year (per share)	$ 65.30

Stock Plans (Summary of Restric

Stock Plans (Summary of Restricted Stock Award Activity) (Details) shares in Thousands	12 Months Ended
	Jan. 03, 2021$ / sharesshares
Restricted Stock Units (RSUs) [Member]
Restricted stock award activity
Performance factor percentage minimum	0.00%
Performance factor percentage maximum	200.00%
Restricted Stock Awards [Member]
Restricted stock award activity
Nonvested at beginning of year | shares	345
Shares, granted | shares	184
Shares, vested | shares	(193)
Shares, forfeited | shares	(40)
Nonvested at end of year | shares	296
Weighted-average grant-date fair value, nonvested at beginning of year (per share) | $ / shares	$ 78.69
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	84.83
Weighted-average grant-date fair value, vested (per share) | $ / shares	72.28
Weighted-average grant-date fair value, forfeited (per share) | $ / shares	86.32
Weighted-average grant-date fair value, nonvested at end of year (per share) | $ / shares	$ 85.67

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 05, 2021	Apr. 04, 2021	Jan. 03, 2021	Oct. 04, 2020	Jul. 05, 2020	Apr. 05, 2020	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Jul. 31, 2020	Jul. 23, 2018
Schedule of Stockholders' Equity [Line Items]
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans											72,251	68,536	66,506
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans											$ 6,900	$ 6,300	$ 5,200
Cash dividends (per share)			$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.28	$ 0.28
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations											$ 6,944	$ 6,313	57,393
Dividends accrued			$ 7,900								7,900
Unrecognized prior service (cost) credit, net of tax											(1,799)	807	(77)
Unrecognized prior service credit (cost), net of tax1											(1,800)	$ 800	$ (100)
Repurchase Program, 07/31/2020 [Member]
Schedule of Stockholders' Equity [Line Items]
Stock Repurchase Program, Remaining Authorized Repurchase Amount			$ 250,000								$ 250,000
Stock Repurchase Program, Authorized Amount														$ 250,000
Repurchase Program, 07/23/2018 [Member]
Schedule of Stockholders' Equity [Line Items]
Stock Repurchase Program, Authorized Amount															$ 250,000
Subsequent Event [Member]
Schedule of Stockholders' Equity [Line Items]
Cash dividends (per share)		$ 0.07
Dividends Payable, Date Declared		Jan. 28, 2021
Subsequent Event [Member] | Repurchase Program, 07/31/2020 [Member]
Schedule of Stockholders' Equity [Line Items]
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans	$ 33,600
Number of common stock repurchased in open market	233,000

Stockholders' Equity (Component

Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Cumulative Translation Adjustment Summary [Roll Forward]
Foreign currency translation adjustment, net of tax, beginning of year	$ (200,437)	$ (176,459)	$ (46,582)
Current year change	169,500	(23,978)	(123,388)
Foreign currency translation adjustment, net of tax, end of year	(30,937)	(200,437)	(176,459)
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax			0
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax			0
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax			(6,489)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	167,685	(23,165)	(123,474)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax			(123,474)
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustments Reclassification From AOCI to Earnings Due to ASU 2018-02	0	0	6,489
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustments Reclassification From AOCI to Earnings, Net of Tax			(6,489)
Unrecognized prior service costs, net of tax	(747)	1,052	245	$ 322
Unrecognized prior service costs, net of tax, current year change	(1,799)	807	(77)
Unrealized (losses) gains on securities, net of tax	(277)	(261)	(267)	(258)
Unrealized (losses) gains on securities, net of tax, current year change	(16)	6	(9)
Other comprehensive income (loss)	167,685	(23,165)	(129,963)
Accumulated other comprehensive income (loss)	$ (31,961)	$ (199,646)	$ (176,481)	$ (46,518)

Derivatives And Hedging Activ_2

Derivatives And Hedging Activities (Details) $ in Thousands, € in Millions	12 Months Ended
	Jan. 03, 2021USD ($)	Jan. 03, 2021EUR (€)	Dec. 29, 2019USD ($)	Dec. 30, 2018USD ($)	Jan. 03, 2021EUR (€)	Dec. 29, 2019EUR (€)	Dec. 30, 2018EUR (€)
Derivative [Line Items]
Company's business conducted outside United States	70.00%	70.00%
Payments for (Proceeds from) Hedge, Financing Activities	$ 4,554		$ 1,280	$ 34,132
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	0
Payments for Hedge, Financing Activities	$ 4,600		$ 1,300
European And Asian Currencies [Member]
Derivative [Line Items]
Maximum maturity period for foreign exchange contracts, in months	12 months	12 months
Duration of foreign currency derivative contract, days	30 days	30 days	30 days
Fair Value Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount	$ 808,000		$ 277,600	223,300
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	(31,248)		(451)
Notional Amount of US Dollar Derivatives [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount	499,000		5,600	$ 5,700
Notional Amount of Euro Derivatives [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount | €					€ 33.4	€ 105.8	€ 37.3
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount	300,000
Unrealized Gain (Loss) on Derivatives	29,300
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Net Investment Hedging [Member]
Derivative [Line Items]
Unrealized Gain (Loss) on Net Investment Hedge in AOCI	(1,800)		8,000
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Net Investment Hedging [Member] | First Amount Removed [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments | €		€ 100
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Net Investment Hedging [Member] | Remaining Amount Removed [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments | €		€ 200
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Net Investment Hedging [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments	497,200
Unrealized Gain (Loss) on Net Investment Hedge in AOCI	$ (49,600)		4,900
Euro Member Countries, Euro | Cross-currency Swap [Member]
Derivative [Line Items]
Derivative, Fixed Interest Rate	2.47%				2.47%
Euro Member Countries, Euro | Cross-currency Swap [Member] | Net Investment Hedging [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments	$ 197,400
United States of America, Dollars | Cross-currency Swap [Member]
Derivative [Line Items]
Derivative, Fixed Interest Rate	5.00%				5.00%
United States of America, Dollars | Cross-currency Swap [Member] | Net Investment Hedging [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments	$ 220,000
Unrealized Gain (Loss) on Net Investment Hedge in AOCI	(18,600)		$ 300
Fair Value of Cross-currency Swap	$ (18,300)

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) € in Millions	12 Months Ended
	Jan. 03, 2021USD ($)	Dec. 29, 2019USD ($)	Dec. 30, 2018USD ($)	Jan. 01, 2017USD ($)	Jan. 03, 2021EUR (€)	Dec. 29, 2019EUR (€)	Sep. 17, 2019USD ($)	Sep. 12, 2019USD ($)	Apr. 11, 2018USD ($)	Dec. 31, 2017USD ($)	Jul. 19, 2016USD ($)	Jul. 19, 2016EUR (€)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 7,300,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	2,953,000	$ 35,481,000	$ 69,661,000							$ 65,328,000
Long-term Debt	$ 1,990,649,000
Business Combination, Contingent Consideration Arrangements, Maximum Period	2 years 10 months 24 days
Business Combination, Contingent Consideration Arrangements, Weighted Average Period	1 year 10 months 24 days
Payments for acquisition related contingent consideration	$ (10,363,000)	(29,942,000)	$ (12,800,000)
Line of Credit, Maturing September 17, 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured revolving credit facility, amount							$ 1,000,000,000
Long-term Debt	155,974,000
Revolving credit facility outstanding balance	158,600,000
Unamortized Debt Issuance Expense	2,600,000
Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €					€ 23.1
Long-term Debt, Percentage Bearing Variable Interest, Amount | €					€ 0.1
Line of Credit, Maturing August 11, 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt		322,000,000
Revolving credit facility outstanding balance		325,400,000
Unamortized Debt Issuance Expense		3,400,000
0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	366,205,000
Debt Instrument, Interest Rate, Stated Percentage									0.60%
Discount on senior unsecured notes	(16,200)	(100,000)							$ (200,000)
Unamortized Debt Issuance Expense		1,100,000
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, face value								$ 850,000,000
Long-term Debt	840,596,000
Debt Instrument, Interest Rate, Stated Percentage								3.30%
Discount on senior unsecured notes	(2,500,000)	(2,700,000)						$ (2,800,000)
Unamortized Debt Issuance Expense	6,900,000	7,400,000
Unsecured senior notes, fair value	957,900,000	872,300,000
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	604,715,000	552,200,000
Debt Instrument, Interest Rate, Stated Percentage											1.875%	1.875%
Discount on senior unsecured notes	(3,300,000)	(3,500,000)									$ (4,400,000)
Unamortized Debt Issuance Expense	$ 2,800,000	3,300,000
Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.10%				1.10%
Maximum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.90%				8.90%
Vanadis Diagnostics AB [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				$ 32,000,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				93,000,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value				$ (56,900,000)
Fiscal Year 2019 Other Acquisitions [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value		634,000
Vanadis Diagnostics AB, DNA Labs and Biosense [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Payment for Contingent Consideration Liability, Financing Activities	$ 10,400,000
Payment for Contingent Consideration Liability, Operating Activities	13,300,000
Payments for acquisition related contingent consideration	23,700,000
Vanadis Diagnostics AB, SSI and DNA Labs [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Payment for Contingent Consideration Liability, Financing Activities		29,900,000
Payment for Contingent Consideration Liability, Operating Activities		20,900,000
Payments for acquisition related contingent consideration		50,900,000
Euro Member Countries, Euro | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt | €					€ 13.9	€ 21.3
Euro Member Countries, Euro | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, face value									$ 300,000,000
Unsecured senior notes, fair value	300,500,000	301,900,000
Euro Member Countries, Euro | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, face value | €												€ 500
Unsecured senior notes, fair value	539,800,000	518,500,000
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt | €					17	23.8
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €					€ 17
United States of America, Dollars | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, fair value	367,100,000	337,400,000
United States of America, Dollars | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, fair value	$ 659,300,000	579,600,000
United States of America, Dollars | Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.10%				1.10%
United States of America, Dollars | Maximum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.30%				4.30%
United States of America, Dollars | Fiscal Year 2019 and 2018 Other Acquisitions [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value		12,700,000
Fair Value, Inputs, Level 2 [Member] | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt | €					€ 23.2	€ 25.7
Fair Value, Inputs, Level 2 [Member] | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	$ 366,200,000	334,200,000
Fair Value, Inputs, Level 2 [Member] | 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	$ 840,600,000	$ 839,900,000

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 2,953	$ 35,481	$ 69,661	$ 65,328
Fair Value, Recurring [Member] | Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	(2,154)	(2,906)
Foreign Currency Contract, Asset, Fair Value Disclosure	31,248	451
Foreign exchange derivative liabilities, net	(21,413)	(1,538)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	2,953	35,481
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	(2,154)	(2,906)
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Foreign exchange derivative liabilities, net	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0	0
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Foreign Currency Contract, Asset, Fair Value Disclosure	31,248	451
Foreign exchange derivative liabilities, net	(21,413)	(1,538)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0	0
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Foreign exchange derivative liabilities, net	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 2,953	$ 35,481

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance beginning of period	$ (35,481)	$ (69,661)	$ (65,328)
Additions		(12,734)
Payments	(23,701)	(50,795)	(16,506)
Change in fair value (included within selling, general and administrative expenses)	8,827	(3,881)	(14,639)
Balance end of period	$ (2,953)	$ (35,481)	$ (69,661)

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Leases [Abstract]
Operating Lease, Cost	$ 56,977	$ 61,205
Schedule Of Supplemental Cash Flow Information Related To Leases [Line Items]
Operating Lease, Payments	$ 47,427	$ 50,155

Leases Supplemental Balance She

Leases Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019
Schedule of Supplemental Balance Sheet Information Related To Leases [Line Items]
Operating Lease, Right-of-Use Asset	$ 207,236	$ 167,276
Operating Lease, Liability, Noncurrent	188,402	146,399
Operating Lease, Liability	$ 228,732	182,972
Operating Lease, Weighted Average Remaining Lease Term	8 years 1 month 6 days
Operating Lease, Weighted Average Discount Rate, Percent	2.90%
Other Current Liabilities [Member]
Schedule of Supplemental Balance Sheet Information Related To Leases [Line Items]
Operating Lease, Liability, Current	$ 40,330	36,573
Other Noncurrent Liabilities [Member]
Schedule of Supplemental Balance Sheet Information Related To Leases [Line Items]
Operating Lease, Liability, Noncurrent	$ 188,402	$ 146,399

Leases Lessee, Operating Lease,

Leases Lessee, Operating Lease, Liability, Maturity (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Operating Lease Liabilities, Maturity [Line Items]
Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months	$ 48,986
Lessee, Operating Lease, Liability, Payments, Due Year Two	40,097
Lessee, Operating Lease, Liability, Payments, Due Year Three	30,044
Lessee, Operating Lease, Liability, Payments, Due Year Four	26,667
Lessee, Operating Lease, Liability, Payments, Due Year Five	24,847
Lessee, Operating Lease, Liability, Payments, Due after Year Five	90,518
Operating Lease, Payments	47,427	$ 50,155
Lessee, Operating Lease, Liability, Payments, Due	261,159
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(32,427)
Operating Lease, Liability	$ 228,732	$ 182,972

Schedule of Sales and Operating

Schedule of Sales and Operating Income from Continuing Operations by Operating Segment (Details) $ in Thousands		3 Months Ended									12 Months Ended
		Jan. 03, 2021USD ($)	[1]	Oct. 04, 2020USD ($)	Jul. 05, 2020USD ($)	Apr. 05, 2020USD ($)	Dec. 29, 2019USD ($)	Sep. 29, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Jan. 03, 2021USD ($)segments	Dec. 29, 2019USD ($)	Dec. 30, 2018USD ($)
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations		$ 510,254		$ 248,006	$ 175,639	$ 44,682	$ 138,248	$ 78,660	$ 91,735	$ 53,330	$ 978,581	$ 361,973	$ 323,884
Number of Operating Segments | segments											2
Revenue from Contract with Customer, Excluding Assessed Tax											$ 3,782,745	2,883,673	2,777,996
Interest and other expense (income), net											72,217	124,831	66,201
Income from continuing operations before income taxes		$ 473,091		$ 233,757	$ 164,827	$ 34,689	$ 65,296	$ 63,254	$ 71,827	$ 36,765	906,364	237,142	257,683
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market											25,400	31,200
Acceleration of executive compensation												7,700
Asset Impairment Charges											7,937	0	0
Significant environmental matters											5,200
Diagnostics [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations											874,206	189,330	153,196
Revenue from Contract with Customer, Excluding Assessed Tax											2,066,942	1,137,512	1,084,785
Asset Impairment Charges											7,900
Discovery & Analytical Solutions [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations	[2]										183,471	238,331	230,481
Revenue from Contract with Customer, Excluding Assessed Tax											1,715,803	1,746,161	1,693,211
Corporate [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations	[3]										(79,096)	(65,688)	(59,793)
Particular Diagnostics Case [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Legal Fees											1,200	100	200
Particular Discovery & Analytical Solutions Case [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Legal Fees											5,900	2,200	5,300
Product [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax											2,778,725	2,017,042	1,935,493
Product [Member] | Diagnostics [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax											1,783,509	962,180	924,594
Product [Member] | Discovery & Analytical Solutions [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax											995,216	1,054,862	1,010,899
Service [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax											1,004,020	866,631	842,503
Service [Member] | Diagnostics [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax											283,433	175,332	160,191
Service [Member] | Discovery & Analytical Solutions [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax											$ 720,587	$ 691,299	$ 682,312
[1]	The fourth quarter of fiscal year 2020 includes a pre-tax loss of $25.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy
[2]	Legal costs for significant litigation matters and settlements in the Company's Discovery & Analytical Solutions segment were $5.9 million, $2.2 million and $5.3 million for fiscal years 2020, 2019 and 2018, respectively. Legal costs for significant litigation matters and settlements in the Company's Diagnostics segment were $1.2 million, $0.1 million and $0.2 million for fiscal years 2020, 2019 and 2018, respectively. (2) Asset impairment in the Company's Diagnostics segment was $7.9 million for fiscal year 2020.
[3]	Costs for significant environmental matters was $5.2 million for fiscal year 2020. Stock compensation expense from acceleration of executive compensation was $7.7 million for fiscal year 2019.

Industry Segment and Geograph_3

Industry Segment and Geographic Area Information Schedule of Depreciation, Amortization and Capital Expenditures (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Schedule of Segment Reporting Information, by Segment [Line Items]
Depreciation and amortization expense	$ 246,507	$ 214,025	$ 180,588
Payments to Acquire Property, Plant, and Equipment	77,506	76,331	93,253
Diagnostics [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Depreciation and amortization expense	149,738	136,476	107,434
Payments to Acquire Property, Plant, and Equipment	55,236	46,863	54,737
Discovery & Analytical Solutions [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Depreciation and amortization expense	93,516	74,445	70,362
Payments to Acquire Property, Plant, and Equipment	20,217	27,778	34,852
Corporate [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Depreciation and amortization expense	3,253	3,104	2,792
Payments to Acquire Property, Plant, and Equipment	2,053	1,690	3,664
All Segments [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Depreciation and amortization expense	246,507	214,025	180,588
Payments to Acquire Property, Plant, and Equipment	$ 77,506	$ 76,331	$ 93,253

Industry Segment and Geograph_4

Industry Segment and Geographic Area Information Schedule of Total Assets by Segment (Details) - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Schedule of Total Assets, by segment [Line Items]
Assets	$ 7,960,315	$ 6,538,564
Diagnostics [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	4,228,943	3,368,598	$ 3,358,964
Discovery & Analytical Solutions [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	3,600,860	3,082,917	2,567,054
Corporate [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	$ 130,512	$ 87,049	49,504
All Segments [Member]
Schedule of Total Assets, by segment [Line Items]
Assets			$ 5,975,522

Industry Segment and Geograph_5

Industry Segment and Geographic Area Information Schedule of Revenue by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 3,782,745	$ 2,883,673	$ 2,777,996
UNITED STATES
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,269,293	974,187	906,398
CHINA
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	492,283	581,688	559,865
UNITED KINGDOM
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	362,591	70,703	72,124
GERMANY
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	200,294	146,577	142,411
ITALY
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	163,056	101,461	95,908
FRANCE
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	148,898	96,994	97,990
KOREA, REPUBLIC OF
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	114,846	71,069	60,126
INDIA
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	103,785	97,423	92,327
JAPAN
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	88,473	82,478	79,238
Other International [Member]
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	839,226	661,093	671,609
Total international [Member]
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 2,513,452	$ 1,909,486	$ 1,871,598

Industry Segment and Geograph_6

Industry Segment and Geographic Area Information Schedule of Long-Lived Assets by Geographic Location (Details) - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	$ 651,158	$ 659,605	$ 490,311
UNITED STATES
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	197,755	269,183	201,649
GERMANY
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	149,105	119,612	99,181
CHINA
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	75,199	71,216	61,261
FINLAND
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	60,559	29,052	16,211
UNITED KINGDOM
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	35,243	51,659	33,429
SINGAPORE
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	24,291	23,063	14,942
INDIA
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	21,975	19,691	14,636
ITALY
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	17,051	14,152	11,324
FRANCE
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	13,325	12,940	3,210
BRAZIL
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	8,627	9,126	8,237
POLAND
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	7,732	7,216	3,212
Other International [Member]
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	34,625	26,210	17,565
Total international [Member]
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	453,403	390,422	288,662
CANADA
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	$ 5,671	$ 6,485	$ 5,454

Quarterly Financial Informati_3

Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended									12 Months Ended
	Jan. 03, 2021		Oct. 04, 2020	Jul. 05, 2020	Apr. 05, 2020	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Quarterly Financial Data [Abstract]
Revenue	$ 1,354,606		$ 964,025	$ 811,718	$ 652,396	$ 805,496	$ 706,923	$ 722,517	$ 648,737	$ 3,782,745	$ 2,883,673
Gross profit	827,065		527,445	447,344	308,023	398,181	342,275	347,793	307,806	2,109,877	1,396,055
Restructuring and other costs, net	(3,062)		4,059	1,158	5,858	1,560	14,068	6,161	7,639	8,013	29,428	$ 11,144
Operating income from continuing operations	510,254	[1]	248,006	175,639	44,682	138,248	78,660	91,735	53,330	978,581	361,973	323,884
Income from continuing operations before income taxes	473,091	[1]	233,757	164,827	34,689	65,296	63,254	71,827	36,765	906,364	237,142	257,683
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	(73)		(37)	(51)	(50)	(48)	(52)	(54)	(41)	(211)	(195)	452
Operating income from continuing operations	380,434	[1]	176,736	137,213	33,715	64,549	58,610	69,141	35,453	728,098	227,753	237,475
Net income	$ 380,361	[1]	$ 176,699	$ 137,162	$ 33,665	$ 64,501	$ 58,558	$ 69,087	$ 35,412	$ 727,887	$ 227,558	$ 237,927
Basic earnings per share:
Income from continuing operations	$ 3.40	[1]	$ 1.58	$ 1.23	$ 0.30	$ 0.58	$ 0.53	$ 0.62	$ 0.32	$ 6.53	$ 2.06	$ 2.15
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share	0		0	0	0	0	0	0	0	0	0	0
Net income	3.40	[1]	1.58	1.23	0.30	0.58	0.53	0.62	0.32	6.53	2.06	2.15
Diluted earnings per share:
Income from continuing operations	3.38	[1]	1.57	1.23	0.30	0.58	0.53	0.62	0.32	6.50	2.04	2.13
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share	0		0	0	0	0	0	0	0	0	0	0
Net income	3.38	[1]	1.57	1.23	0.30	0.58	0.52	0.62	0.32	6.49	2.04	$ 2.13
Cash dividends per common share	$ 0.07		$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.28	$ 0.28
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market										$ 25,400	$ 31,200
Tax Adjustments, Settlements, and Unusual Provisions										10,800	(23,400)	$ (8,100)
Diagnostics [Member]
Quarterly Financial Data [Abstract]
Operating income from continuing operations										$ 874,206	$ 189,330	$ 153,196
[1]	The fourth quarter of fiscal year 2020 includes a pre-tax loss of $25.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy

Subsequent Events (Details)

Subsequent Events (Details) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Apr. 04, 2021USD ($)	Jan. 03, 2021USD ($)employees	Jan. 02, 2022employees$ / shares
Horizon Discovery Group plc [Member]
Subsequent Event [Line Items]
Entity Number of Employees | employees		400
Oxford Immunotec Global PLC [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Entity Number of Employees | employees			275
United States of America, Dollars | Horizon Discovery Group plc [Member]
Subsequent Event [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | $		$ 399,400
United States of America, Dollars | Oxford Immunotec Global PLC [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | $	$ 591,000
Business Acquisition, Share Price | $ / shares			$ 22,000

Uncategorized Items - pki-20210

Label	Element	Value
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 202,370,000
Accounting Standards Update 2016-13 [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	(1,328,000)
Accounting Standards Update 2016-13 [Member] | AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update 2016-13 [Member] | Common Stock [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update 2016-13 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	(1,328,000)
Accounting Standards Update 2016-13 [Member] | Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update 2018-02 [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update 2018-02 [Member] | AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	(6,489,000)
Accounting Standards Update 2018-02 [Member] | Common Stock [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update 2018-02 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	6,489,000
Accounting Standards Update 2018-02 [Member] | Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update 2016-02 [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	13,289,000
Accounting Standards Update 2016-02 [Member] | AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update 2016-02 [Member] | Common Stock [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update 2016-02 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	13,289,000
Accounting Standards Update 2016-02 [Member] | Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update_2016-16 [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	(2,062,000)
Accounting Standards Update_2016-16 [Member] | AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update_2016-16 [Member] | Common Stock [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update_2016-16 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	(2,062,000)
Accounting Standards Update_2016-16 [Member] | Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	10,209,000
Accounting Standards Update 2014-09 [Member] | AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update 2014-09 [Member] | Common Stock [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	0
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	10,209,000
Accounting Standards Update 2014-09 [Member] | Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Pronouncement in Period of Adoption	pki_CumulativeEffectOfNewAccountingPronouncementInPeriodOfAdoption	$ 0